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SYNTHESIS, CHARACTERIZATION AND BIOACTIVITIES OF 
DITHIOCARBAZATE-SCHIFF BASE LIGANDS AND THEIR METAL 
COMPLEXES 
By 
LOW MAY LEE 
2014 
 
 
There is an urgent need to discover new drugs with novel mechanisms of action, 
higher activity and improved selectivity to address the severe challenge of multi-
drug resistance in treating bacterial infections and cancer. In view of this, Schiff 
bases derived from S-substituted dithiocarbazate and their corresponding metal 
complexes with a plethora of potentially exciting biological activities and 
coordination chemistry are attractive candidates for consideration. Macroacyclic and 
open chain metal complexes of tetradentate NNSS and bidentate NS Schiff base 
ligands derived from the condensation of S-benzyldithiocarbazate (SBDTC) and S-
methyldithiocarbazate (SMDTC) with 2,5-hexanedione, methyl levulinate, levulinic 
acid, 4-carboxybenzaldehyde and 3-acetylcoumarin have been prepared. The 
compounds were fully characterized with various physico-chemical and 
spectroscopic methods. A total of 11 crystals structure were determined throughout 
this work. In order to provide more insight into the behaviour of the complexes in 
solution, electron paramagnetic resonance (EPR) and cyclic voltammetry (CV) 
experiments were performed. Conjugation of the most promising antimicrobial 
compound (Schiff base of SBDTC with 4-carboxybenzaldehyde) to various vectors 
(polyarginine, polyethylene glycol (PEG) and phe-arg-!-napthylamide (PA!N) was 
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achieved using either standard solid phase or solution synthetic methodologies to 
prepare improved therapeutic agents. Among the conjugates, the nonaarginine (R9) 
derivatives showed the most encouraging synergistic effect upon conjugation and 
complexation to copper ion with enhanced water solubility, bacteria cell membrane 
permeability and bioactivity. The Cu(II) R9 derivatives possess remarkable 
antibacterial activity against a wide spectrum of bacteria and in particular, highly 
efficacious against S. aureus with MIC values up to 1-0.5 µM when tested against 
nine strains of Gram-positive and Gram-negative bacteria. This appears to be the 
pioneer study to show that the conjugation of polyarginine to dithiocarbazate 
compounds can greatly influence their therapeutic potential. Cytotoxic assay was 
also carried out for selected non-conjugated compounds. All the selected Cu(II) 
complexes assayed against breast cancer cells lines (MCF-7 and MDA-MB-231) 
exhibited good cytotoxicity with lower IC50 values in comparison to their respective 
ligands. This work highlights the relevance of metal complexation strategy to 
stabilize the ligands and improve their bioactivity. The structure-activity 
relationships of the compounds are discussed. 
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SINTESIS, PENCIRIAN DAN AKTIVITI BIOLOGI LIGAN 
DITIOKARBAZAT-BES SCHIFF DAN KOMPLEKS LOGAM  
Oleh 
LOW MAY LEE 
2014 
 
Terdapat keperluan segera untuk menemui ubat-ubatan baru dengan mekanisme 
baru, aktiviti yang lebih tinggi dan tindakan yang lebih khusus bagi menangani 
cabaran yang serius iaitu rintangan terhadap pelbagai ubat-ubatan dalam rawatan 
jangkitan bakteria dan kanser. Memandangkan situasi ini, bes Schiff dan kompleks 
logam yang berasal daripada S-gantian ditiokarbazat yang mempunyai pelbagai 
potensi aktiviti biologi dan kimia koordinasi menarik merupakan calon-calon yang 
baik untuk pertimbangan. Kompleks logam bersistem makro-bukan-kitaran dan 
rantaian-terbuka masing-masing dengan ligan tetradentat NNSS dan bidentat NS bes 
Schiff yang berasal daripada kondensasi antara S-benzilditiokarbazat (SBDTC) dan 
S-metilditiokarbazat (SMDTC) dengan 2,5-heksanadion, metil levulinat, asid 
levulinik, 4-carboxibenzaldehid dan 3-asetilcoumarin telah disediakan. Semua 
sebatian tersebut telah dicirikan sepenuhnya dengan pelbagai kaedah fiziko-kimia 
dan spektroskopi. Sebanyak 11 struktur kristal telah ditentukan sepanjang kajian ini. 
Untuk memberi gambaran yang lebih jelas terhadap sifat-sifat kompleks dalam 
larutan, eksperimen elektron resonans paramagnet (EPR) dan voltammetri berkitar 
(CV) telah dijalankan. Konjugasi sebatian yang paling berpotensi antimikrob (bes 
Schiff SBDTC dengan 4-carboxibenzaldehid) dengan pelbagai vektor (poliarginine, 
polietilena glikol (PEG) dan phe-arg-!-naptilamida (PA!N)) telah berjaya dicapai 
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sama ada melalui metodologi sintetik standard peptida fasa pepejal atau larutan bagi 
penyediaan agen terapeutik yang lebih baik. Antara sebatian yang dikonjugasi, 
nonaarginine (R9) derivatif menunjukkan kesan sinergi yang paling menggalakkan 
melalui konjugasi dan juga pengkompleksan dengan ion kuprum yang turut 
membawa kepada perningkatan kelarutan dalam air, ketelapan terhadap membran 
sel bakteria dan bioaktiviti sebatian. Cu(II) R9 derivatif memiliki aktiviti 
antibakteria yang terbaik terhadap spektrum bakteria yang luas dan khususnya, 
sangat berkesan terhadap S. aureus dengan nilai-nilai MIC sehingga 1-0.5 "M 
apabila diuji terhadap sembilan jenis bakteria Gram-positif dan Gram-negatif. Ini 
merupakan kajian perintis yang menunjukkan bahawa konjugasi antara polyarginine 
dengan sebatian ditiokarbazat boleh mempengaruhi potensi terapeutik mereka. 
Kajian sitotoksik juga dijalankan untuk segelintir sebatian yang tidak dikonjugasi. 
Semua Cu(II) kompleks yang diuji terhadap sel-sel kanser payudara (MCF-7 dan 
MDA-MB-231) menunjukkan sifat sitotoksik yang baik dengan nilai-nilai IC50 yang 
lebih rendah berbanding dengan ligan masing-masing. Ini menunjukkkan  
kesesuaian strategi pengkompleksan dengan ion logam untuk menstabilkan ligan dan 
meningkatkan bioaktiviti mereka. Perhubungan di antara struktur dan aktiviti 
sebatian juga dibincang. 
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SYNTHÈSE, LA CARACTÉRISATION ET DE BIOACTIVITÉS 
DITHIOCARBAZATE - BASE DE SCHIFF LIGANDS ET LEUR MÉTAL 
COMPLEXES  
Par  
LOW MAY LEE  
2014 
Il y a de nos jours un besoin urgent de découvrir de nouveaux médicaments avec de 
nouveaux mécanismes d'action, une activité plus élevée et une meilleure sélectivité 
pour relever le défi de la multirésistance dans le traitement des infections 
bactériennes et le cancer. Dans cette perspective, des bases de Schiff dérivées de 
dithiocarbazates S-substitué et leurs complexes métalliques correspondants sont des 
candidats intéressants puisqu’ils peuvent être facilement synthétisés et permettent 
une grande diversité de coordination. Dans cette étude, des complexes 
macroacycliques tetradentes SSNN et bidente NS dont les ligands sont issus de la 
condensation de la S-benzyldithiocarbazate (SBDTC) ou de la S-
methyldithiocarbazate (SMDTC) avec la 2,5-hexanedione, le lévulinate de méthyle, 
l'acide lévulinique, le 4-carboxybenzaldéhyde ou le 3-acétylcoumarine ont été 
préparés. Les ligands et complexes synthétisés ont été entièrement caractérisés par 
différentes méthodes spectroscopiques et physico-chimiques. 11 structures 
cristallines ont été obtenues au cours de ce travail et afin d’étudier en détail la 
géométrie, la stabilité et les propriétés de ces complexes en solution, des expériences 
de résonance paramagnétique électronique (RPE), de titration calorimétrique 
isotherme et de voltamétrie cyclique (CV) ont été réalisées. L’activité 
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antibactérienne de ces complexes a ensuite été étudiée et a permis de sélectionner un 
complexe « leader » (plus efficace, s et fonctionnalisable). Ce complexe a alors été 
modifié afin d’augmenter sa stabilité en milieux biologique, sa solubilité dans l’eau 
ainsi que son activité. Il a été conjugué avec différentes entités  des peptides 
pénétrants, un polyéthylène glycol (PEG) et un peptide inhibiteur des pompes 
d’efflux bactériennes (Phe-Arg-!-napthylamide (PA!N)). Parmi les conjugués 
obtenus, ceux comportant un peptide avec 9 arginines (R9) ont montré un effet 
synergique lors de la formation des complexes puisque l’activité anti-bactérienne 
des complexes s’est avérée meilleure que celle des ligands et du cuivre seuls. Ces 
complexes ont montré une remarquable activité antibactérienne sur neuf souches de 
bactéries Gram-positives et Gram-négatives et en particulier, ils se sont avérés très 
efficaces contre S.aureus avec des valeurs de concentration minimale inhibitrice 
(CMI) de 1 à 0,5 µM. L’activité anti-cancéreuse des complexes non-conjugués a 
également été étudiée. Tous les complexes de cuivre sélectionnés et testés sur des 
cellules de cancer du sein MCF7 et MDA-MB- 231 ont montré une cytotoxicité 
élevée avec des valeurs de CI50 plus faibles pour les complexes par rapport à leurs 
ligands respectifs. Ceci met à nouveau en évidence la pertinence d’utiliser les 
complexes métalliques, pour à la fois stabiliser les ligands et générer des composés 
plus actifs. Les relations structure-activité des composés sont discutées. 
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vehicles. 
 
4.3 CPP loading and targeting strategies.  
 
4.4 Chromatograms of PEG-SB4CB synthesized via Fmoc strategy. 
(a) Crude (b) Purified. Detection at ! = 220 nm (top) and 280 nm 
(bottom). The peak at 17.5 min corresponds to the expected 
product. 
 
4.5 RP-HPLC chromatograms obtained on a C8 column. Samples 
were eluted  using a gradient of acetonitrile from 5 to 95% in 
water over 30 min with 1 mL min-1  flow rate at room 
temperature (both solvents contain 0.1% TFA). Detection: ! = 
220 nm (top) and 280 nm (bottom). 
 
4.6 Chromatograms of PA!N-SB4CB synthesized in solution. (a) 
Crude (b) Purified. The peak at 21.5 min corresponds to the 
expected product. 
 
4.7 1H and 13C spectra of the Schiff base-conjugate (R1-SB4CB). 
 
4.8 MALDI spectra of R9-SB4CB. The hydrolyzed fragment 
(cleavage of C=N bond) is noticeable during MALDI 
characterization. 
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4.9 UV-Vis titration of various ligands (concentration set at ca.  2.5 
x 10-5 M) with Cu(OAc)2.H2O (concentration set at ca. 5 x 10-4 
M)  at 25°C. a) Titration of R1-SB4CB in methanol and its 
corresponding titration curve monitored at 340 nm. b) Titration 
of SM4CB in acetate buffer pH 6 and its corresponding titration 
curve monitored at 340 nm. c) Titration of R9-SM4CB in acetate 
buffer pH 6 and its corresponding titration curve monitored at 
340 nm. 
 
4.10 UV-Vis spectra obtained by addition of Cu(OAc)2.H2O at 25°C 
to a solution of R9-SB4CB (ca. 2.5 x 10-5 M) at a) pH 4 (0.1 M 
acetate buffer), b) pH 7.4 (0.01 M PBS buffer) and at c) pH 9 
(0.1 M borate buffer).  
 
4.11  LC chromatogram of Cu(R1-SB4CB)2 (top) and R1-SB4CB 
(bottom) showing the two isomeric peaks with similar molecular 
mass. A linear gradient elution developed from holding time of 5 
min at 100% (0.1% formic acid in water ) and then from 0-60% 
(0.1% formic acid in acetonitrile) in 30 min. Experiments were 
carried out at a flow rate of 10 µL min-1 at room temperature 
with peaks detection at 220 nm and 280 nm. 
 
 4.12 ITC titration of Cu(R9-SB4CB)2, Cu(OAc)2 (concentration at ca. 
5 x 10-5 M) was added every 300 s to the ligand R9-SB4CB 
solution (concentration at ca. 1 x 10-5 M) in 0.1M acetate buffer 
at pH 6.. The top curve represents the corrected heat flow with 
time. The bottom curve represents the heat of reaction (measured 
by peak integration) as a function of Cu/ligand ratio. The solid 
line is the best theoretical fit to the experimental data. The three 
first points were removed for the fitting. 
 
4.13 The EPR spectra of both parent and conjugated compounds (1 
mM) in frozen DMF were indicative of the same species being 
formed with approximate calculated g! and g! values of ~2.05 
and ~2.15, respectively. Microwave frequency 9.50 GHz, 
microwave power 0.25 mW, modulation amplitude 0.2 mT, 
modulation frequency 100 kHz, time constant 164 ms, T = 50 K. 
 
 4.14 EPR spectra of 1mM Cu(R9-SB4CB)2 and Cu(OAc)2 in frozen 
acetate buffer pH 6 (0.1 M) are different from one another. 
Microwave frequency 9.50 GHz, microwave power 0.2 mW, 
modulation amplitude 0.2 mT, modulation frequency 100 kHz, 
time constant 164 ms, T = 50 K. 
 
 4.15 Cyclic voltammograms of Cu(R1-SB4CB)2 and Cu(SB4CB)2, 
1.7 mM in anhydrous deoxygenated DMF with 0.1 M 
tetrabutylammonium perchlorate as the supporting electrolyte. 
Working electrode glassy carbon; counter electrode Pt wire; 
reference electrode Ag/AgCl, scan rate 100 mV/s. All sweeps 
were initiated in the direction of the arrow. 
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CHAPTER 1 
INTRODUCTION 
 
The use of novel, exotic original compounds from nature’s chest to treat diseases has 
been a quest of mankind since ancient time (Li and Vederas, 2009). Although 
natural products have historically been a rich source of lead therapeutic molecules, 
Harvey (2008, p. 894) pointed out that “the difficulties in access and supply, 
complexities of natural product chemistry and inherent slowness of working with 
them” have contributed to the de-emphasis of natural products programs in industry 
over the years. It is foreseeable that developments in the field of synthesis will only 
continue as synthetic compounds hold the upper hand in meeting the demand of the 
highly competitive pharmaceutical industry to adapt to the current state-of-the-art 
advancement in science and technology (Ferguson, 1975; Li and Vederas, 2009; 
Strohl, 2000).   
 
In term of metal-containing drugs, the platinum drug cisplatin introduced clinically 
in 1971 and approved by Food and Drug Administration  (FDA) in late 1978, has 
been the most e!ective metal-based anticancer drug in the market (Hoeschele, 2009; 
Swarts et al., 2008). The resounding therapeutic success of cisplatin and its 
analogues has triggered tremendous effort in search of alternative metal-based 
chemotherapeutic agents in the past few decades (Ronconi and Fregona, 2009; 
Jakupec et al. 2008). The rationale for these studies is that metal centers other than 
platinum might open up new avenues in the development of clinically useful drug 
(Ronconi et al., 2006). Furthermore, there is an urgency to discover and characterize 
new drugs with enhanced activity, selectivity, bioavailability and fewer side-effects 
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than conventional drugs to treat current diseases. Figure 1.1 highlights the steady 
decrease in not only the commercialization but also the discovery for new antibiotics 
after the 1980s while the serious threat of antimicrobial resistance continues to 
prevail as reflected in the increasing occurrence of Methicillin-resistant 
Staphylococcus aureus (MRSA) over the same period (Bandow and Metzler-Nolte, 
2009; Patra et al., 2012b).  In addition, parallel concern over acquired drug 
resistance and serious side-effects of current anti-cancer drugs in the midst of the 
rise of cancer, in particular breast cancer as one of the leading causes of death 
worldwide, also drives the need to develop better alternatives (Ahmad et al., 2013; 
Yang et al., 2013; Ronconi and Fregona, 2009).   
 
Figure 1.1. (a) Decade-wise approval of new antibiotics and (b) prevalence of 
MRSA (Source: Patra et al., 2012b) 
 
Many publications have highlighted the rich diversity and potential of metal 
complexes for the design of novel therapeutic agents (Fricker, 2007; Haas and 
Franz, 2009; Ronconi and Sadler, 2007; Hambley, 2007; Thompson and Orvig, 
2006; Meggers, 2009). The intrinsic nature of metal centers, characteristic 
coordination modes, accessible redox states and tuneable thermodynamic and kinetic 
properties allow metal complexes to offer potential advantages over organic agents 
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alone (Rijt and Sadler, 2009). In addition, Sadler (2009, p. 10647) stated that “the 
ligands not only control the reactivity of the metal but also play critical roles in 
determining the nature of interactions involved in the recognition of biological target 
sites such as deoxyribonucleic acid (DNA), enzymes and protein receptors” (p. 
10647). The great expansion of research in the coordination chemistry of nitrogen- 
and sulphur-containing ligands such as Schiff bases derived from 
thiosemicarbazones and dithiocarbazates has taken place during recent years (Pelosi, 
2010; Beraldo and Gambinob, 2004; Ali and Livingstone, 1974). Schi! base metal 
complexes have played a prominent role in the development of coordination 
chemistry. This area of research has a wide spectrum, ranging from synthesis to 
application in many diverse fields. Schiff bases are condensation products of 
primary amines and aldehydes or ketones (e.g. RCH=NR’, where R and R’ may 
represents alkyl and/or aryl substituents) that have often been used as chelating 
ligands for preparation of complex compounds which are useful as catalysts, in 
various biological systems, polymers and dyes besides some uses as antifertility and 
enzymatic agents (Kumar et al., 2009; Soliman and Linert, 2007). Since this class of 
ligands possess both hard nitrogen and soft sulphur donor atoms, they are capable to 
act as good chelating agents for various metal ions (Mohamed et al., 2009). The 
flexibility and bioactivity of nitrogen and sulphur containing Schiff bases have also 
been associated with the presence of both imino (-N=CH-) and thioamino (-(C=S)-
NH-) moieties in their structures (Tarafder et al., 2008). Coordination of such 
compounds with metal ions often enhances their activities (Lobana et al., 2009). The 
low cost as well as the relatively easy preparation of Schiff base derivatives also 
provide a major attraction in creating novel leads that can be synthesized in a 
practical and step-economical fashion.   
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 S-substituted dithiocarbazate 
Schiff base ligands formed from dithiocarbazates are a class of particularly 
important Schiff bases which have been of immense interest owing to their 
potentially beneficial pharmacological properties and their wide variety of bonding 
modes and stereochemistry. Dithiocarbazates easily form “an interesting series of 
ligands whose properties can be modified by introducing different organic 
substituents” to form stable complexes with a wide variety of metal ions (Tarafder et 
al., 2002b, p. 2691). In 1974, Ali and Livingstone first reviewed the chemistry of 
nitrogen-sulphur (NS) chelating ligands. Since then, much has been published about 
metal complexes with dithiocarbazate. Most of the work has focused upon S-methyl 
and S-benzyldithiocarbazate Schiff bases and complexes, while other S-substituted 
derivatives have been studied recently (Figure 2.1). They include S-allyl (Islam et 
al., 2014), isomeric S-2-/3-/4-picolyl (Khoo et al., 2014; Crouse et al., 2004; Khoo, 
2008), isomeric S-2-/3-/4-methylbenzyl (Ravoof et al., 2011; Ravoof et al., 2010; 
Ravoof, 2008), S-napthylmethyl (How, 2008), S-quinolin-2yl-methyl (How, 2008), 
S-4-nitrobenzyl (Pavan et al., 2010; Maia et al., 2010) and S-4-chlorobenzyl (Li et 
al., 2009).   
 
 
 
 
 
5 
 
 
 
Figure 2.1. Various S-substituents at position R1 in dithiocarbazates. 
 
2.2 Schiff bases and metal complexes 
Many Schiff base ligands have been obtained by the condensation of an aldehyde or 
a ketone with dithiocarbazate. Figure 2.2 illustrates the different carbonyl 
compounds that have been used as precursors for the ligands preparation with 
condensation at position R2. The resulting Schiff bases and their respective metal 
complexes of these selected examples of alkyl, aryl and heteroatomic carbonyl 
compounds are biologically active and will be discussed in the following section. 
Other Schiff bases with substituents involving amino acid, sugars and calixarene are 
shown in Figure 2.3a. Apart from the varied S-substituents, modifications at N1 
atom of the dithiocarbazate derivatives have also been reported (Figure 2.3b). The 
ligands can be further classified as mono(dithiocarbazate) and bis(dithiocarbazate) 
which could result in open chain and macroacyclic metal complexes upon 
complexation. There are also reports of mixed ligand complexes of dithiocarbazate 
derived ligands with saccharinate ion (Ravoof et al., 2007), phenanthroline bases 
(Sasmal et al., 2008) and triphenylphosphine (Maia et al., 2010) as co-ligands.  
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(a) Alkyl and aryl series 
 
 
 
(b) Heteroatomic series 
 
 
Figure 2.2. Examples of different carbonyl compounds that have been used 
for the preparation of dithiocarbazate ligands (a) alkyl and aryl series (b) 
heteroatomic series.   
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(a) Schiff bases with sugars, amino acid and calixarene. 
 
 
                                          
 
(Sources: Iskander et al., 2003; Cattabriga et al., 1998; Sun et al., 2009) 
 
(b) Other derivatives with modifications at N1 atom 
 
   
 
Figure 2.3. Examples of different dithiocarbazate derivatives (a) with sugars, 
amino acid and calixarene (b) with modifications at N1 atom 
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Structural determination show that these dithiocarbazate related compounds could 
exist differently either as E or Z diastereoisomers relative to the azomethine C=N 
bond or as cis-cis, cis-trans, trans-cis and trans-trans conformations around the C-N 
and C-S bonds (Figure 2.4) (Lanfredi et al., 1977). They also form thiol-thione 
tautomers and, if a hydroxy functional group is present, S=C or C=S conformation 
could result based on the direction of the thiocarbonyl group either towards or away 
from the intramolecular hydrogen bonding (Figure 2.5) (Krasowska et al., 2010).  In 
general, dithiocarbazate related compounds normally crystallize in trans-cis 
configuration around the C=S bond in both the S-substituted dithiocarbazate and its 
Schiff base ligands. They also commonly form intermolecular bonds via NH···S 
hydrogen bonding and CH···S interactions. The Schiff base coordinates divalent 
metal ion in its iminothiolate form. Therefore, deprotonation of thioamide N-atom is 
typical in dithiocarbazate Schiff base coordination chemistry. The conversion of 
C=S double bond to a single C-S bond is also anticipated due to “tautomerism of the 
dithiocarbazate ligand to its iminothiolate form” (Ravoof et al., 2007, p 1163).  A 
number of bonding modes and geometries (e.g. tetrahedral,  square planar, square 
pyramidal and octahedral) have been observed for the dithiocarbazate derivatives 
with transition, non-transition and heavy metals as well as actinides (Tarafder et al., 
2002b; Maia et al., 2010; Ravoof et al., 2004; Takjoo et al., 2011).  !
 
Figure 2.4. Different conformations of dithiocarbazate (Source: Lanfredi et al., 
1977) 
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(a)                                                           (b)     
 
Figure 2.5. (a) Thione-thiol tautomerism (b) C=S and S=C conformers (Source: 
Krasowska et al., 2010) 
 
2.3 Biological activity 
Dithiocarbazate derivatives are of great interest particularly in the development of 
novel therapeutic compounds because of their vast spectrum of biological activity. 
Many researchers have synthesized these compounds as target structures and have 
evaluated their biological activities.  A compilation of literature reports focusing on 
the significant bioactivities of a variety of dithiocarbazate carried out during the past 
several decades will be presented herein.  
  
2.3.1 Anticancer activity  
The Schiff base derived from S-methyldithiocarbazate (SMDTC) with isatin 
(SMISA) and its Co(II), Ni(II), Cu(II), Zn(II) and Cd(II) metal complexes were 
evaluated in vitro against MDA-MB-231 (human breast carcinoma cells not 
expressing nuclear estrogen receptors,  ER-) and MCF-7 (human breast carcinoma 
cells expressing nuclear estrogen receptors, ER+) cancer cell lines. SMISA was 
found to be inactive, however Ni(SMISA)2 and Cu(SMISA)2 exhibited marked 
activity against the MCF-7 with IC50 (!g/mL) values of 3.5 and 0.45, respectively, 
whereas Zn(SMISA)2 and Cd(SMISA)2 were moderately active. Cd(SMISA)2 was 
also active against the MDA-MB-231 with IC50 value of 1.7 !g/mL. The active 
compounds demonstrated better IC50 values than the standard drug tamoxifen (IC50 
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against MCF-7= 5.0 !g/mL; IC50 against MDA-MB-231= 8.0 !g/mL) (Manan et al., 
2011b). Another closely related study involving S-benzyldithiocarbazate (SBDTC) 
Schiff bases derived from 5-fluoroisatin, 5-chloroisatin, 5-bromoisatin showed that 
the cytotoxic activity of the halo substituted isatins against the MCF-7 breast cancer 
cell lines tested was in the order of Br (2.6 !g/mL) > F (3.2 !g/mL) > Cl 
(14.0 !g/mL) (Manan et al., 2011a). The ONS Schiff base of SBDTC with 
salicylaldehyde and its Zn(II) and Sb(III) complexes were also strongly active 
against human cell T-lymphoblastic leukemia CEM-SS (IC50= 2.3 to 4.3 !g/mL) 
while the Cu(II), U(VI) and Th(IV) complexes were moderately active. The Ni(II), 
Zr(IV) and Cr(III) complexes were found to be inactive. Complexation seems to 
reduce the cytotoxicity of this ligand (Tarafder et al., 2000a). 
   
A bridged dimeric Cu(II) complex of the Schiff base product of condensation 
of SBDTC and 2-acetylpyridine, Cu2Cl2(L)2  (Figure 2.6) was identified as the best 
inhibitor of cell motility with nanomolar potency from the screening performed by 
Beshir et al (2008). The compound appeared to be selective for certain cell lines as it 
was most active towards Madin-Darby canine kidney (MDCK) cells followed by 
human breast carcinoma T47D cells, less in human breast carcinoma BT20 cells and 
show a weaker activity in human colorectal carcinoma HCT116 cells.  From the 
structure-activity relationship investigation, Beshir et al. (2008) concluded that a 
two-ligand structure with bulky nonpolar S-substituents in a transoid conformation 
is important for the antimigratory activity of these metal-ligand complexes.  
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Figure 2.6. Compounds with antimigratory activity (Source: Beshir et al., 2008) 
 
 
 
The Schiff base of SMDTC with 2-acetylpyridine and its Mn and Co complexes 
have been synthesized. The free ligand (IC50= 21.7 !M) and its metal complexes 
(IC50= 4.5 !M for Mn and 25.4 !M for Co) exhibited significant and different 
antitumor activity against human acute myelocytic leukemia cell line (K562) (Chen 
et al., 2011). 
 
The tridentate NNS Schiff base derived from SMDTC with pyridine-2-
carboxaldehyde and the Mn complex of analogous Schiff base prepared by 
condensing SBDTC with pyridine-2-carboxaldehyde showed significant antitumor 
activity against leukemia cell line K562 with IC50 values in the !M range, 37 !M 
and 31 !M, respectively (Zhang et al., 2011a). The Schiff base SBDTC-pyridine-2-
carboxaldehyde was also cytotoxic with an IC50 value of 5.90 !g/mL against CEM-
SS cells while the Cu(II), Cd(II), Zn(II), Sb(II) and Co(II) complexes were strongly 
cytotoxic with IC50 values of 2.20 !g/mL, 2.30 !g/mL, 5 !g/mL, 1.6 !g/mL and 
0.35 !g/mL, respectively (Tarafder et al., 2000c; Tarafder et al., 2000c). In addition, 
the Cu(II) and Cd(II) complexes were effective against human colon 
adenocarcinoma cells (HT-29) with their corresponding IC50 values of 2.60 !g/mL  
and 3.10 !g/mL  (Tarafder et al., 2001b).  Another Schiff base synthesized by 
12 
 
reacting S-4-picolyldithiocarbazate (S4PDTC) with pyridine-2-carboxaldehyde 
(Pc4PDTC) showed moderate cytotoxicity against human myeloid leukemia cells 
(HL-60) with IC50 value of 9 !g/mL while the Schiff base synthesized by reacting  
S4PDTC with 4-carboxybenzaldehyde (Cb4PDTC) was inactive. Complexing 
Pc4PDTC with Cd(II) and Cu(II) enhanced its cytotoxicity from moderately to 
highly active (IC50 value of 1.20-1.70 !g/mL). Pc4PDTC containing two pyridine 
rings and its Cd(II) and Cu(II) complexes were also highly active against colon 
cancer cells HT-29 with IC50 value " 1.0 !g/mL (Khoo et al., 2014). S-2-
picolyldithiocarbazate (S2PDTC) proved moderately active against HT-29 and 
weakly active toward CEM-SS with IC50 values of 9.5 and 24.0 !g/mL, respectively, 
while among its Schiff bases reported herein, only the NNS Schiff base with 
pyridine-2-carboxaldehyde showed strong activity toward CEM-SS and HT-29 with 
IC50 values of 2.3 !g/mL. All of the Ni(II) complexes were inactive against CEM-SS 
cancer cells (Crouse et al., 2004). 
 
SBDTC-2-acetylthiophene (SB2ATP), IC50 = 13 !g/mL and Cd(SB3ATP)2, IC50 = 9 
!g/mL showed significant bioactivity towards human promyelocytic leukemia cells 
(HL-60). SB2ATP, SBDTC-3-acetylthiophene (SB3ATP), Co(SB2ATP)2, 
Cu(SB2ATP)2, Cu(SB3ATP)2, Zn(SB2ATP)2 and Cd(SB2ATP)2  were also 
selective with significant chemotherapeutic activity against MCF-7 with IC50 = 1.4–
4.2 !g/mL. The Schiff bases however displayed higher cytotoxic activity compared 
to their metal complexes except for Cu(SB3ATP)2 (Chan et al., 2008).  The Zn 
complex of the Schiff base, SBDTC-5-methyl-2-furaldehyde was also found to be 
highly active against CEM-SS leukemia cell line with IC50 value of 2.0 !g/mL, 
while the Cd complex was slightly less active than that of Zn with IC50 value of 4.95 
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!g/mL (Tarafder et al., 2002a).  The Cd(II) complexes of SMDTC with 2-furyl-
methylketone and 5-methyl-2-furaldehyde and Co(II) complex of SMDTC-2-furyl-
methylketone were found to be very active against CEM-SS and cervical cancer 
cells (HELA) with IC50 values between 1.8 and 3.6 !g/mL (Chew et al., 2004). The 
Pb(II) complex of SBDTC with 5-methyl-2-furaldehyde was highly cytotoxic 
against leukemic cells CEM-SS with IC50 of 3.25 !g/mL (Tarafder et al., 2002b). 
The Cu (II), Ni (II) and Zn (II) complexes of SMDTC with 2-furylmethylketone 
showed very good activity against CEM-SS cells with IC50 values of 1.6, 2.1 and 3.0 
!g/mL, respectively. The Cu(II) and Zn(II) complexes were also highly active 
against HELA cells with IC50 values of 1.5 and 2.1 !g/mL (Tarafder et al., 2002c).  
 
The comparison of cytotoxic activity of SMDTC-2-benzolpyridine, SBDTC-2-
benzolpyridine and their metal complexes indicated that the presence of bulky 
nonpolar S-substituents on dithiocarbazate moiety and complexation with metals can 
enhance the cytotoxic activities. In particular, the Zn(II) complex of the S-benzyl 
derivative effectively inhibited K562 leukemia cell line at a concentration more than 
61-fold lower than the Schiff base ligand and the IC50 values of both Zn(II) 
complexes were also higher against the normal hepatocyte QSG7701 cell line, 
demonstrating that the compounds were able to distinguish the tumor cells from 
normal cells (Li et al., 2012). The pentadentate Schiff base of 2,6-diacetylpyridine 
with SBDTC exhibited marked cytotoxicity against CEM-SS giving IC50 value of 
4.3 !g/mL, but its Ni(II) complex was inactive (Ali et al., 2001a). The Schiff bases 
of both SMDTC- and SBDTC-6-methyl-2-formylpyridine exhibited strong 
cytotoxicity against human ovarian cancer (Caov-3) cell lines with the S-methyl 
derivative (IC50 = 1.0 !g/mL) being twice as active as the S-benzyl derivative. The 
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Pt complex of the S-methyl derivative was moderately active but the Pd(II) complex 
was only weakly active against this cancer. None of the complexes of S-benzyl 
derivatives are active against the ovarian cancer cell line (Caov-3) (Ali et al., 2006). 
The mixed-ligand complexes of general formula, [Cu(NNS)(sac)] involving six 
NNS Schiff bases ligands (SBDTC or SMDTC with 2-acetylpyridine, 2-
benzoylpyridine and 6-methyl-2-formylpyridine, respectively) and sac (the 
saccharinate anion)  (Figure 2.7) were found to be highly active against the leukemic 
cell line HL-60 with IC50 values of 0.25-0.80 !g/mL but only the Cu complex with 
SBDTC-2-acetylpyridine exhibit strong cytotoxicity against Caov-3, IC50 = 0.40 
!g/mL (Ravoof et al., 2007; Ravoof et al., 2004).  
(a)        (b) 
      
Figure 2.7. (a) Schiff bases of SBDTC with 2-acetylpyridine, 2-benzoylpyridine 
and 6-methyl-2-formylpyridine, respectively in thione form (b) saccarinate 
anion (Source: Ravoof et al., 2007) 
 
A tridentate nitrogen-sulfur Schiff base synthesized by condensation of 6-methyl-2-
formylpyridine with S-3-methylbenzyldithiocarbazate was strongly active against 
MCF-7 and MDA-MB-231 cell lines with IC50= 0.3 and 2.2 !g/mL, respectively. Its 
metal complexes also showed high selectivity with Cu(II), Ni(II) and Zn(II) 
complexes strongly active against only MCF-7, whereas the Cd(II) complex was 
strongly active only against MDA-MB-231, although the complexes were less active 
in comparison to the ligand itself (Ravoof et al., 2010). 
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The OS donor ligand derived from the reaction of SBDTC with benzoyl chloride and 
its Cu(II), Ni(II) and Pb(II) complexes displayed marked cytotoxicity against HL-60 
leukemia cells with IC50" 5.0 !g/mL while Cd(II) and Co(II) complexes were only 
moderately cytotoxic. In this case, the ligand was more potent compared to its metal 
complexes (How et al., 2008). SBDTC and its Sn(II) complex were very effective 
against renal carcinoma Tk10 kidney cancer cells and leukemia TK6 cell line. The 
IC50 values were in the range 1.0-4.0 !g/mL with SBDTC being the most active 
compound. The SNNS quadridentate Schiff base of SBDTC with benzil and its 
Sn(II) complex were also effective against skin cancer cells (UACC melanoma) with 
IC50 of 5.2 and 2.7 !g/mL, respectively (Tarafder et al., 2000b). The NS Schiff base 
prepared by condensing SBDTC with 2,3-butanedione (1:1 mole ratio) was strongly 
active against leukemic cells CEM-SS with IC50 value of 2.05 !g/mL (Tarafder et 
al., 2001a).    
 
2.3.2 Antibacterial and antifungal activity 
The Schiff base formed from pyridine-2-carboxaldehyde SMDTC and its Zn 
complex showed marked and broad antimicrobial and antifungal activities compared 
to the S-benzyl derivatives with MIC values as low as 12.5 !g/mL (Zhang et al., 
2011a).  The antibacterial activity of the Schiff bases of SBDTC with ferrocene-
based chalcones containing a F or Cl substituent in the para position or a pyridine 
ring were the most active in the series and their activity against Gram-negative 
bacterial (Escherichia coli (E. coli) and Pseudomonas aeruginosa (P. aeruginosa)) 
strains was found to be higher than that for the drugs ketoconazole, kanamycin and 
penicillin (Liu et al., 2012). In another closely related investigation, the Zn(II) and 
Cu(II) complexes of SBDTC with ferrocene-based chalcone Schiff base ligand 
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containing  a  para-Cl substituent and the Zn(II) complex of SBDTC with ferrocene-
based chalcone having a methyl group in the aromatic ring were the most active in 
the series with  MIC values in the range of 1.319 ! 10"8 M to 3.750 ! 10"7 M against 
bacteria and fungi tested (Staphylococcus aureus (S. aureus), Bacillus cereus (B. 
cereus), E. coli, P. aeruginosa, Aspergillus niger (A. niger), Aspergillus fumigatus 
A. fumigates) (Liu et al., 2013). SMDTC-2-benzolpyridine and its Cu(II) 
complex showed excellent activity against Gram positive bacteria (Bacillus subtilis 
(B. subtilis), S. aureus) and yeast (Candida lusitaniae (C. lusitaniae)) with MIC 
values of 1-5 !g/mL. It was found that the SMDTC derived ligand was more potent 
than the SBDTC derivative towards the tested microorganisms and complexation 
with metals also had a synergetic effect resulting in enhanced antimicrobial activity 
(Li et al., 2012). Both the Cu(II) complex of the Schiff base S4PDTC with pyridine-
2-carboxaldehyde and the Cd(II) complex of S4PDTC 4-carboxybenzaldehyde 
(Cb4PDTC) showed good antifungal activity against Candida albicans (C. albicans) 
with MIC values lower than Nystatin (Khoo et al., 2014) . The Schiff base derived 
from SBDTC with pyrrole-2-carboxaldehyde was a stronger antifungal agent than 
Nystatin against Saccaromyces ceciricaee (S. ceciricaee) and Candida lypolytica ( 
C. lypolytica) (Tarafder et al., 2002a). The NSS Schiff bases of S2PDTC with 2-
acetylfuran showed better activity than Nystatin toward against the fungus, C. 
lypolytica while its metal complexes were not active (Crouse et al., 2004).  Co(II) 
complex of SMDTC with 2-furyl-methylketone and Cd (II) complex of SMDTC 
with 5-methyl-2-furaldehyde gave the most effective activity against fungi tested (C. 
lypolytica and Aspergillus ochraceus (A. ochraceous) (Chew et al., 2004) while the 
Cu(II) complex of  SMDTC with 2-furylmethylketone showed clear activity against 
C. lypolytica  with better activity than Nystatin (Tarafder et al., 2002c). Bi(III) and 
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As(III) metal complexes of SBDTC-3-acetylcoumarin (L) with the formula 
[ClBi(L)2] and [PhAs(L)2] showed low MIC values (10#!g/mL for bacterial strain B. 
subtilis and 16#!g/mL for fungal strain Fusarium oxysporum (F. oxysporum)). The 
metal complexes were more active against fungal strains compared to bacterial 
strains and had better activity than the free ligands (Dawara et al., 2012). In the 
series with salicylaldehyde Schiff base of isonicotinoyldithiocarbazic acid, the best 
activity was shown by the Ni(II) complex (MIC = 75 !g/mL) against the gram-
negative pathogenic strain of E. coli (Kalia et al., 2012). The Cd complex of the 
SNNS Schiff base SBDTC-benzil was active against bacteria P. aeroginosa and B. 
cereus with the MIC values better or comparable to kanamycin (Tarafder et al., 
2000b). The Cu(II) complex of SBDTC-salicylaldehyde proved to be the best in the 
series against B. cereus (MIC=79.6 !g/mL) (Tarafder et al., 2000a).  
 
2.3.3 Iron chelators 
All dithiocarbazate ligands derived from either SBDTC or SMDTC with 2-
acetylpyridine, di-2-pyridylketone and 2-pyridinecarbaldehyde were more effective 
than standard desferrioxamine B (DFO) at releasing intracellular Fe and SMDTC-2-
pyridinecarbaldehyde was the most active of all compounds tested. Furthermore, the 
three SMDTC derivatives were more effective at mobilising intracellular 59Fe than 
their corresponding SBDTC analogues. 2-pyridinecarbaldehyde derivatives with 
both SMDTC and SBDTC exhibit no apparent cytotoxicity (>10 !M). This property, 
in combination with their high activity in sequestering intracellular Fe present ideal 
properties for a chelator in the treatment of Fe overload. The other four 
dithiocarbazates (with 2-acetylpyridine and di-2-pyridyl ketone) showed moderate to 
potent anti-proliferative activity which may be problematic for treatment of Fe 
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overload. On the other hand, the anti-proliferative activity of these compounds can 
be advantageous in the treatment of cancer (Basha et al., 2012). 
 
2.3.4 Antituberculosis activity 
Ni, Co and Zn complexes of a non-Schiff base isonicotinoyldithiocarbazic acid 
ligand synthesized from isoniazid with carbon disulphide showed MIC values of 2, 2 
and 50 !g/mL against Mycobacterium tuberculosis (M. tuberculosis) H37Rv, and 10, 
100 and 50 !g/mL against a multi-drug-resistant strain of M. tuberculosis. They had 
little cytotoxic effect on the transformed human rhabdomyosarcoma cell line RD 
cells making them potentially useful to treat multi-drug resistant tuberculosis 
infections (Kanwar et al., 2008). Others dithiocarbazate derivatives such as 2-/3-/4-
pyridinecarbonimidoyldithiocarbazic acid esters, methyl 3-[amino(pyrazin-2-
yl)methylidene]-2-methyldithiocarbazate and benzyl 3-[amino(pyrazin-2-
yl)methylidene]-2-methyldithio carbazate have been studied and were among the 
promising classes of compounds showing action against tuberculosis (Olczak et al., 
2010). In another study by Pavan et al. (2010), dithiocarbazate compounds derived 
from benzoylacetone showed poor activity. The low activity was associated with the 
difference in the molecular structures from the potent analogues which contained 
pyridine rings further affirming that the aromatic heteroatom N moiety played an 
important role in the anti-tuberculosis activity of the compounds (Pavan et al., 
2010).  
 
2.3.5 Antiamoebic activity 
Mixed ligand Pt(II) and Pd(II) complexes prepared with ONS Schiff bases derived 
from SBDTC and 2-hydroxyacetophenone (Figure 2.8) or SBDTC and 4-phenyl-
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2,4-butanedione, and neutral phosphine ligands exhibited biological activity on 
extra- and intra-cellular forms of Trypanosoma cruzi  in a time- and concentration-
dependent manner with IC50 values ranging from 7.8 to 18.7 !M. Nonetheless, the 
most active compound with IC50 = 0.6 !M was the ligand SBDTC-4-phenyl-2,4-
butanedione which also presented a trypanocidal activity on trypomastigote form 
better than the drug benznidazole (Maia et al., 2010).  
 
Figure 2.8. Mixed ligand Pt(II) and Pd(II) complexes with Schiff base (derived 
from SBDTC and 2-hydroxyacetophenone) and phosphine ligands (Source: 
Maia et al., 2010) 
 
Pd(II) complexes of Schiff bases SMDTC-2-acetylpyridine and SBDTC-2-
acetylpyridine also showed potent activity against HK-9 strain of  Entamoeba 
histolytica (E. histolytica) trophozoites with IC50 = 0.19 and 0.16 !g/mL, 
respectively (Neelam et al., 2000). Dioxovanadium(V) complexes of Schiff bases 
formed between bromo substituted salicylaldehyde and dithiocarbazates (IC50 = 1.35 
!M) (Maurya et al., 2003) , the dinuclear potassium dioxovanadium(V) complex of 
SBDTC-5,5-methylbis(salicylaldehyde) (IC50 = 0.092 !M) (Maurya et al., 2012) and 
Pd(II) complex of SBDTC-5-nitrothiophene-2-carboxaldehyde (IC50 = 0.28 !g/mL)  
(Bharti et al., 2002) were the most active among their respective series and each 
showed substantially better amoebocidal action than metronidazole, a commonly 
used drug against the protozoan parasite E. histolytica. 
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2.3.6 Other biological properties 
Methyl 3-phenyldithiocarbazate was found to decrease the rate of brassinin (a 
crucial plant defense produced by crucifers) detoxification making it among 
potential detoxification inhibitors (Pedras and Jha, 2006). Oxovanadium(IV) 
complexes with mixed-ligands  SMDTC-salicylaldehyde and N,N-donor 
phenanthroline bases like 1,10-phenanthroline (phen), dipyrido[3,2-d:2$,3$-
f]quinoxaline (dpq) and dipyrido[3,2-a:2$,3$-c]phenazine (dppz) (Figure 2.9) showed 
good binding to calf thymus DNA with binding constant values in the range of 
7.4 ! 104–2.3 ! 105 M"1. The complexes also showed poor chemical nuclease 
activity in the dark in the presence of 3-mercaptopropionic acid (MPA) or hydrogen 
peroxide while both dpq and dppz complexes showed efficient DNA cleavage 
activity under UV-A radiation (365 nm) via a type-II mechanistic pathway involving 
formation of singlet oxygen (1O2) as the reactive species (Sasmal et al., 2008).  
 
Figure 2.9.  Ternary structures of VO complexes and the phenanthroline bases 
used. (Source: Sasmal et al., 2008) 
 
A series of dithiocarbazate Schiff bases of SBDTC with various hydroxyl-
substituted benzaldehydes were tested for their xanthine oxidase (XO) inhibitory 
activity. The Schiff base with the hydroxy substituent in the para-position on the 
benzaldehyde unit was the most potent. It displayed significantly increased potency 
over the benchmark allopurinol under the assay conditions employed (95±4% 
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inhibition at 50 !M and IC50 = 0.7±0.1 !M) (Leigh et al., 2011). SBDTC (Tarafder et 
al., 2001b) and the Ni and Cu complexes of SBDTC-2,3-butanedione (Tarafder et 
al., 2001a) were found to be stronger antioxidants than Vitamin E.  Antioxidant 
properties of SBDTC and two other Schiff bases synthesized by reacting  S4PDTC 
with pyridine-2-carboxaldehyde (Pc4PDTC) and 4-carboxybenzaldehyde 
(Cb4PDTC) were also found to be comparable to the commercially available  
synthetic antioxidant buthylatedhydroxytoluene (BHT) (Tarafder et al., 2001b; Khoo 
et al., 2014). Alkyl pyridine-carbonyldithiocarbazates were shown to be uncouplers 
of oxidative phosphorylation in mitochondria. Greater activity was observed with 
increasing alkyl chain length, the optimum being C9, indicating the influence of 
hydrophobicity towards the activity (Terada et al., 1978; Kubota et al., 1978). 
Technetium-nitrido complexes of the Schiff base S-methyl 3-(2-hydroxyphenyl 
methylene) dithiocarbazate had been investigated as potential Tc-99m nitrido tumor 
imaging disposition in mice (Borel et al., 1992). N-methyl-SMDTC had also been 
effectively used for high-yield preparation of nitrido Tc-99m and Re-188 
radiopharmaceuticals (Uccelli et al., 2011; Boschi et al., 2010). The anti-fertility 
data indicated a highly significant decline in the motility of sperm as well as in 
sperm count in the treated animals in the case of dimethyltin(IV) complex derived 
from SBDTC-4-nitrobenzanilide (Singh et al., 2009). The results suggested that the 
ligand of SBDTC-3-acetylcoumarin was most effective in reducing fertility and 
complexation with bismuth and arsenic enhanced its activity (Dawara et al., 2012). 
The pescticide activity and DNA cleavage activity of Ge(IV) complex with SBDTC-
3-fomylchromone Schiff base were found to be better in comparison to the ligand 
itself (Dawara et al., 2011). 
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At this stage, it is impossible to draw any meaningful correlations from this limited 
and diverse group. A library of compounds must be systematically designed and 
their activities determined in order to achieve that. The above reports on 
dithiocarbazate, its Schiff bases and metal complexes highlight that even subtle 
change in the structures lead to dramatic alterations of the biological properties of 
this class of compounds. The pharmacological activities of these metal complexes 
depend on the type of metal ion, its ligands and the structure of the compounds. 
These factors play important roles in the recognition of target sites.  In conjunction 
with the continuous effort to develop new derivatives that possess potent biological 
activities, the major aim of the present work is to expand the synthesis involving 
multidentate dithiocarbazate derivatives to include bioconjugation and to explore the 
biological potential of the compounds synthesized to determine their cytotoxicity 
and their potencies against selected bacterial strains expressing a multi-drug 
resistance phenotype. Although many new dithiocarbazate derivatives have been 
added to the family in recent years, there is still no clear structure-activity 
relationship to explain their activity. The actual mechanism of action is still 
unknown. Electron paramagnetic resonance (EPR) and electrochemistry have been 
carried out in this work to connect the biological activities to their structures and 
redox properties in order to identify features that promote better activity. It is 
expected that this structure-activity analysis will serve to orient further synthetic 
efforts towards determining the optimum features essential to promote higher 
bioactivities and ultimately to guide future work designed to reveal their mode of 
action.   
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2.4 Objectives 
1. To synthesize bioactive Schiff bases (i.e. potentially bi-, tri- or tetradentate 
ligands) and their open chain or macroacyclic metal complex systems 
derived from S-substituted dithiocarbazates. 
2. To incorporate grafting work with vectors (i.e. polyarginine, polyethylene 
glycol (PEG) and phe-arg-%-napthylamide (PA%N)) in order to prepare 
improved therapeutic agents.  
3. To characterize the synthesized compounds using various physico-chemical 
and spectroscopic techniques.  
4. To study the biological activity of the compounds prepared and to attempt to 
elucidate their structure-activity relationships. 
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CHAPTER 3 
NON-CONJUGATED PARENTS COMPOUNDS 
 
In this work, three series of parent compounds: (i) tetradentate NNSS ligands (ii) 
potentially bidentate NS or tridentate ONS ligands with acid or ester functionalities 
and (iii) potentially bidentate NS or tridentate ONS ligands with natural ketone 
moiety were prepared by condensation of S-substituted dithiocarbazates with 2,5-
hexanedione, methyl levulinate, levulinic acid, 4-carboxybenzaldehyde and 3-
acetylcoumarin. All were complexed with copper to synthesize their respective 
metal complexes.   
 
 3.1 Introduction 
3.1.1 Ligand systems 
3.1.1.1 Tetradentate NNSS 
Macrocyclic and macroacyclic Schiff bases have been widely studied (Vigato and 
Tamburini, 2004). They show various coordination abilities and potential 
applications in biology which range from therapeutic drug candidates to diagnostic 
agents (Holland et al., 2008) and they provide synthetic models for the metal 
containing sites in metalloproteins and metalloenzymes (Gennari et al., 2012). It is 
therefore worthwhile to explore these interesting properties by investigating the 
synthesis and characterization of new Cu(II) bis(dithiocarbazate) in this work. The 
compounds are analogues of the Cu(II) bis(thiosemicarbazone) that have garnered 
much attention resulting in biological breakthroughs (Paterson and Donnelly, 2011) 
particularly as radiopharmaceuticals (Donnelly, 2011).  
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It is anticipated that the replacement of nitrogen atom with sulphur may provide 
interesting results warranting further exploration into dithiocarbazate compounds. 
Moreover, to form the Schiff bases, the 2,5-hexanedione has been chosen to expand 
the ligand flexibility by introducing backbones containing more than two carbons. 
This enhanced flexibility may facilitate increased tetrahedral distortion leading to 
incorporation of metal cations that prefer non-square planar geometries such as 
Cu(I) ion. Previous studies have shown that physico-chemical properties such as 
redox potential as well as biological activity have been related to the geometry at the 
metal site (Durot et al., 2005; Drew et al., 1995; Rorabacher, 2004; Basha et al., 
2012; Jansson et al., 2010). These were fine examples demonstrating the marked 
influence of ligand environment towards the redox potential of their respective 
Cu(II)/Cu(I), Fe(III)/Fe(II) and Mn(III/II) metal systems. While choice of the metal 
ions and substituent functional groups of the ligands have been carefully chosen to 
affect the geometry of metal complexes (Ostermeier et al., 2010; Jones and 
McCleverty, 1970; Cowley et al., 2004; Stefani et al., 2012), the studies by Diaz et 
al. (1998;1999) that highlighted the differences in coordination geometry identified 
using EPR by comparing the open chain and cyclic metal complex system which 
subsequently affect their biological activity was found to be particularly attractive 
since this analytical tool enabled a structural view of the complexes in solution. The 
group noted that the Cu(II) complexes of the open chain mono(thiosemicarbazone) 
with a higher degree of tetrahedral distortion should be further explored as 
potentially better SOD-like mimics than the macroacyclic bis(thiosemicarbazone) 
complexes. Although the reports were primarily focused on superoxide dismutase 
(SOD) mimics, it would also be meaningful to carry out such comparison in this 
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work as the open chain system will be envisaged to offer interesting diversity and 
aid towards the understanding of the structure-bioactivity relationship.   
 
3.1.1.2 Potentially bidentate NS or tridentate ONS ligands with an acid or ester 
functionality  
The open chain series in this work consisting ligands of methyl levulinate and 
levulinic acid with SBDTC and SMDTC as well as their corresponding Cu(II) 
complexes will be a worthy comparison to their macroacyclic Cu(II) tetradentate 
system with 2,5-hexanedione bis(dithiocarbazate). Furthermore, the Schiff base 
derivatives containing the acid or ester functional group have proved to be attractive 
from both biological and physico-chemical aspects. For instance, recent attention 
was dedicated to metal complexes of &-ketoglutaric acid (Baldini et al., 2004) and 
pyruvic acid thiosemicarbazone (Diaz et al., 1994; Wiecek et al., 2009). These 
aliphatic ligands with a variety of potential donor atoms and many possible 
conformations provided a versatile chelating behavior. In addition, the metal 
complexes were found to be potent against the selected human leukemia and cancer 
cell lines tested and thus may be regarded as potentially significant antitumor agent 
(Baldini et al., 2004; Diaz et al., 1994; Wiecek et al., 2009). Similiarly, the 
analogous Schiff base keto-ester methylpyruvate with SMDTC has been screened by 
the National Cancer Institute, Bethesda, Maryland and has been found to exhibit 
promising activity against leukemia cells as mentioned by Ali et al. (2001b). The 
authors also stated that the “ligand coordinated to the metal(II) ion as a 
uninegatively charged tridentate chelating agent via the carbonylic oxygen atom, the 
azomethine nitrogen atom and the thiolato sulfur atom” but resulted in varied 
conformation geometry with different metal (Ali et al., 2001b p. 1037). The Cu(II) 
27 
 
complexes have the general formula, CuLX (L= Schiff base; X=Cl", Br") with a 
distorted square-planar structure whereas the Zn(II), Cd (II) and Ni(II) complexes of 
empirical formula, ML2 supported a six-coordinate distorted octahedral structure for 
these complexes as confirmed by the  X-ray crystallographic structural analysis (Ali 
et al., 2001b; Ali et al., 1999; Ali et al., 2004). To date, metal complexes of methyl 
levulinate or levulinic acid dithiocarbazate have not been reported although 
semicarbazone derivatives of levulinic acid have been identified as potent 
anticonvulsant agents showing broad spectrum of activity with low neurotoxicity 
(Navneet and Pradeep, 2005). 
 
Since the carbonylic oxygen atom and the azomethine nitrogen atom are further 
apart with three carbons in between them, these ligands could adapt NS bidentate 
chelation ability different from the ONS chelating ligands with &-ketoglutaric acid, 
pyruvic acid or methyl pyruvate. In addition, 4-carboxybenzaldehyde was utilized to 
form the Schiff bases in order to provide insight on the influence of an aromatic 
acid.  As most sulphur-nitrogen chelating ligands and their complexes are highly 
hydrophobic and their low solubility in water imposes experimental limitations in 
biological studies, the introduction of a hydrophilic group such as -COOH in 
systems should permit increased solubility in water (Pogni et al., 2000). Besides 
that, the presence of a carboxylic functional group would allow for further ligand 
optimization via bioconjugation to improve the properties of the compounds and 
their applications.  
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3.1.1.3 Potentially bidentate NS or tridentate ONS ligands with natural potent 
aldehyde or ketones moieties. 
In order to expand the synthesis and exploration of dithiocarbazate derivatives, 
attention was also directed herein to aromatic dithiocarbazate derived from natural 
aldehydes or ketones that had well established medicinal properties. The rationale 
behind this attempt was based on the prospect of the synergistic effects developed 
from integration of the promising bioactivity of individual components (i.e. metal 
center and ligand comprising the carbonyl group and substituted dithiocarbazate 
moiety). A number of publications had highlighted the potential of utilizing such 
natural aromatic compounds like chromone (Barve et al., 2006; Khan et al., 2009), 
chalcone (Zhang et al., 2011b) and curcumin (Padhye et al., 2009). This prompted 
the preparation of new metal complexes with Schiff base formed from the 
condensation of SBDTC and 3-acetylcoumarin in this work. Coumarin derivatives 
are attractive because of their wide variety of biological activities including 
antioxidant, antibacterial, antifungal and cytotoxic (Datta et al., 2011; Bagihalli et 
al., 2008; Phaniband et al., 2011; Kulkarni et al., 2009; Creaven et al., 2009). 
Moreover, the reported coumarin Schiff bases and their metal complexes were 
shown to exhibit outstanding luminescence properties which may provide advantage 
for application of these compounds as probes (Datta et al., 2011). Further findings 
reveal that the coumarin derivatives interact strongly with DNA and can cause DNA 
cleavage (Phaniband et al., 2011; Kulkarni et al., 2009).   
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3.1.2 Choice of metals  
3.1.2.1 Copper 
Copper complexes represent a class of compounds that have been subjected to 
intensive research because of their potential therapeutic applications (Duncan and 
White, 2012) in particular as effective antitumor (Chakraborty et al., 2010: Afrasiabi 
et al., 2003) and antibacterial agents (Li et al., 2000; Joseph et al., 2012). A number 
of related thiosemicarbazone copper complexes have been found to be active in cell 
destruction, as well as in the inhibition of DNA synthesis (Ferrari et al., 2002a; 
Ferrari et al., 2002b; Bisceglie et al., 2012; Ferrari et al., 2004) Cancer cells have 
also been shown to take up greater amounts of copper than normal cells (Jansson et 
al., 2010). The altered metabolism of cancer cells and the differential response 
between normal and cancer cells to copper are the basis for the development of 
copper complexes endowed with anticancer characteristics (Gandin et al., 2013). 
Recently, copper(II) complexes of thiosemicarbazone NNSS ligands have been 
explored extensively as radiopharmaceuticals for the specific targeting of hypoxic 
tissue (Donnelly, 2011).  They are also known to be stable (Kass = 1018), neutral and 
can easily cross cellular membranes (Paterson and Donnelly, 2011; Donnelly, 2011; 
Ngarivhume et al., 2005). Copper complexes with such multidentate Schiff base 
ligands are attractive for study because of their rich spectroscopic and magnetic 
properties that often change during the course of enzyme catalysis (Ferrari et al., 
2002b). Copper also exhibits different oxidation states affirming its important role as 
a model to provide better understanding of biological metalloenzymes and 
metalloprotein systems (Balamurugan et al., 2006; Knoblauch et al., 1999; 
'ura(ková et al., 1999). For instance, the CuN2S2 chromophore is present in blue 
copper proteins such as plastocyanine (Donnelly, 2011; Sarkar et al., 2009). With 
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these examples in mind and following the interest concerning the electrochemical 
investigation into the Cu(I)-Cu(II) redox couple,  it is only logical for copper ion to 
serve as an excellent choice in the continuing search for new and effective 
metallodrugs.  
 
3.1.2.2 Zinc 
In addition to Cu(II) complexes, another two metal complexes, zinc(II) and 
rhenium(I) will be presented as well. Both are important as their complexes are 
diamagnetic and this facilitates complementary methods of detection to EPR 
spectroscopy for the Cu(II) complex through the use of nuclear magnetic resonance 
(NMR) spectroscopy for Zn(II) and Re(I) species (Kirin et al., 2005). In addition, 
one of the most promising previous findings by Awidat (2005) was that bis (S-
methyl-%-N-(2-acetylfuran)dithiocarbazate) (SMDB) complexed with zinc was 
found to shown remarkable selectivity towards brain cancer cells with a toxicity 
towards normal cells that was relatively much lower than tamoxifen, the current 
drug of choice in the treatment of brain cancer. The IC50 values for SMDB-Zn on 
glioma cell lines A172, U87MG, T98G and normal brain cell line HCN-2 were at 
3.7 !g/mL, 1.76 !g/mL, 2.7 !g/mL and 7 !g/mL, respectively (Awidat, 2005). 
Zn(II) complexes of the analogous bis(thiosemicarbazone) were also found to be 
weakly fluorescent owing to intraligand excitation and this fluorescence has been 
used to track the uptake and intracellular distribution of the Zn(II) complexes in 
diverse cancer cell lines (Lim et al., 2010). The understanding of intracellular 
distribution of these complexes is important to design compounds that are selective 
towards specific tissues and organelles (Holland et al., 2007). 
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3.1.2.3 Rhenium 
Although different dithiocarbazate metal complexes have been investigated, few 
works deal with Re complexes (Mevellec et al., 2002; Boschi et al., 2010) and none 
has yet to report on a Re(I) tricarbonyl core. Much significant progress in targeted 
rhenium (Re-188 and Re-186) radiopharmaceuticals recently has focused on the use 
of the Re carbonyl core (Donnelly, 2011). The use of radionuclides has increased the 
demand for new complexes containing carrier-free radionuclides having reasonable 
half lives and proper energy of radiation (Fuks et al., 2010). The carbonyl approach 
exploits the stability of the metal tricarbonyl core whilst allowing a variety of bi- 
and tridentate ligands to react with it to further functionalize these with 
biomolecules or targeting vectors (Donnelly, 2011; Amoroso et al., 2007; Santos et 
al., 2004; Clède et al., 2013). Because of the small size and charge of the  fac-
Re(CO)3+ group, it does not significantly influence biological properties of even the 
smallest biomolecules used in the synthesis of radiopharmaceuticals making it an 
attractive candidate not just for medicinal therapeutic application but also as 
diagnostic agents (Fuks et al., 2010; François et al., 2014; Clède et al., 2012) For 
instance, an innovative approach to prepare a rhenium tricarbonyl complex with a 4-
(2-pyridyl)-1,2,3-triazole (pyta) ancillary ligand endowed with luminescent and 
infrared properties allowed a relevant bio-imaging correlative study using both 
infrared (IR) and luminescence modalities (Clède et al., 2012). Vibrational 
spectroscopies are attractive for bio-imaging as in the case of vibrational excitations 
in the IR region where no photo-bleaching is induced in contrast to what is observed 
with organic fluorophores in the visible or UV-range. Furthermore, IR-probes also 
show advantages in their stability in biological environments and intense absorption 
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in the 1800-2200 cm"1 range which is the transparent IR window of biological media 
(Clède et al., 2013; Clède et al., 2012; Policar et al., 2011).  
 
3.2 Methodology 
3.2.1 Materials 
All chemicals and solvents were of analytical grade and were used as received 
without further purification. Common solvents for solution synthesis were obtained 
from either Carlo Ebra or VMR. Anhydrous DMF was from Sigma Aldrich or Acros 
Organics and DMSO of HPLC grade was from Alfa Aesar. Chemicals: Benzyl 
chloride (Aldrich), iodomethane (Merck), potassium hydroxide (Merck), 
hydrazinium hydroxide (Merck), carbon disulfide (Merck), 2,5-hexanedione 
(Merck), methyl levulinate (Alfa Aesar), levulinic acid (Janssen), 4-
carboxylbenzaldehyde (Acros Organics), 3-acetylcoumarin (Aldrich), copper (II) 
acetate monohydrate (HmbG chemicals), zinc (II) acetate (Touzart), rhenium (I) 
pentacarbonyl chloride (Strem chemicals), tetrabutylammonium perchlorate (Fluka), 
tetrabutylammonium hexafluorophosphate (Fluka). SBDTC and SMDTC were 
prepared as previously reported (Chan et al., 2008; Chew et al., 2004).  
 
3.2.2 Instrumentation 
The IR spectra were recorded in the range of 550–4000 cm"1 on a Perkin-Elmer 100 
series FT-IR spectrophotometer in ATR mode. Microanalyses were carried out using 
either a Leco CHNS-932 analyzer, a LECO TruSpec CHN/CHNS instrument or 
performed at the CNRS (Gif-sur-Yvette and Vernaison, France). The UV–Vis 
spectra were recorded on a Cary 300 bio spectrophotometer (200-800 nm) or Perkin 
Elmer Lambda 45 with a 1 cm optical path quartz cuvette. 1H NMR and 13C NMR 
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spectra were recorded with Bruker DRX300 spectrometers. The chemical shifts 
(!/ppm) were calibrated relative to residual solvent signals. Electrospray-ionization 
(ESI) mass spectra were recorded with a Finnigan Mat 95S in the BE configuration 
at low resolution. High resolution (HR) mass spectra were obtained on a JEOL MS 
700 spectrometer (CI or FAB) or on a Bruker hybride APEX spectrometer. EPR 
spectra were recorded on an X-band Bruker Elexsys 500 spectrometer equipped with 
a continuous flow helium cryostat (Oxford Instruments) and a temperature control 
system. The field modulation frequency was 100!kHz. The spectra were all recorded 
under non-saturating conditions. Cyclic voltametry (CV) measurements were 
recorded under argon using a 620C electrochemical analyzer (CH Instruments, Inc). 
The working electrode was a glassy carbon disk, a Pt wire was used as counter-
electrode and the reference electrode was an Ag/AgCl electrode (0.223!V versus 
NHE). Immediately before the measurement of each voltammogram, the working 
electrode was carefully polished with alumina suspensions (1, 0.3 and 0.05 !m, 
successively), sonicated in an ethanol bath and then washed carefully with ethanol. 
The solutions were made up of 100 µL of the complexes in anhydrous deoxygenated 
DMF (0.01 M) with 0.5 mL of tetrabutylammonium perchlorate or 
tetrabutylammonium hexafluorophosphate (0.1 M) as the supporting electrolyte. 
Peak potentials, Ep, and half-wave potentials, E1/2, were referenced to the 
ferrocene/ferrocinium couple, 0.54 V in DMF versus SCE. The 
ferrocene/ferrocinium half-wave potential under the conditions used was 0.07 V.  
RP-HPLC analysis was carried out using Waters HPLC system connected to Breeze 
software that consisted of combination of a dual wavelength UV-Vis absorbance 
detector (Waters 2487) and a binary pump (Waters 1525) equipped with an 
analytical cell for reaction monitoring or purity checking. The analytical 
 measurements were performed using either a ACE C8 or C18 column (250x4.5mm) 
packed with spherical 5 µm particles of 300 Å pore size. Experiments were carried 
out at a flow rate of 1 mL min
Sample concentration
for single crystal X-ray diffraction (SCXRD) determination: 
For CuSMHD, CuSBHD and SMHD
perfluoropolyether oil and cooled rapidly to 1
analyzed using an Oxford Cryosystems C
using an Agilent Xcaliber Eos Gemini diffractometer (graphite
K& radiation, " = 0.71073 Å). Intensity data were processed with 
software suite (Pro, 2011
program SIR92 (Altomore et al., 1994)
Subsequent full-matrix least
Program Suite (Betteridge et al., 2003)
parameters of all non
difference map. Those attached to carbon atoms were repositioned geometrically. 
The H atoms were initially refined with soft restraints on the bond lengths and 
angles to regularize their geometry, after which the positions were refined 
riding constraints.  
For SBPY, SMML, SBML, SBEL, SBML, Cu(SMLA)
Re2(SBCM)2: X-ray diffraction data was collected by using a Kappa X8 APPEX II 
Bruker diffractometer with graphite
Å). The crystal was mounted on a CryoLoop (Hampton Research) with Paratone
(Hampton Research) as cryoprotectant and then flash frozen in a nitrogen
at 100 K. The temperature of the crystal was maintained at the selected value (100K) 
-1 at room temperature. Injection volume was 50 
 was approximately 1 mg/mL. Two methods were employed 
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-monochromated Mo 
). The structures were solved using the direct
 which located all non
-squares refinement was carried out using CRYSTALS 
. Coordinates and anisotropic thermal 
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within an accuracy of ±1 K by means of a 700 series Cryostream cooling device. 
The data were corrected for Lorentz polarization, and absorption effects. The 
structure was solved by direct methods using SHELXS-97 (Sheldrick, 1997a) and 
refined against F2 by full-matrix least-squares techniques using SHELXL-97 
(Sheldrick, 1997b) with anisotropic displacement parameters for all non-hydrogen 
atoms. Hydrogen atoms were located on a difference Fourier map and introduced 
into the calculations as a riding model with isotropic thermal parameters. All 
calculations were performed by using the crystal structure crystallographic software 
package WINGX (Farrugia, 1999).   
 
3.2.3 Synthesis 
3.2.3.1   Macroacyclic Cu(II) system with  tetradentate NNSS ligands 
SBHD The title compound was synthesized with some modification of the method 
described by Ali et al. (1987). 2,5-hexanedione (0.587 mL, 0.005 mol, 1 equiv) was 
added to a hot solution of SBDTC (1.983 g, 0.01 mol, 2 equiv) in absolute ethanol 
(150 mL) and the mixture was further heated for 5 min. A white precipitate was 
formed and was immediately filtered off, washed with cold ethanol and dried in 
vacuo over silica gel to yield the expected Schiff base (0.997 g, Yield 42%). 
Elemental analysis for C22H26N4S4: Calcd. C 55.66, H 5.52, N 11.80; Found C 
54.79, H 5.59, N 11.75.  1H NMR (300 MHz, DMSO-d6) ) 12.18 (s, 2H), 7.39 -7.20 
(m, 10H), 4.40 (s, 4H), 1.96 (s, 6H). 13C NMR (75 MHz, DMSO-d6) ) 197.16, 
158.26, 137.15, 129.15, 128.41, 127.05, 37.56, 34.05, 17.74. IR: # (cm-1) = 3147 (m, 
b), 1640 (w), 1054 (s), 981 (m), 828 (m). UV-Vis in DMSO: "max nm (log ! ) = 276 
(4.32), 308 (4.41), *360 (3.32, sh). RP-HPLC: RT (min) = 15.3, 18.3, 22.4. 
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SMHD SMDTC (1.222 g, 0.01 mol, 2 equiv) was dissolved in hot ethanol (150 mL) 
and 2,5-hexanedione (0.587 mL, 0.005 mol, 1 equiv) was added to this solution. The 
mixture was heated while being stirred to reduce the volume to 1/3 of the original 
volume. The mixture was kept at 4°C overnight and white precipitate was formed. 
The product was filtered off, washed with cold ethanol and dried in vacuo over silica 
gel to afford 1.129 g of SMHD (Yield 70%). The compound was further 
recrystallized from methanol and crystals suitable for X-ray diffraction analysis 
were obtained from the same solvent through slow evaporation at room temperature. 
Elemental analysis for C10H18N4S4: Calcd. C 37.24, H 5.63, N 17.37; Found C 
37.86, H 4.87, N 17.84. 1H NMR (300 MHz, DMSO-d6) ) 12.13 (s, 2H), 2.57 (s, 
4H), 2.43 (s, 6H), 2.00 (s, 6H). 13C NMR (75 MHz, DMSO-d6) ) 198.95, 157.63, 
33.97, 17.77, 16.94. IR: # (cm–1) = 3111 (m, b), 1628 (m), 1046 (s), 988 (m), 827 
(m).  UV-Vis in DMSO: "max nm (log ! ) = 276 (4.25), 305 (4.37), *360 (2.75, sh). 
RP-HPLC: RT (min) = 6.4, 11.1, 18.7. 
 
CuSBHD The copper complex was prepared by adding copper (II) acetate 
monohydrate, Cu(OAc)2.H2O (0.020 g, 0.0001 mol, 1 equiv) in acetonitrile (20 mL) 
to a solution of SBHD (0.047 g, 0.0001 mol, 1 equiv) in acetonitrile (150 mL) at 
room temperature. The solution was stirred for an hour and then concentrated to 
reduce volume before being placed at 4°C overnight. The product was filtered off to 
yield 0.039 g (Yield 73%). The compound was recrystallized from acetonitrile and 
black crystals of diffraction quality were obtained from the same solvent after 
several days through slow evaporation at 4°C. Elemental analysis for C22H25CuN4S4: 
Calcd. C 49.27, H 4.51, N 11.85; Found C 49.40, H 4.63, N 10.46. ESI-MS: m/z = 
[M+H]+ Calcd. 536.04, Found 536.02; [M+Na]+ Calcd. 558.02, Found 558.01; 
37 
 
[M+K]+ Calcd. 573.99, Found 573.98; [2M+3H]+ Calcd. 1073.08, Found 1073.04. 
IR: # (cm–1) = 1629 (m), 1606 (w), 992 (s), 955 (s), 857 (m). UV-Vis in DMSO: "max 
nm (log !) = 275 (4.37), *294 (4.26, sh), *340 (4.01, sh), *400 (3.55, sh), *600 
(2.45, sh). RP-HPLC: RT (min) = 28.5. 
  
CuSMHD The copper complex was prepared by adding Cu(OAc)2.H2O (0.200 g, 
0.001 mol, 1 equiv) in methanol (20 mL) to a hot solution of the above SMHD 
(0.322 g, 0.001 mol, 1 equiv) in methanol (100 mL). The reaction was heated until 
the volume reduced to 1/3 of the original volume and then placed at 4°C overnight. 
The product which formed was filtered off to afford 0.296 g of CuSMHD (Yield 
77%). The compound was further recrystallized from acetonitrile and black crystals 
of diffraction quality were obtained from the same solvent after several weeks 
through slow evaporation at room temperature. Elemental analysis for: 
C10H17CuN4S4: Calcd. C 31.27, H 4.20, N 14.59; Found C 31.35, H 4.24, N 14.64. 
ESI-MS: m/z = [M + H]+ Calcd. 383.97, Found 383.96; [M+Na]+ Calcd. 405.96, 
Found 405.94; [M+K]+ Calcd. 421.93, Found 421.92. IR: # (cm–1) = 1628 (m), 
1611(w), 1000 (s), 964 (s), 821 (m). UV-Vis in DMSO: "max nm (log !) = 273 (4.34), 
*294 (4.24, sh), *340 (3.99, sh), *400 (3.49, sh) *600 (2.43, sh). RP-HPLC: RT 
(min) = 23.3.  
 
SBPY SBPY was a side product from the initial attempt to synthesize SBHD. 
Prolonged heating and purification via column chromatography caused the desired 
compound to undergo cyclization forming a pyrrole. Single crystals of diffraction 
quality were obtained from DMSO and analyzed by single crystal X-ray diffraction. 
ESI-MS: m/z = [M + H]+ Calcd. 277.08, Found 277.08; [M + Na]+ Calcd. 299.07, 
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Found 299.06.  1H NMR (300 MHz, DMSO-d6): ! (ppm) = 12.29 (s, 1H), 7.45 – 
7.20 (m, 5H), 5.69 (s, 2H), 4.45 (s, 2H), 2.00 (s, 6H). 13C NMR (75 MHz, DMSO-
d6): ! (ppm) = 204.09, 136.30, 129.02, 128.55, 127.43, 126.50, 104.34, 38.17, 
10.99. IR: # (cm–1) = 3264 (m), 2917 (w), 1055 (s), 972 (w), 828 (w). UV-Vis in 
DMSO: "max nm (log ! ) = 282 (4.02). RP-HPLC: RT (min) = 22.3.  
 
3.2.3.2 Open chain Cu(II) system with bidentate NS ligands with acid or ester   
functionality 
Preparation of ligands  
The general procedure used to prepare the ligands can be summarized as follows: to 
a solution (the solvent differs depending on the compound; each is reported below) 
of S-substituted dithiocarbazate, an equimolar amount of levulinic acid/ methyl 
levulinate/4-carboxybenzaldehyde (dissolved in the same solvent) was added 
dropwise. The mixture was heated to reduce the volume by about 1/3 of the original 
volume and then placed in the refrigerator overnight. The products formed were 
filtered, washed with diethyl ether and dried in vacuo over silica gel. Each 
compound was recrystallized from the solvent used for its synthesis and crystals 
suitable for X-ray diffraction analysis were obtained from the same solvent through 
slow evaporation at room temperature. The structures of four ligands were 
successfully solved by SCXRD analysis. The purity and stability of the products 
dissolved in the minimum quantity of CH3OH or DMSO-water mixture were 
checked by RP-HPLC.  
 
SMML 1.222 g (0.01 mol, 1 equiv) of SMDTC was solubilized in 100 mL of hot 
ethanol. An equimolar amount (1.22  mL, 0.01 mol, 1 equiv) of methyl levulinate 
was added dropwise to the solution of the dithiocarbazate, heated and stirred for one 
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to two hours until the volume was reduced to yield 1.062 g of product (Yield 45 %). 
HR-MS: m/z = [M+Na]+ Calcd. 257.03889, Found 257.03934. 1H NMR (300 MHz, 
CD3OD) ) 3.66 (s, 3H), 2.65 (s, 4H), 2.51 (s,3H), 1.99 (s, 3H).  13C NMR (75 MHz, 
CD3OD) ) 202.68, 175.37, 156.36, 52.27, 34.23, 30.81, 30.61, 17.79, 17.31. IR: # 
(cm–1) = 3224 (m) 1717 (s) 1640 (m) 1025 (s) 990 (s) 834 (m). UV-Vis in DMSO: 
"max nm (log ! ) = 274 (3.97), 304 (4.29). RP-HPLC: RT (min) = 6.4 (SMDTC) and 
15.3 (SMML).  
 
SMLA 0.611 g (0.005 mol, 1 equiv) of SMDTC was solubilized in 50 mL of hot 
acetonitrile. An equimolar amount (0.50 mL, 0.005 mol, 1 equiv) of levulinic acid 
was added dropwise to the solution of the dithiocarbazate, heated and stirred for one 
to two hours until the volume was reduced to yield 0.357 g of product (Yield 33 %). 
HR-MS: m/z = [M+Na]+ Calcd. 243.02324, Found 243.02334. 1H NMR (300 MHz, 
CD3OD) ) 2.63 (s, 4H), 2.52 (s, 3H), 1.99 (s, 3H). 13C NMR (75 MHz, CD3OD) ) 
202.70, 176.84, 156.56, 34.39, 30.69, 17.81, 17.38. IR: # (cm–1) = 3163 (w, b) 1715 
(m) 1638 (m) 1067 (s) 923 (w) 819 (m). UV-Vis in DMSO: "max nm (log ! ) = 273 
(4.05), 304 (4.32). RP-HPLC: RT (min) = 6.3 (SMDTC) and 11.7 (SMLA).  
 
SBML 1.000 g (0.005 mol, 1 equiv) amount of SBDTC was solubilized in 50 mL of 
hot ethanol. An equimolar amount (0.61 mL, 0.005 mol, 1 equiv) of methyl 
levulinate was added dropwise to the solution of the dithiocarbazate, heated and 
stirred for one to two hours until the volume was reduced to yield 0.911 g of product 
(Yield 59 %). HR-MS: m/z = [M+Na]+ Calcd. 333.07019, Found 333.07034. 1H 
NMR (300 MHz, CD3OD) ) 7.40 – 7.20 (m, 5H), 4.44 (s, 2H), 3.47 (s, 3H), 2.61 (s, 
4H), 1.98 (s, 3H). 13C NMR (75 MHz, CD3OD) ) 200.87, 175.39, 156.61, 138.50, 
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130.53, 129.65, 128.40, 52.12, 40.01, 34.15, 30.47, 17.38. IR: # (cm–1) = 3201 (w) 
1717 (s) 1642 (w) 1029 (s) 984 (m) 782 (m). UV-Vis in DMSO: "max nm (log ! ) = 
275 (4.15), 306 (4.33). RP-HPLC: RT (min) = 15.3 (SBDTC) and 20.0 (SBML). 
 
SBLA SBDTC (2.000 g, 0.01 mol, 1 equiv) was dissolved in 100 mL of hot 
acetonitrile. An equimolar amount (1 mL, 0.01 mol, 1 equiv) of levulinic acid was 
added dropwise to the solution of the dithiocarbazate, heated and stirred for one to 
two hours until the volume was reduced to yield 1.595 g of product (Yield 54 %). 
HR-MS: m/z = [M+Na]+ Calcd. 319.05454, Found 319.05468. 1H NMR (300 MHz, 
CD3OD) ) 7.40 – 7.17 (m, 5H), 2.60 (s, 4H), 4.47 (s, 2H), 1.98 (s, 3H).13C NMR 
(300 MHz, CD3OD) ) 200.88, 176.77, 156.91, 138.70, 130.47, 129.59, 128.30, 
39.81, 34.38, 30.64, 17.44. IR: # (cm–1) = 3116 (w, b) 1698 (s) 1652 (w) 1047 (s) 
925 (s) 778 (m). UV-Vis in DMSO: "max nm (log ! ) = 275 (4.10), 306 (4.28). RP-
HPLC: RT (min) = 15.3 (SBDTC) and 17.5 (SBML).  
 
SBEL 1.000 g (0.005 mol, 1 equiv) of SBDTC was solubilized in 50 mL of hot 
ethanol. An equimolar amount (0.61 mL, 0.005 mol, 1 equiv) of levulinic acid was 
added dropwise to the solution of the dithiocarbazate, heated and stirred for one to 
two hours until the volume was reduced to yield 0.327 g of product. (Yield 44%). 
HR-MS: m/z = [M+Na]+ Calcd. 347.08584, Found 347.08601. 1H NMR (300 MHz, 
CD3OD) ) 7.39 – 7.20 (m, 5H), 4.44 (s,2H),  3.93 (q, J = 6, 2H), 2.59 (s, 3H), 1.98 
(s, 4H), 1.02 (t, J = 6, 3H).  13C NMR (75 MHz, CD3OD) ) 200.83, 174.98, 156.62, 
138.43, 130.57, 129.69, 128.43, 61.68, 40.09, 34.09, 30.64, 17.43, 14.50. IR: # (cm–
1) = 3217 (w) 1717 (s) 1642 (w) 1029 (s) 983 (m) 782 (m). UV-Vis in DMSO: "max 
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nm (log ! ) = 275 (4.11), 306 (4.30). RP-HPLC: RT (min) = 15.3 (SBDTC) and 21.1 
(SBEL).  
 
SM4CB 0.611 g (0.005 mol, 1 equiv) amount of SMDTC was solubilized in 40 mL 
of hot acetonitrile. An equimolar amount (0.751 g, 0.005 mol, 1 equiv) of 4-
carboxybenzaldehyde was dissolved in  200 mL of hot acetonitrile, added dropwise 
to the solution of the dithiocarbazate, heated and stirred for 2 hours until the volume 
was reduced to yield 0.817 g of product. (Yield 73%). HR-MS: m/z = [M+H]+ Calcd. 
255.02565, Found 255.02574. 1H NMR (300 MHz, DMSO-d6) ) 13.44 (s, 1H), 
13.16 (s, 1H), 8.29 (s, 1H), 7.92 (dd, J = 55.5, 9, 4H), 2.54 (s, 3H). 13C NMR (75 
MHz, DMSO-d6) ) 199.01, 166.83, 145.14, 137.40, 132.25, 129.90, 127.43, 16.82. 
IR: # (cm–1) = 3108 (w, b) 1688 (s) 1612 (w) 1046 (s) 927 (s) 795 (m). UV-Vis in 
DMSO: "max nm (log ! ) = 348 (4.54), *360 (4.48,sh). RP-HPLC: RT (min) = 13.3. 
 
SB4CB 0.496 g (0.0025 mol, 1 equiv) amount of SBDTC was dissolved in 20 mL of 
hot acetonitrile. An equimolar amount (0.375 g) of 4-carboxybenzaldehyde was 
dissolved in 150 mL of hot acetonitrile, added dropwise to the solution of the 
dithiocarbazate, heated and stirred for 2 hours until the volume was reduced to yield 
0.462 g of product. (Yield 56 %). HR-MS: m/z = [M+H]+ Calcd. 331.05695, Found 
331.05700. 1H NMR (300 MHz, DMSO-d6) ) 13.48 (s, 1H), 13.15 (s, 1H), 8.29 (s, 
1H), 7.89 (dd, J = 57, 9, 4H), 7.46-7.24 (m, 5H), 4.49 (s, 2H). 13C NMR (75 MHz, 
DMSO-d6) ) 197.13, 166.81, 145.47, 137.26, 136.63, 132.30, 129.90, 129.31, 
128.54, 127.50, 127.31, 37.69. IR: # (cm–1) = 3089 (w, b) 1688 (s) 1611 (w) 1036 (s) 
929 (m) 797 (s). UV-Vis in DMSO: "max nm (log ! ) = 349 (4.51), * 364 (4.44,sh). 
RP-HPLC: RT (min) = 16.8.  
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Preparation of Cu(II) complexes  
To a solution of the ligand (the solvent differs depending on the compound and is 
reported below), a solution containing an half-molar amount of Cu(OAc)2·H2O 
dissolved in methanol was added dropwise. The resulting mixture was stirred 
overnight at room temperature, concentrated and then let to stand at room 
temperature. Only for obtaining complexes with the ligands SM4CB and SB4CB, 
was the solution heated to reduce the volume by about 1/3 of the original volume 
and then let to cool to room temperature or placed in the refrigerator overnight. The 
black or brown products formed were filtered, washed with pentane and dried in 
vacuo over silica gel. The structures of two Cu(II) complexes were successfully 
solved by single crystal X-ray analysis. The purity and stability of the products 
dissolved in the minimum quantity of CH3OH/DMSO-water mixture were analyzed 
by RP-HPLC.  
 
Cu(SMML)2 0.234g (0.001 mol, 1 equiv) of SMML was solubilized in 50 mL of 
methanol. 0.100 g (0.0005 mol, 0.5 equiv) of Cu(OAc)2·H2O was then dissolved in 
10 mL of methanol, added to the ligand solution, and stirred overnight. Black solid 
was precipitated. The solid was collected by filtration, washed with pentane and 
dried to give Cu(SMML)2 (0.419 g, 79 %). Black crystals of diffraction quality were 
obtained from ethanol solution after several days through slow evaporation at room 
temperature. Elemental analysis for C16H26CuN4S4O4: Calcd. C 36.24, H 4.94, N 
10.64; Found C 36.41, H 5.03, N 10.64. ESI-MS: m/z = [M+H]+ Calcd. 530.03, 
Found 530.02; [M+Na]+ Calcd. 552.01, Found 552.00. IR: # (cm–1) = 1726 (s), 1610 
(m), 1009 (s) 983 (s) 860 (m). UV-Vis in DMSO: "max nm (log !) = 273 (4.45), 428 
(3.32), *607 (3.08,sh). RP-HPLC: RT (min) = 14.1 and 21.4. 
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Cu(SMLA)2 0.131 g (0.0006 mol, 1 equiv) of SMLA was solubilized in 25 mL of 
methanol. 0.060 g (0.0003 mol, 0.5 equiv) of Cu(OAc)2·H2O was then dissolved in 
10 mL of methanol, added to the ligand solution, and stirred overnight. The solution 
was concentrated to reduce volume, triturated with acetonitrile and allow to stand. 
Black solid was precipitated. The solid was collected by filtration, washed with 
pentane and dried to give Cu(SMLA)2 (0.065 g, 43 %).  Black crystals of diffraction 
quality were obtained from methanol after several weeks through slow evaporation 
at 4°C. Elemental analysis for C14H26CuN4S4O6: Calcd. C 31.24, H 4.87, N 10.41; 
Found C 31.58, H 4.31, N 10.48. ESI-MS: m/z = [M+H]+ Calcd. 502.00, Found 
501.99; [M+Na]+ Calcd. 523.98, Found 523.97. IR: # (cm–1) = 3660- 2160 (b) 1701 
(s) 1608 (m) 948 (s) 914 (m) 853 (m). UV-Vis in DMSO: "max nm (log !) = 270 
(4.46), 307 (4.14,sh), 428 (3.10), *488(3.00,sh) * 608 (2.85,sh). RP-HPLC: RT 
(min) = 16.6. 
 
Cu(SBML)2 0.186 g (0.0006 mol, 1 equiv) of SBML was solubilized in 30 mL of 
toluene. 0.060 g (0.0003 mol, 0.5 equiv) of Cu(OAc)2·H2O was then dissolved in 10 
mL of methanol, added to the ligand solution, and stirred overnight. The solution 
was concentrated to reduce volume, triturated with pentane and allow to stand. 
Black solid was precipitated. The solid was collected by filtration, washed with 
pentane and dried to give Cu(SBML)2 (0.131 g, 64%). Elemental analysis for 
C28H34CuN4S4O4: Calcd. C 49.28, H 5.02, N 8.21; Found C 50.07, H 5.09, N 8.31. 
ESI-MS: m/z = [M+Na]+ Calcd. 704.08, Found 704.06. IR: # (cm–1) = 1726 (s) 1614 
(m) 1009 (s) 981 (s) 764 (m). UV-Vis in DMSO: "max nm (log !) = 273 (4.51), 433 
(3.28), * 496 (3.18,sh), *608 (3.05,sh). RP-HPLC: RT (min) = 19.0 and 25.0. 
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Cu(SBLA)2 0.178 g (0.0006 mol, 1 equiv) of SBLA was solubilized in 30 mL of 
toluene. 0.060 g (0.0003 mol, 0.5 equiv) of Cu(OAc)2·H2O was then dissolved in 10 
mL of ethanol, added to the ligand solution, and stirred overnight. The solution was 
concentrated to reduce volume, triturated with pentane and allow to stand. Black 
solid was precipitated. The solid was collected by filtration, washed with pentane 
and dried to give Cu(SBLA)2 (0.125 g, 64%). Elemental analysis for 
C28H30CuN4S4O4: Calcd. C 47.72, H 4.62, N 8.56; Found C 47.15, H 4.64, N 8.51. 
ESI-MS: m/z = [M+Na]+ Calcd. 676.04, Found 676.03. IR: # (cm–1) = 3330-2300 (b) 
1698 (s) 1613 (w) 1600 (w) 948 (s) 919 (s) 763 (w). UV-Vis in DMSO: "max nm (log 
!) = 272 (4.48), 431 (3.30), *471(3.24, sh), *608 (3.05, sh). RP-HPLC: RT (min) = 
16.8 and 21.2.  
 
Cu(SM4CB)2 0.203 g (0.0008 mol, 1 equiv) of SM4CB was solubilized in 150 mL 
of hot acetonitrile. 0.080 g (0.0004 mol, 0.5 equiv) of Cu(OAc)2·H2O was then 
dissolved in 20 mL of acetonitrile, added to the ligand solution, and heated at 82°C 
(reflux temperature) with stirring for one-two hour until the volume was reduced. 
The solution was allowed to stand at 4°C overnight. Brown solid was precipitated. 
The solid was collected by filtration, washed with pentane and dried to give 
Cu(SM4CB)2 (0.167 g, 73 %). Elemental analysis for C20H18CuN4S4O4: Calc C 
42.13, H 3.18, N 9.83; Found C 41.84, H 3.39, N 9.65. ESI-MS: m/z = [M+3Na-
2H]+ Calcd. 635.91, Found 635.90; [M+2Na-H]+ Calcd. 613.93, Found 613.92; 
[M+Na]+ Calcd. 591.95, Found 591.94. IR: # (cm–1) = 3280-2320 (b) 1687 (s) 1607 
(m) 964 (m) 939 (m) 819 (m). UV-Vis in DMSO: "max nm (log !) = 322 (4.45). RP-
HPLC: RT (min) = 13.3. 
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Cu(SB4CB)2 0.1322 g (0.0004 mol, 1 equiv) of SB4CB was solubilized in 75 mL of 
acetonitrile. 0.040 g (0.0002 mol, 0.5 equiv) of Cu(OAc)2·H2O was then dissolved 
in 10 mL of acetonitrile, added to the ligand solution, and heated at 82°C (reflux 
temperature) with stirring for one-two hour until the volume was reduced. The 
solution was allowed to stand at 4°C overnight. Brown solid was precipitated. The 
solid was collected by filtration, washed with pentane and dried to give Cu(SB4CB)2 
(0.106 g, 73 %). Elemental analysis for C32H26CuN4S4O4: Calcd. C 53.21, H 3.63, N 
7.76; Found C 53.39, H 3.81, N 7.65. ESI-MS: m/z = [M+3Na-2H]+ Calcd. 787.98, 
Found 787.96, [M+2Na-1H]+ Calcd. 765.99, Found 765.98, [M+Na]+ Calcd. 744.01, 
Found 744.00. IR: # (cm–1) = 3280-2350 (b) 1687 (s) 1605 (m) 958 (m) 915 (m) 816 
(m). UV-Vis in DMSO: "max nm (log !) = 322 (4.48). RP-HPLC: RT (min) = 16.8.  
 
3.2.3.3 Open chain Cu(II) system with bidentate NS ligands with natural ketone 
moiety 
SBCM This compound was prepared by a slight modification of a previously 
reported procedure (Dawara et al., 2012). SBDTC (0.397 g, 0.002 mol) was 
dissolved in hot absolute ethanol (40 mL). An equimolar amount of 3-
acetylcoumarin also dissolved in hot absolute ethanol (0.378 g, 60 mL) was added 
dropwise to the solution of the dithiocarbazate. The mixture was heated over 2-3 
hours until finally the volume was 1/3 of the original volume to produce orange 
precipitate. The solution was allowed to stand for a few hours at 4°C. The product 
was filtered off, washed with pentane and dried in vacuo over silica gel to afford 
0.619 g of SBCM (Yield 84 %). HR-MS: m/z = [M+Na]+ Calcd. 391.05454, Found 
391.05492. 1H NMR (300 MHz, DMSO-d6) ) 12.56 (s, 1H), 12.50 (s, 0H), 8.19 (s, 
1H), 8.10 (s, 0H), 7.85 (dd, J = 7.8, 1.4, 1H), 7.77 – 7.60 (m, 2H), 7.50 – 7.21 (m, 
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12H), 4.48 (s, 2H), 4.42 (s, 1H), 2.34 (s, 3H), 2.20 (s, 1H). IR: # (cm–1) = 3025 (w) 
2872 (w) 1700 (s) 1559 (m) 1042 (m) 999 (s) 841 (m). UV-Vis in DMSO: "max nm 
(log ! ) = 286 (4.22), *342 (4.12, sh). RP-HPLC: RT (min) = 23.7. 
 
Cu(SBCM)2 The ligand (0.0368g, 0.0001 mol, 1 equiv) was dissolved in hot 
solution of ethanol:acetonitrile (2:1 ratio, 100 mL). Cu(OAc)2·H2O (0.010 g, 
0.00005 mol, 0.5 equiv) dissolved in 10 ml of ethanol was added and the reaction 
mixture was stirred at room temperature overnight. The solution was concentrated to 
reduce volume and allow to stand. Dark brown solid was precipitated. The solid was 
collected by filtration, washed with pentane and dried under vacuum to afford the 
expected complexes Cu(SBCM)2. (0.031 g, 78 %) Elemental analysis for 
C38H30CuN4S4O4: Calcd. C57.16 H 3.79 N 7.02; Found C 56.53, H 3.80, N 7.02. 
ESI-MS: m/z = [M+K]+ Calcd. 836.02, Found 836.01; [M+Na]+ Calcd. 820.04, 
Found 820.03; [M+H]+ Calcd. 798.06, Found 798.05. IR: # (cm–1) = 1726 (s) 1565 
(m) 986 (s) 965 (s) 853 (w) 839 (w). UV-Vis in DMSO: "max nm (log !) = 285 
(4.48), *341 (4.42, sh), 606 (2.95). RP-HPLC: RT (min) = 23.5 and 28.0. 
 
Zn(SBCM)2 The ligand (0.0368g, 0.0001 mol, 1 equiv) was dissolved in hot 
solution of ethanol:acetonitrile (2:1 ratio, 100 mL). Zn(OAc)2 (0.009 g, 0.00005 mol, 
0.5 equiv) dissolved in 10 ml of ethanol was added and the reaction mixture was 
stirred at room temperature overnight. The solution was concentrated to reduce 
volume allow to stand. White solid was precipitated. The solid was collected by 
filtration, washed with pentane and under vacuum to afford the expected complexes 
Zn(SBCM)2. (0.033 g, 83%) Elemental analysis for C38H30ZnN4S4O4: Calcd. C 
57.03, H 3.78, N 7.00; Found C 56.49, H 3.84, N 7.10. ESI-MS: m/z = [M+H]+ 
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Calcd. 799.1, Found 799.5. 1H NMR (300 MHz, DMSO-d6) ) 8.22 (s, 2H), 7.76 (t, J 
= 7.1, 4H), 7.52 (dd, J = 16.7, 8.4, 4H), 7.36 – 7.20 (m, 10H), 3.87 (s, 4H), 2.53 (s, 
6H). IR: # (cm–1) = 1706 (s) 1567 (m) 984 (s) 952 (m) 843 (w). UV-Vis in DMSO: 
"max nm (log !) = 292 (4.50), *344 (4.41, sh). RP-HPLC: RT (min) = 23.4. 
 
Re(SBCM)2  
The ligand (0.074 g, 0.0002 mol, 1 equiv) was dissolved in toluene (30 mL) at 110 
°C. Re(CO)5Cl (0.072 g, 0.0002 mol, 1 equiv) was added and the reaction mixture 
was refluxed overnight. A yellow precipitate appeared. The reaction was cooled 
down to room temperature, filtered and the solid was washed with toluene.  The 
solid dried under vacuum to afford the expected complexes (0.0441 g, 33 %). 
Yellow-orange crystals of diffraction quality were obtained from toluene after 
several weeks through slow evaporation at room temperature.  Elemental analysis 
for C44H30ReN4S4O10: Calcd. C 41.44, H 2.37, N 4.39; Found C 40.04, H 2.41, N 
4.43. ESI-MS: m/z = [M+H]+ Calcd. 1275.00, Found 1275.00, [M+Na]+ Calcd. 
1296.98, Found 1296.98. 1H NMR (300 MHz, DMSO-d6) ) 1H NMR (300 MHz, 
DMSO) ) 8.30 (s, 2H), 7.73 – 7.65 (m, 4H), 7.50 – 7.40 (m, 8H), 7.38 – 7.24 (m, 
7H), 4.45 (s, 4H), 2.52 (s, 4H). IR: # (cm–1) = 2017 (s) 1914 (s) 1892 (s) 1724 (s) 
1566 (m) 1022 (m) 1004(m) 846 (w) UV-Vis in DMSO: "max nm (log !) = 2.86 
(4.53), *325 (4.44,sh). RP-HPLC: RT (min) = 25.7. 
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3.3 Results and discussion 
3.3.1. Synthesis  
The synthesis of S-substituted dithiocarbazates were performed as already described 
(Chan et al., 2008; Chew et al., 2004). Carbon disulfide and hydrazine were reacted 
in basic ethanolic conditions. After workup the expected dithiocarbazate was 
directly engaged into the nucleophilic substitution with methyl iodide or benzyl 
chloride to afford SMDTC and SBDTC, respectively. The tetradentate NNSS Schiff 
base ligands were then prepared with variations from the method described by Ali et 
al. (1987) involving the condensation reaction between the respective S-substituted 
dithiocarbazates and 2,5-hexanedione in 2:1 ratio (Scheme 3.1: a-d). The initial 
attempt to synthesize the ligand SBHD with prolonged heating or purification using 
column chromatography showed that this compound underwent cyclization to its 
pyrrole derivative as confirmed by NMR, ESI, elemental analysis and single crystal 
X-ray diffraction. The bis(dithiocarbazate) was postulated to form first, subsequently 
hydrolyzed into mono(dithiocarbazate) and SBDTC (Patel et al., 2009; Chaviara et 
al., 2005). It is likely that the mono(dithiocarbazate) then underwent cyclization to a 
pyrrole via the Paal-Knorr reaction. However, such a side reaction was not 
previously described during the formation of bis(thiosemicarbazone) with 2,5-
hexanedione (Gingras et al., 1962) although there have been reports of the formation 
of pyrazole upon reaction with 1,3-diketones (Ali et al., 2013b; Iskander et al., 1982; 
Casas et al., 2008; Centore et al., 2013) and others cyclic byproducts from related 
reactions (Christlieb and Dilworth, 2006; Ali et al., 2013a). To our knowledge, this 
is the first description of a pyrrole derived from a dithiocarbazate. Encouraged by 
the remarkable pharmacological properties of functionalized pyrrole (Liu et al., 
2008; Fürstner, 2003), the compound was tested for its antimicrobial activity and the 
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results are discussed in Chapter 5. The Schiff base SBHD was finally obtained by 
either stirring the dione and SBDTC at room temperature for 30 min or by heating 
for only 5 min. 
                                                
Scheme 3.1. Synthesis of the non-conjugated parent compounds. (a) CS2, KOH, 
EtOH, 0°C, 1 hr (b) CH3I or PhCH2Cl, EtOH, 0°C, 5 hr (c) For SMHD (2,5- 
hexanedione, EtOH, 79°C, 1 hr), for SBHD (2,5 hexanedione, EtOH, 79°C, 5 
min) (d) For CuSMHD (Cu(OAc)2·H2O, MeOH, 65°C , 1hr), for CuSBHD 
(Cu(OAc)2, acetonitrile, r.t., 1hr). (e) For SMML and SBML (methyl levulinate, 
EtOH, 79°C, 1 hr), for SMLA and SBLA (levulininc acid, acetonitrile, 82°C, 
1h), for SM4CB and SB4CB (4-carboxy benzaldehyde, acetonitrile, 82°C, 2h)  
(f) For Cu(SMML)2  and Cu(SMLA)2 (Cu(OAc)2·H2O, MeOH, r.t, overnight), 
for Cu(SBML)2  and Cu(SBLA)2 (Cu(OAc)2·H2O, toluene, r.t, overnight), for 
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Cu(SM4CB)2 and Cu(SB4CB)2 (Cu(OAc)2·H2O, acetonitrile, 82°C, 2h). (g) 3-
acetylcoumarin, EtOH, 79°C, 2 hr. (h) Cu(OAc)2·H2O or Zn(OAc)2,  
EtOH:ACN (2:1 ratio), r.t, overnight   (i) Re(CO)5Cl, toluene, 110 °C, 
overnight.  
 
White precipitates were formed. The SMHD ligand was synthesized by heating to 
reduce the volume without the occurrence of such side reaction. The expected 
compound SMHD that precipitated was filtered off and recrystallized to afford pure 
SMHD with good yields. The tetra-coordinated Cu(II) complexes with NNSS 
coordination of these ligands were obtained from the reaction of copper(II) acetate 
with equimolar amounts of the respective ligand in acetonitrile for SBHD and in 
methanol for SMHD. The complexes were isolated by filtration with yields of 77% 
and 73% for CuSMHD and CuSBHD, respectively. Black crystals were grown from 
acetonitrile.   
 
Six bidentate Schiff base ligands with acid or ester functionality were prepared via 
the condensation reaction between the respective S-substituted dithiocarbazates and 
carbonyl compounds in equimolar amount (Scheme 3.1: a,b,e-f).The reactions with 
methyl levulinate were carried out in ethanolic solution at 79°C whereas the 
reactions involving both levulinic acid and 4-carboxybenzaldehyde containing the 
acid-COOH functionality were done in hot acetonitrile solution. The attempt to 
synthesize the ligand SBLA in ethanol did not yield the expected compound. 
Instead, an esterification reaction occurred with the concomitant formation of a 
ligand bearing an ethyl ester (SBEL). The reaction of copper(II) acetate salts with 
the Schiff base ligands in 1:2 ratio yielded crystalline complexes of the formula, 
CuL2 in which the ligands were bidentate. Depending on the ligands, different 
reaction conditions have been set up in order to optimize the yield and purity of the 
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complexes. Early trials at high temperature and and in polar alcoholic solution often 
resulted in oily products and further efforts to crystallize the complexes were futile. 
The structures of four Schiff bases (SMML, SBML, SBEL, SBLA) and two Cu (II) 
complexes, Cu(SMML)2 and Cu(SMLA)2 were confirmed by single-crystal X-ray 
analyses.   
 
The synthesis of the bidentate NS Schiff base with natural ketone moiety, SBCM 
and its proposed structures of metal complexes are schematically represented in 
Scheme 3.1 (a,b,g-i). The complexes Cu(SBCM)2 and Zn(SBCM)2 were prepared by 
reacting SBCM with metal(II) acetate in ethanol:acetonitrile (2:1 ratio) solution 
mixture at room temperature whereas the adduct, Re2(SBCM)2, was obtained by 
refluxing the free ligand with ReCl(CO)5 in toluene. The single crystal of the Re(I) 
complex was also grown from toluene.  
 
The purity and stability of the ligands and their corresponding complexes at 
physiological pH are important prerequisites for the evaluation of their biological 
activity. Therefore RP-HPLC experiments have been performed to gain insights into 
their stability in aqueous solutions. The tetradentate ligands and their respective 
Cu(II) complexes were eluted on a C18-column with an increasing amount of 
acetonitrile (CH3CN) in H2O (from 5% to 100% of CH3CN over 30 minutes), 
containing 0.1 % trifluoroacetic acid (TFA) to maintain the pH. The compounds 
were detected using a UV detector at 220 nm and 280 nm. The chromatograms of 
the pure ligands of the tetradentate series showed 3 peaks that could correspond 
respectively to the hydrolyzed hydrazone, the expected ligand and the pyrrole 
byproduct (Figure 3.1) whereas the complexes showed only a single peak 
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corresponding to the copper complexes (Figure 3.2). The bidentate series with acid 
or ester functionality were also eluted on a RP-HPLC C8-column with a solvent 
system similar to those used for the tetradentate ligands. For the aliphatic Schiff 
bases (SMML, SMLA, SBML, SBLA, SBEL), the chromatograms of the ligands 
showed two peaks corresponding to the starting S-substituted dithiocarbazate and 
the expected ligand whereas the complexes showed mainly a single peak 
corresponding to the copper complexes. Another peak (the intensity differed from 
one compound to the other) was also visible for the copper(II) complexes that may 
be due to either isomerization or to dissociation to 1:1 Cu:L complexes. The 
chromatograms of SMML and Cu(SMML)2 are shown in Figure 3.3 and 3.4 
respectively as examples, the rest of the chromatograms can be found in the 
Appendices. The aromatic acid Schiff bases (SM4CB and SB4CB) on the other hand 
showed only one peak corresponding to the ligands which indicated their enhanced 
stability as compared to their aliphatic counterparts (Figure 3.5). Similiarly, the 
chromatograms of SBCM and its complexes showed mainly a single peak 
highlighting the stability of the aromatic coumarin derivatives. In conclusion, the 
observations indicated that the -C=N- hydrazone bond in the aliphatic free ligands 
could undergo hydrolysis but when complexed, the stability of the ligands was 
significantly increased in acidic conditions and it appears clearly that aromatic 
Schiff bases were more stable. The difference in the ligands and metal complexes 
stability is noteworthy as metal-complexation could then be used as a mean to 
protect the ligand from degradation that could occur in the biological before it could 
reach its target. 
53 
 
 
Figure 3.1. RP-HPLC chromatogram of SBHD at 220 nm (top) and 280 nm 
(bottom).  
 
 
Figure 3.2. RP-HPLC chromatogram of CuSBHD. 
 
 
 Figure 3.3. RP-HPLC chromatogram of SMML. 
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Figure 3.4. RP-HPLC chromatogram of Cu(SMML)2. 
 
Figure 3.5. RP-HPLC chromatogram of SM4CB. 
 
The proposed structures and stoichiometry was initially established by elemental 
analysis and mass spectrometry. The analytical data for the metal complexes agreed 
well with the formulations proposed. All the mass spectra show signals 
corresponding to the molecular weight of either the protonated complexes or the 
complexes with sodium or potassium. These results confirm 1:1 metal to ligand 
stoichiometry for CuSMHD, CuSBHD and a dimeric Re2(SBCM)2 whereas 
Cu(SMML)2, Cu(SMLA)2, Cu(SBML)2, Cu(SBLA)2, Cu(SM4CB)2, Cu(SB4CB)2, 
Cu(SBCM)2 and Zn(SBCM)2 demonstrated  1:2 metal to ligand stoichiometry. Upon 
complexation of metal ion with S-substituted dithiocarbazate derived Schiff base 
ligand, a deprotonation of the nitrogen of the dithiocarbazate is expected, leading to 
an iminothiolate. Coordination via NS atoms would be anticipated. However, the O 
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atom present in the ligands containing acid, ester or coumarin moiety could also 
potentially participate in metal coordination. In order to confirm the formation of the 
metal complexes and to characterize them, several other techniques were employed. 
 
3.3.2 Characterization of metal complexes in solid state 
3.3.2.1 FT-IR 
Two examples of the FT-IR spectra used to monitor complexation, one from 
tetradentate series and the other from bidentate series are shown in Figure 3.6 and 
3.7, respectively. The IR spectra for the rest of the compounds can be found in the 
Appendices. The IR spectra of the tetradentate ligands and bidentate SMML and 
SBML ligands exhibit characteristic bands +NH at ca. 3130 and 3200 cm-1, 
respectively. Strong broad structured bands spanning from around 3300–2300 
cm"1 appeared in the spectra of the ligands SMLA, SBLA, SM4CB and SB4CB 
which contained the acid functionality and their respective Cu(II) complexes due 
to +OH, +NH and +CH overlapping stretching vibrations. The IR spectrum of 
coumarin-derived SBCM however showed only a weak band at 
3056 cm"1 assignable to #(NH) stretching. Another band attributed to #(SH) was 
noticeable at 2872 cm"1. These observations demonstrated that while most of the 
ligands existed in thione form, SBCM existed in both thione and thiolate forms in 
the solid state. In addition, all the ligands possess bands +(C=N) at 1652-1559 cm-1, 
+(C=S) at 1067-1025 cm-1, +(CSS) at 990-923 cm-1and v(NN) at 841-778 cm-1. 
Upon formation of the complexes, the band corresponding to the +(NH) stretching of 
the ligands disappeared. The +(C=N) attributed to azomethine bond was observed to 
experience a downward shift of 5-40 cm-1  in most of the spectra with the exception 
of metal complexes of SBCM that shifted to higher wavenumbers (~1566 cm-1). A 
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second band due to +(N=C) in complexes containing anionic dithiocarbazate 
moieties was also resolved (Rapheal et al., 2007) for CuSMHD, CuSBHD and 
Cu(SBLA)2. The hydrazinic +(N-N) band also shifted to either higher and lower 
wavenumbers upon complexation. All these observations indicates the deprotonation 
of the Schiff base ligands and coordination via the azomethine nitrogen atom during 
complexation with metal ion which resulted in the adoption of a more stable 
structure where the conjugated system was elongated in the complexes as compared 
to the free ligands. The disappearance of +(C=S) and the splitting of the asymmetric 
+(CSS) band into two peaks in the spectra of the all metal complexes were strong 
evidence of coordination via the thiolate sulfur atoms (Crouse et al., 2004; Akbar Ali 
and Tarafdar, 1977). In the bidentate series, the strong band at 1717-1687 cm"1 of 
the ligands can be assigned to the carbonyl +(C=O). The band remained unchanged 
upon complexation in the spectra of Cu(SM4CB)2, Cu(SB4CB)2 and Cu(SBLA)2 but 
slightly shifted for Cu(SMML)2, Cu(SBML)2, Cu(SMLA)2, Cu(SBCM)2, 
Zn(SBCM)2 and Re2(SBCM)2. Despite the shift in wavenumbers, the X-ray 
structures solved for Cu(SMML)2, Cu(SMLA)2 and Re2(SBCM)2 revealed that the 
metal ions were coordinated by the bidentate ligands via only the azomethine 
nitrogen and thiolate sulfur atoms. No coordination via the carbonylic oxygen was 
observed. Such a shift can be interpreted as being caused by the vibrational coupling 
of the C=O in the solid state H-bonded structure (Ferrari et al., 2000). Single crystal 
X-ray analyses of the ligands and complexes indicated the formation of 
intermolecular hydrogen bonds involving the carbonylic oxygen and the presence of 
other short contacts. Previous publications had also reported comparable shifting 
that did not correspond to coordinated O atoms (Creaven et al., 2009). Fac-geometry 
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around the rhenium atom is also confirmed by the three characteristic Re-(CO) 
vibrations at 2017, 1914 and 1892 cm-1. 
 
Figure 3.6. FT-IR spectra recorded for ligand SBHD and complex CuSBHD. 
 
Figure 3.7. FT-IR spectra recorded for ligand SMML and complex 
Cu(SMML)2. 
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3.3.2.2 Single crystal XRD description  
The ORTEP diagrams of the compounds in the tetradentate series SBPY, SMHD, 
CuSMHD and CuSBHD with atomic numbering schemes are shown in Figure 3.8. 
Selected bond lengths and bond angles are depicted in Table 3.1 and 3.2. 
 
  
 
Figure 3.8. ORTEP drawing of (a) SMHD (b) SBPY (c) CuSMHD and (d) 
CuSBHD. Ellipsoids are drawn at the 50% probability level. 
 
 
 
 
(a) (b) 
(d) 
(c) 
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Table 3.1. Selected bond lengths for SBPY, SMHD, CuSMHD and CuSBHD. 
 
Compound Bond lengths  (Å) 
 C=S C-S C-N N-N C=N 
SMHD 1.657(4) 1.763(3) 1.337(4) 1.392(3) 1.281(4) 
CuSMHD 1.738(2), 
1.737(1) 
1.753(1), 
1.758(2) 
1.290(2), 
1.289(2) 
1.407(1), 
1.418(2) 
1.288(2), 
1.292(2) 
CuSBHD 
 
1.734(2), 
1.740(2) 
1.758(2), 
1.756(2) 
1.287(2), 
1.287(2) 
1.418(2), 
1.401(2) 
1.291(2), 
1.284(2) 
SBPY 1.647(2) 1.748(2) 1.354(2) 1.380(2) 1.386(2), 
1.389(2) 
 N-Cu N-Cu S-Cu S-Cu N-Cu 
CuSMHD 2.071(1) 1.993(1) 2.246(4) 2.266(4) 2.071(1) 
CuSBHD 1.978(1) 2.056(1) 2.252(4) 2.248(4) 1.978(1) 
  
Table 3.2. Selected bond angles for CuSMHD, CuSBHD, CuATSM (Blower et 
al., 2003) and CuAATSM (Cowley et al., 2004). 
 
Bond angles (°) CuSMHD CuSBHD CuATSM CuAATSM 
S-Cu-N 85.75(3) 84.36(4) 85.13 86.79(5) 
N-Cu-N 104.21(5) 99.61(5) 80.60 96.10(7) 
N-Cu-S 84.89(3) 85.26(4) 85.11 85.60(5) 
S-Cu-S 92.80(2) 91.67(2) 109.23 91.74(2) 
 
The crystal structure of SMHD reveals an (E, E’) conformation with respect to the 
hydrazone bond and a center of symmetry at the middle of the C7-C7’ single bond. 
The molecule crystallized in trans-cis configuration around the S(NH)C=S moiety 
(highlighted in Figure 3.8 (a)) very similar to most Schiff bases derived from 
dithiocarbazate (Low et al., 2013; Ravoof et al., 2007). The S-methyl group was cis 
across the C2-S1 bond while the ketone moiety was trans along the C2-N4 bond 
with respect to the terminal thione S atom. The bond lengths N5-C6 (1.281 Å) and 
S3-C2 (1.657 Å) are consistent with a double-bond of a hydrazone and a 
thiocarbonyl, respectively. The values are comparable to related NNSS tetradentate 
ligands (Jasinski et al., 2003; Xu et al., 2002; Paterson et al., 2010). The bond 
lengths N4-C2 (1.337 Å) and S1-C9 (1.763 Å) are shorter than typical covalent 
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single-bond distance (N-C 1.47 Å and C-S 1.81 Å), indicating higher order bond 
character. This can result from delocalization of electron density within the 
dithiocarbazate S1-C2(=S3) and N4-C2(=S3) ,-systems. The ligand appears 
essentially planar in the solid state and no hydrogen bonding was observed. The 
pyrrole byproduct SBPY crystallized in a monoclinic system with a space group of P 
21/c. The central C7S1C8S2N1 residue is planar while both the benzyl and pyrrole 
rings are inclined to this plane forming interplanar angles of 71.87o and 88.30o, 
respectively. A comparison of the selected bond lengths and bond angles with 
SMHD show that the molecule also crystallized in trans-cis configuration around the 
S(NH)C=S moiety similar to the Schiff bases with intermediate bond length 
indicative of extensive conjugation and ,-delocalization over the molecules and 
other intermolecular interactions. 
 
It is expected that the Cu(II) ion would be four-coordinated by the ligands in their 
iminothiolate form. N-deprotonation is typical in dithiocarbazate Schiff base 
coordination chemistry (Manan et al., 2011b; Jasinski et al., 2003; Paterson et al., 
2010). Tautomerism of the dithiocarbazate ligand to its iminothiolate form is also 
anticipated to convert the C=S bond to a single C–S bond but in most cases the bond 
length lies between the C-S single bond (1.82 Å) and C=S double bond (1.56 Å) 
indicative of a partial double bond character (Ravoof et al., 2007). This is the case 
for both complexes where the C-S distance is 1.738 Å and 1.734 Å for CuSMHD 
and CuSBHD, respectively. The increase in the C-S bond distance as compared to 
the uncoordinated neutral ligand showed that the ligand is dianionic upon 
coordination. In addition, the C2-N4 bond length is about 1.337 Å in the free ligand 
whereas this bond shortened in both metal complexes (1.290 Å and 1.287 Å for 
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CuSMHD and CuSBHD, respectively) suggesting an enhancement of their double 
bond character. In order to accommodate the metal, the ethylene from the 
hexanedione adopts a gauche conformation forming a seven-membered chelate ring 
surrounding the Cu ion. It has been reported that seven membered chelate rings with 
two hydrazone bonds have a tendency to favour tetrahedral coordination of metal 
ions (Nandi et al., 1984). The deviation from planarity can be assessed by measuring 
the sum of the four angles, N-Cu-S, S-Cu-S, S-Cu-N and N-Cu-N, for which 360° 
would be obtained for an ideal planar arrangement and 437.6° for an ideal 
tetrahedral arrangement (Knoblauch et al., 1999). The sum of these angles around 
the central copper metal in this complex are consistent with a slightly distorted 
square planar geometry with CuSMHD showing a more significant distortion than 
CuSBHD (367.65° and 360.9° respectively). The interplanar angles between two N-
Cu-S planes of 35.65° and 31.22° for CuSMHD and CuSBHD, respectively, 
confirms that CuSBHD is the more planar molecule. The Cu-N (1.98-2.07 Å) and 
Cu-S (2.24-2.27 Å) bond distances of both CuSMHD and CuSBHD are almost 
similar to the typical Cu(II) N2S2 complexes of related ligands (Blower et al., 2003; 
Cowley et al., 2004). When compared with other Cu(II) complexes of the same 
family with zero (CuATSM), one (CuAATSM) or two carbons (CuSMHD and 
CuSBHD) linking the two hydrazones, it appears clearly that the distortion from 
planar geometry increases with the number of carbons (360.07°, 360.23°, 360.9° and 
367.65° for CuATSM, CuAATSM, CuSBHD and CuSMHD respectively).  
 
Since the substituents are remote from the metal center, the solid state structures of 
the two complexes are almost identical. In the crystallographic lattice, the two 
benzyl groups adopt different orientations (syn/anti) with respect to their adjacent 
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coordinated S-donor atoms similar to the Cu(II) complex reported by Ali et al. 
(2013b). Together these data show that the tetradentate Cu(II) complexes are indeed 
formed and adopt a slightly distorted square planar geometry. 
 
The crystal structures of the Schiff base ligands (SMML, SBML, SBEL, SBLA) and 
two Cu(II) complexes (CuSMML and CuSMLA) with their atom numbering 
schemes and intermolecular hydrogen bonds are shown in Figures 3.9 and Figure 
3.10. Selected bond lengths and bond angles are given in Tables 3.3 to 3.8. 
(a) 
?
 
 ?
 
(b) 
 
  
Figure 3.9. ORTEP diagrams and intermolecular hydrogen bonds (shown as 
dotted line) of (a) SMML and (b) SBLA?? Ellipsoids are drawn at the 50% 
probability level. 
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(c) 
  
(d) 
 
 
Figure 3.9 (continued). ORTEP diagrams and intermolecular hydrogen bonds 
(shown as dotted line) of (c) SBML (d) SBEL. Ellipsoids are drawn at the 50% 
probability level. 
 
SBML and SBEL crystallized in space group of P 21/n whereas SMML and SBLA 
crystallized in space groups P 21/c and P-1, respectively. The Schiff bases are in the 
thione form with C=S bond distances ranging from 1.662 to 1.681 Å. As observed 
for the tetradentate ligands, the bond lengths were intermediate between a C–S 
single bond and a C=S double bond possibly due to the extensive conjugation over 
the C=N-N-C chain and other intermolecular interactions. The N-N bond distance 
varied from 1.378 to 1.394 Å in the Schiff bases, showing that the bond was shorter 
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than a single bond, indicating significant ,-charge delocalization along the 
dithiocarbazate moiety. The attachment of the methyl levulinate/levulinic acid 
groups to the imino nitrogen atoms was probably responsible for the shortening of 
the N-N distance. Trans-cis conformation was observed in all the Schiff bases 
around the -SC(=S)NH- moiety. The methyl levulinate/levulinic acid moiety was 
trans with respect to the terminal thione S atom about the C-N bond while the S-
methyl/S-benzyl group was cis with respect to the terminal thione S atom about the 
C-S bond. The bond angles in the Schiff bases were close to 120º consistent with sp2 
hybridization. The C"O (carbonylic) and C"O (hydroxylic) distances of 1.21 and 
1.33 Å demonstrate typical localized bonds like those reported for carboxylic groups 
in thiosemicarbazone &-ketoglutaric acid (Ferrari et al., 2002a).  
 
SMML and SBLA featured centrosymmectric H-bonded dimeric motifs held by 
strong intermolecular hydrogen bonds (N–H···O, 2.932 Å) and (O-H·· ·O, 2.662 Å), 
respectively. The (N-H·· ·O) motif was also observed in SBML and SBEL but they 
were different from the dimeric SMML. Two (N–H···O) bonds linked the dimeric 
SMML together while the individual (N-H···O, 2.902 Å for SBEL and 2.933 Å for 
SBML) bond from one ligand were linked to two separate ligands forming a 
continuous chain in both SBML and SBEL.  
  
The Schiff bases are also not planar. Both the benzyl rings and the methyl 
levulinate/levulinic acid moieties are in a twisted conformation at particular angles. 
A remarkable difference in the Schiff bases is the orientation of the 
=C(CH3)CH2CH2COOR chains (where R = H, CH3, CH2CH3 ) highlighted by the 
varied inclination angles between the allylic (=C(CH3)CH2CH2) and the terminal 
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carbocyclic acid/ester (-COOR) planes. The deviation from planarity between the 
two plans can be arranged as SBLA< SBML < SBEL < SMML while the order of 
planarity of the dithiocarbazate plane with respect to the allylic plane in the Schiff 
bases can be placed as follows SBLA > SMML > SBML > SBEL. The benzyl ring 
in all S-benzyl derivatives was almost perpendicular to the dithiocarbazate plane. 
The perpendicularity of the benzyl ring towards the dithiocarbazate plane can be 
ordered SBLA > SBEL > SBML.  
 
Table 3.3. Selected bond lengths for SMML, SBML, SBEL and SBLA. 
 
Compound Bond lengths  (Å) 
 C=S C-S C-N N-N 
SMML 1.6635 1.7560 1.3427 1.3797 
SBLA 1.6806 1.7758 1.3624 1.3940 
SBEL 1.6663 1.7567 1.3390 1.3989 
SBML 1.6617 1.7636 1.3418 1.3941 
 C=N C=O C-O  
SMML 1.2846 1.2112 1.3352  
SBLA 1.2944 1.2418 1.3303  
SBEL 1.2853 1.2110 1.341  
SBML 1.2854 1.2102 1.3346  
 
Table 3.4. Selected bond angles for SMML, SBML, SBEL and SBLA. 
  
Compound Bond angles (°)  
 S-C=S S=C-N N-N=C S-C-N 
SMML 125.24 121.55 119.04 113.19 
SBLA   124.30 122.81 120.49 112.89 
SBEL 125.68 121.47 116.00 112.83 
SBML   126.64 120.57 116.37 112.79 
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Table 3.5. Intermolecular hydrogen bonds for SMML, SBML, SBEL and 
SBLA. 
 
Compound D-H-A (Å) 
SMML N1-H1?O1 (2.932) 
SBLA O1-H1?O2 (2.662) 
SBEL NI-H1?O1  (2.902) 
SBML N2-H1?O1 (2.933) 
 
Table 3.6. Selected dihedral angles between the two planes for SMML, SBML, 
SBEL and SBLA.  
 
Compound Dihedral 
angles (°) 
Compound Dihedral 
angles (°) 
SMML   SBEL 
S2C2S1N1N2 
(dithiocarbazate) and 
C3C4C5C6 (ML) 
S2C8S1N1N2 
(dithiocarbazate)  and 
O1C7O2C8(ML) 
C3C4C5C6 (ML)  and 
O1C7O2C8(ML) 
 
 
5.74 
 
 
77.67 
 
79.19 
S1C8 S2N1N2 
(dithiocarbazate) and 
C9C10C11C12 (EL) 
S1C8 S2N1N2 
(dithiocarbazate) and 
O1C13O2C14C15 (EL) 
S1S2C8N1N2 
(dithiocarbazate) and 
C1C2C3C4C5C6C7 (benzyl) 
C9C10C11C12 (EL) and 
O1C13O2C14C15 (EL) 
 
30.62 
 
 
68.59 
 
 
77.52 
 
74.96 
 
 
SBLA 
 
 
 
SBML 
 
 
S2C8S1N1N2 
(dithiocarbazate) and 
C9C10C11C12 (LA) 
S2C8S1N1N2 
(dithiocarbazate)  and 
C13O2O1(LA) 
S2C8S1N1N2 
(dithiocarbazate) and 
C1C2C3C4C5C6C7 
(benzyl) 
C9C10C11C12 (LA) 
and C13O2O1(LA) 
 
3.49 
 
 
2.68 
 
 
78.54 
 
 
2.48 
S1C7S2N2N1 
(dithiocarbazate)  and 
C3C4C5C6 (ML) 
S1C7S2N2N1 
(dithiocarbazate)  and 
O1C2O2C1(ML) 
S1C7S2N2N1 
(dithiocarbazate) and 
C8C9C10C11C12C13C14 
(benzyl) 
C3C4C5C6 (ML) and 
O1C2O2C1(ML) 
 
18.64 
 
 
77.62 
 
 
72.71 
 
 
74.43 
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Cu(SMML)2 crystallized in the C 2/c space group as a centrosymmetric complex in 
which the two ligands were symmetrically related to each other and have the same 
bond angles and distances. The central copper atom was bis-chelated by the 
uninegatively charged bidentate ligand through the azomethine nitrogen atoms (N2) 
and thiolate sulfur atoms (S1). Both nitrogen and sulfur atoms in the two ligands are 
coordinated at the same position relative to each other. The sum of the four angles, 
N-Cu-S, S-Cu-S, S-Cu-N, and N-Cu-N, in the complex was 374.33° confirming 
significant deviation from the square-planar geometry about the copper ions. Neither 
the carbonylic nor hydroxylic oxygen of the methyl levulinate moiety participated in 
complexation. The conjugation system of the moieties was influenced by 
coordination with the metal as shown by slight lengthening of the N–N bond 
distance (1.407 Å). The bond lengths in the dithiocarbazate moiety that are expected 
to be most affected by coordination are azomethine C–N and C–S. The C1–S1 and 
C1-N1 bond lengths in the complex were 1.737 and 1.296 Å respectively. The C1–
S1 distance was longer than that observed in the Schiff base, SMML, indicating 
single bond character as expected when complexation involves the ligand in its thiol 
form. The C1–N1 bond distances in the complex were also typical for double bonds 
in Schiff bases compounds clearly indicating that complexation involves 
deprotonation at N1.  
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Figure 3.10. ORTEP diagrams of (a) Cu(SMML)2 and (b) Cu(SMLA)2 with 
intermolecular hydrogen bonds (shown as dotted lines) in (c). Ellipsoids are 
drawn at the 50% probability level. 
 (a)  
 
             (b)  
 
                 (c) 
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Table 3.7. Selected bond lengths for Cu(SMML)2 and Cu(SMLA)2 
 
Compound Bond lengths (Å) 
 C=S C-S C-N N-N C=N 
Cu(SMML)2 1.7366 1.7466 1.2958 1.4066 1.2962 
Cu(SMLA)2 1.7423(1) 
1.7420(1) 
1.7372(1) 
1.7469(1) 
1.2987 
1.2861(1) 
1.4096(1) 
1.4099(1) 
1.2875(1) 
1.2873(1) 
 N-Cu N-Cu S-Cu S-Cu  
Cu(SMML)2 2.0109 2.0109 2.2195 2.2195  
Cu(SMLA)2 1.9898(1) 1.9912(1) 2.2356(1) 2.2287(1)  
 
Table 3.8. Selected bond angles for Cu(SMML)2 and Cu(SMLA)2. 
 
Bond  
angles (°) 
Cu(SMML)2 
 
Cu(SMLA)2 
S-Cu-N 86.15 84.57 
N-Cu-N 106.43 102.28 
N-Cu-S 86.15 85.89 
S-Cu-S 95.60 107.38 
 
 
Cu(SMLA)2 crystallized in P 21/n space group within an asymmetric unit in which  
two nonequivalent ligand molecules were present with one methanol molecule. 
Similar to Cu(SMML)2, deprotonation of the ligand lead to tautomerization to the 
iminothiolate. While coordinating in the iminothiolate form, the negative charge 
generated on the sulfur atom was delocalized in the C=N-N=C chain as indicated by 
the intermediate C(2)-N(1) = (1.2987 and 1.2861(1) Å), N(1)-N(2) = (1.4096(1) and 
1.4099(1) Å) and N(2)-C(3) = (1.2875(1) and 1.2873(1) Å) bond lengths. The 
lengthening of the C-S bond in the complex can be attributed to enethiolization. The 
380.12° sum of angles around the Cu2+ ion in Cu(SMLA)2 indicated that the 
complex was appreciably distorted from regular square-planar geometry. The Cu–S 
(2.2356(1) and 2.2287(1) Å) and Cu–N (1.9898(1) and 1.9912(1) Å) bond lengths 
are similar to those of the bis-chelated four coordinate copper(II) complex of the 
related isatin Schiff base of SMDTC (Manan et al., 2011b; Ali et al., 2008). The 
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difference between the bond lengths in the same complex can be ascribed to the 
constraints imposed by chelation. The packing for Cu(SMLA)2 was also determined. 
In addition to the interactions between the (O3-H·· ·O4) bond involving two 
neighbouring independent molecules similar to its free ligand SBLA, an extended 
network of hydrogen bonds involving the crystallized methanol molecule and the 
other ligand in Cu(SMLA)2 that was closed to the solvent molecule was also 
observed. The linkage involved the hydroxylic oxygen atom (O2) of one complex 
molecule, the alcoholic oxygen atom (O3) of methanol and the uncoordinated 
azomethine nitrogen atom (N1) from another complex molecule. The continuous 
hydrogen bond networks developed were (O2–H2···O5, 2.655 Å) and (O5-H5···N1, 
2.854 Å). As a consequence of these H-bond systems, the two ligands were not 
planar in the portion involved in metal coordination and the terminal chains with the 
carboxylic group which bridged the adjacent molecule were fairly distorted as can 
be seen from the dihedral angles involving the levulinic acid moiety (84.78° for C3–
C4–C5 and C6-C7-O1-O2, 89.31° for C10–C11–C12 and C13-C14-O4-O3). The 
presence of methanol in the lattice highlights the spatial effect in which the terminal 
chains with the carboxylic group were forced to align in parallel whereas in 
Cu(SMML)2 the ester terminal chains were almost 180° from one another  
minimizing steric constraints. This explains the observation that Cu(SMLA)2 was 
more distorted from square planar than  Cu(SMML)2. 
 
The ORTEP diagram of Re2(SBCM)2 complex with atomic numbering scheme is 
shown in Figure 3.11. Selected bond lengths and bond angles are given in Tables 3.9 
and 3.10. The complex crystallized in P 21/c space group with unit cell parameters 
a=14.7072(4), b=12.6588(3), c=12.1386(3) and &=90o, %=99.374(1)o, -=90o. A 
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number of thiosemicarbazone complexes of Re(I) carbonyl compounds have been 
studied by X-ray diffraction (Carballo et al., 2002; Santos et al., 2004). However, to 
date, this is the first Re(I) tricarbonyl complex with a dithiocarbazate Schiff base 
ligand to have been characterized structurally by X-ray diffractometry.  
Crystallographic analysis of the complex Re2(SBCM)2 in this work showed that the 
rhenium atom was octahedrally coordinated to (i) three carbonyl carbon atoms in 
fac arrangement, (ii) the N and S atoms of the deprotonated bidentate 
dithiocarbazate Schiff base ligand with 3-acetylcoumarin in which the metal forms a 
five-membered chelate ring and (iii) the sulfur atom of a neighbouring molecule that 
had replaced the chloride atom resulting in a centrosymmetric dimer. The Re-S-
Re bridge (Re-S = 2.4669 (1) and 2.5565 (1) Å) was more asymmetric than Re 
complex (a) (data adopted from Carbolla et al., 2002). Like Re complex (a), the 
planar Re2S2 diamond for Re2(SBCM)2  in which the Re-Re distance was too long 
for any significant bonding interaction, had bond angles close to 90°. The three Re-
C distances were close to one another with an average bond distance of 1.916 Å in 
the range shown by numerous other Re(I) complexes containing the 
Re(CO)3+ core (Czerwieniec et al., 2005; Fuks et al., 2010). The Re-N (2.2002(1) 
Å), Re-S (2.4669(1) Å) and Re-S’ (2.5565(1) Å) distances do not differ significantly 
from those determined for Re complex (a). Therefore, it can be concluded that in the 
dimeric Re2(SBCM)2 complex the geometry around each Re center was slightly 
distorted octahedral. The C12-S1 was shorter (1.7755 Å) in this complex in 
comparison to (a), but it was longer than in most free dithiocarbazate Schiff bases 
(ca 1.6 Å) suggesting a predominantly thiol character upon complexation. This 
conclusion was reinforced by the observed shortening of N2-C12 (ca. 1.34 Å from 
the previous series in this work and 1.2638 Å in Re2(SBCM)2). The configuration 
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around this latter bond was Z (because of the N1-S1 chelation to the rhenium) and 
the configuration with respect to C10-N1 was E (C8C10N1N2 = 179.94). The 
dihedral angle between the dithiocarbazate plane and the plane of the coumarin ring 
was 83.07° whereas the dithiocarbazate plane and the plane of benzyl ring were at 
75.22° to one another. The experimentally found N1-Re-S1 bond angle was only 
79.13°. Such deviation from the ideal value of 90° can be explained by the relatively 
strong tensions in the six-membered ring formed by the bidentate ligand and the 
Re(I) cation. It can be also seen that both C-Re-S axial angles are about 174°. The 
two CO molecules present in the equatorial plane form with Re(I) the angles 96.43° 
and 93.16°, respectively. There were also intermolecular interactions from the apical 
carbonyl oxygen from one molecule to the equatorial carbonyl oxygen and the 
uncoordinated nitrogen of the neighbouring molecule forming (O5-O3, 2.932 Å and 
O5-N2, 2.906 Å) bonds. It is plausible that the short distances were due to hydrogen 
bonding.   
 
Figure 3.11. ORTEP diagram and intermolecular interactions (shown as dotted 
red line) for Re2(SBCM)2. Ellipsoids are drawn at the 50% probability level. 
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Figure 3.11 (continued). ORTEP diagram and intermolecular interactions 
(shown as dotted red line) for Re2(SBCM)2. Ellipsoids are drawn at the 50% 
probability level. 
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Table 3.9. Main bond lengths (Å) and angles (°) in the coordination sphere 
around the rhenium atom.  
 
Reference for compound (a): Data 
adopted from (Carbolla et al., 2002) 
 
 
 
 
 
 
 
 
 
Table 3.10. Bond lengths (Å) and angles (°) in the dithiocarbazate fragments. 
 
 
   
Bond angles Re2(SBCM)2 (a) 
C20-Re-C22 90.26 90.3(6) 
C20-Re-C21 88.8 88.7(6) 
C22-Re-C21 86.74 91.1(5) 
C20-Re-N 89.06 91.3(5) 
C22-Re-N 172.13 171.7(4) 
C21-Re-N 101.08 97.1(4) 
C20-Re-S 96.43 90.8(5) 
C22-Re-S 93.16 94.1(4) 
C21-Re-S 174.77 174.8(4) 
N-Re-S 79.13 77.8(3) 
C20-Re-S’ 175.62 172.0(4) 
C22-Re-S’ 93.99 91.5(4) 
C21-Re-S’ 92.5 99.0(5) 
N-Re-S’ 86.58 85.8(3) 
S-Re-S’ 82.29 81.34(12) 
Re-X-Re’ 97.71 98.66(12) 
C12-S-Re 95.48 95.4(4) 
C10-N-Re 128.54 130.0(8) 
N2-N1-Re 118.98 116.4(7) 
Bond lengths Re2(SBCM)2 (a) 
Re1-C20 1.9161 1.868(17) 
Re1-C22 1.9185 1.924(13) 
Re1-C21 1.9123 1.901(14) 
Re-N 2.2002 2.210(9) 
Re-S 2.4669 2.465(3) 
Re-S 2.5565 2.537(4) 
Re-Re’ 3.7830 3.794(11) 
C20-O3 1.1421 1.162(16) 
C22-O5 1.1416 1.135(14) 
C21-O4 1.1539 1.159(15) 
Bond 
lengths 
Re2(SBCM)2 
S1-C12 1.7755 
S2-C12 1.7509 
N2-C12 1.2638 
N2-N1 1.4203 
N1-C10 1.2887 
C8-C10 1.4879 
Bond 
angles 
Re2(SBCM)2  
C12-N2-N1 116.70 
C10-N1-N2 111.83 
N2-C12-S2 119.94 
N2-C12-S1 127.24 
S1-C12-S2 112.78 
N1-C10-C8 120.79 
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3.3.3 Characterization of metal complexes in solution 
3.3.3.1 NMR 
The NMR spectra of ligands SMML (Figure 3.12), SMLA, SBML, SBLA and 
SBEL were recorded in CD3OD whereas SM4CB, SB4CB (Figure 3.13), SBCM, 
SMHD, SBHD, Zn(SBCM)2 and Re2(SBCM)2 were carried out in DMSO-d6 due to 
their low solubility in CD3OD at room temperature. The NH signal was not observed 
in any of the 1H NMR spectra in CD3OD due to fast exchange with solvent. 
However, the spectra illustrated the expected hydrogens for each compound. The S-
methyl derivatives (SMML and SMLA) showed characteristics signals at ca. 2.52 
ppm attributed to S-CH3 while the S-benzyl derivatives (SBML, SBLA and SBEL) 
displayed distinct multiplets of their five aromatic protons and singlets of their S-
CH2 protons at ca. 7.40-7.17 ppm and 4.45 ppm, respectively. The proton signals for 
the two CH2 groups of both levulinic acid and methyl levulinate were found to be 
identical at ca. 2.62 ppm whereas the -CH3 group was at ca. 1.98 ppm. Other 
distinctive signals arising from the protons of the ester Schiff bases were observed at 
3.66 ppm (-OCH3 of SMML), 3.47 ppm (-OCH3 of SBML) and 3.93 ppm in 
addition to 1.02 ppm (-OCH2CH3 of SBEL). The spectra of aromatic acid ligands 
SM4CB and SB4CB in DMSO-d6 demonstrated signals at  8.29 ppm and 8.01-7.80 
ppm attributed to  -CH=N and aromatic hydrogens of 4-carboxybenzaldehyde 
moiety, respectively. Both ligands also showed characteristic signals of their S-
substituted dithiocarbazate similar to those discussed above. The -NH 
(dithiocarbazate) signal of both SM4CB and SB4CB occurred at ca. 13 ppm whereas 
for SMHD and SBHD occurred at ca.12.15 indicating the presence of thioimine NH. 
This signal and the absence of the C-SH signal at ca. 4 ppm indicated that in 
solution the thione tautomer remains as the predominant species (Roy et al., 2007). 
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The NH signals above 12 ppm indicate that the Z-configurational isomer is 
predominant (Rebolledo et al., 2005). The presence of -SC(=S)NH- at ca. 200 ppm 
in the 13C NMR spectra of all the Schiff bases indicated that the thione form 
predominates in solution. This signal was shifted downfield due to the deshielding 
effect of the neighbouring amine nitrogen and electronegative sulphur.  The C=N 
signal appeared at ca. 156 ppm of the result of hydrazone bond formation when 
carbonyl compounds react with the S-substituted dithiocarbazate. The -S-CH2 peak 
occurred upfield at ca. 40 ppm while the S-CH3 peak was found at ca. 17 ppm. The 
aromatic carbons were observed at ca. 138 - 127 ppm as expected. The 1H NMR 
spectrum of SBCM in DMSO-d6 however showed double set of signals due to 
existence of SBCM in two isomeric forms. Such observation has been reported by 
Hunoor et al. (2010) with 3-acetylcoumarin-isonicotinoylhydrazone. The relative 
percentage of the two isomers was found to be 60% and 40%. The singlets at 12.56, 
4.48 and 2.34 are assigned to -NH, -CH2-S-, -CH3 (3-acetylcoumarin), respectively. 
Overlapping signals from the coumarin and benzyl rings were observed in the 
aromatic region at 7.85-7.21 ppm. Upon complexation of SBCM with Zn(II) and 
Re(I), the hydrazone proton signal disappeared, which clearly indicates 
deprotonation of NH by enolisation. The downfield shift of methyl protons for both 
complexes further supports the coordination through azomethine nitrogen. The 
others protons in the 1H NMR spectra of the complexes have not shown considerable 
change. Due the low solubility of the coumarin derivatives, it was impossible to 
record good 13C-NMR spectra.   
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Figure 3.12.  1H NMR and 13C NMR spectra of SMML 
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Figure 3.13.  1H NMR and 13C NMR spectra of SB4CB 
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3.3.3.2 UV-VIS 
Electronic spectra of all the metal complexes in DMSO were scanned in the region 
200–800 nm at concentrations between 25 µM and 1 mM. The electronic spectra of 
the Schiff bases showed two bands, from ca. 273 nm to 364 nm arising from ,.,* 
and n.,* transitions. For all the metal complexes, the first band corresponding to 
the ,.,* (256-300 nm) transition is always observed, whereas the second 
intraligand band at higher wavelength (300-400 nm) ascribed to n.,* band showed 
either a blue shift with a reduction of intensity or disappeared. This is due to 
donation of the lone pair of electrons to the metal and hence the coordination of the 
azomethine group (Latheef and Kurup, 2008). Most Cu(II) complexes with the 
exception of Cu(SM4CB)2 and Cu(SB4CB)2 showed the presence of ligand-to-metal 
charge transfer (LMCT) band (400-450 nm) arising from S.M(II) interaction. 
Some spectra of the d9 Cu(II) complexes also revealed the presence of a broad d-d 
band at ca. 604 nm attributed to 2B1g.2A1g for a distorted square planar 
environment around the copper(II) ion due to Jahn-Teller distortion (West et al., 
1993; Nair and Joseyphus, 2008). There was a slight hypsochromic shift at 325 nm 
in the spectrum of the Re2(SBCM)2 complex whereas in the Zn(SBCM)2 complex a  
slight batochromic shift was seen at 292 nm. Two examples of the UV-Vis spectra 
each for tetradentate series and bidentate series are shown in Figure 3.14. 
 
Cu(SM4CB)2 and Cu(SB4CB)2, however, showed neither the sulfur-to-copper 
LMCT band at 400 nm nor the d-d band. The absence of these bands even at high 
concentration (1 mM) suggests that the ligand does not have a suitable low-lying 
antibonding ,* orbital (Ali et al., 2001b). These two complexes showed a broad 
band spanning 300-400 nm with / max at ca. 322 nm. The spectra of the complexes 
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were different from those of the free ligands that showed intra-ligand transitions at 
ca. 349 nm and 362 nm. The changes observed for the complexes were in agreement 
with the results of titration experiment carried out in both DMSO and 0.1M acetate 
buffer solution in order to ascertain the formation of the Cu(II) complexes with the 
proposed 1:2 metal to ligand stoichiometry. In these titration experiments, the 
changes in the UV-Vis spectra were obvious with an absorption band at 300-325 nm 
arising when the complex formed while the intensity of ligand band at "max * 345 nm 
decreased upon addition of Cu(OAc)2 Complexation proceeded with a sharp end-
point at 0.5 equivalents with clear isosbestic points indicative of a single 
complexation event (Figure 3.15).   
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Figure 3.14. (a) UV-Vis spectra recorded for tetradentate series at 25 !M in 
DMSO using a cell length of 1 cm. The insert shows the d-d band of the two 
complexes at concentration of 1 mM. (b)  UV-Vis spectra recorded for SMML 
and Cu(SMML)2 at 25 !M. Insert shows d-d band of the complex at 1 mM. 
 
(b) 
(a) 
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Figure 3.15. UV-Vis spectra obtained by addition of Cu(OAc)2.H2O at 25°C to a 
solution of SM4CB (ca. 2.5 x 10-5 M)  in DMSO solution as well as in 0.1 M 
acetate buffer, pH6.  
 
3.3.3.3 EPR  
Examples of EPR spectra are shown in Figure 3.16. EPR parameters for all 
complexes are summarized in Table 3.11. Spectra of the frozen solutions for all 
tetradentate and bidentate Schiff base Cu(II) parent complexes in DMF showed the 
presence of one major species. They are typical of mononuclear d9 Cu(II) complexes 
with axial symmetry and distorted square planar geometry with the unpaired 
electrons lying mainly in the dx2-dy2. The spectra also exhibited partially resolved 
superhyperfine features. The g! values for all the complexes are similiar to those 
previously reported for Cu(II)N2S2 complexes (Jasinski et al., 2003; Diaz et al., 
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1998; Hueting et al., 2010). It have reported that g|| higher than 2.3 are indicative of 
a predominantly ionic character for metal-ligand bonds, whereas g|| smaller than 2.3 
reveal metal-ligand bonds with predominantly covalent character, which was the 
case here. In addition, the relatively small g! value (g! near 2.20) suggested a strong 
nitrogen character in the singly occupied molecular orbital (Kivelson and Neiman, 
2004; Chikate et al., 2005). EPR spectroscopy is sensitive to angular distortions at 
the Cu(II) centre, particularly those involving distortions from planar to tetrahedral 
geometry. As a general rule, distortion from planar towards tetrahedral geometry 
results in a decrease in A! and an increase in g! (Ali et al., 2005). The empirical 
factor f (= g||/0||) (Joseph et al., 2012; Krishna et al., 2008) is a measure of deviation 
from idealized geometry. Its value ranges between 105 and 135 cm for square planar 
complexes, depending on the nature of coordinated atoms, while for a structure 
distorted toward the tetrahedron the values can be much larger and values from 160 
to 242 cm suggest a moderate to considerable distortion in the geometry. For 
macroacylic Cu(II) complexes, CuSBHD reflects only a slightly higher degree of 
tetrahedral distortion compared with CuSMHD in solution but both complexes 
appear close to square planar geometry. They are however less planar than other 
reported C-C backbone analogues most likely due to the extension of carbon 
backbone (Jasinski et al., 2003; Diaz et al., 1998; Hueting et al., 2010). In the 
bidentate series, the complexes with aliphatic acid or ester substituents 
(Cu(SMML)2, Cu(SMLA)2, Cu(SBML)2 and Cu(SBLA)2) were more distorted (with 
f values at ca. 147 cm) than those with aromatic acid or coumarin substituents 
(Cu(SM4CB)2 and Cu(SB4CB)2 at ca. 125 cm; Cu(SBCM)2 at f = 135 cm), which 
are within the perfect range for square planar complexes. Finally, molecular orbital 
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coefficient &2 (in-plane 1-bonding) was calculated using the equations below 
(Rapheal et al., 2007; Chandra and Sangeetika, 2004) : 
&2=(A!/0.036)+(g!"2.0036)+3/7(g""2.0036)+0.04 
The &2 value of 0.5 indicates complete covalent bonding, while 1.0 suggests 
complete ionic bonding. The observed values between 0.61 and 0.70 for all series 
indicated that these copper complexes have some covalent character as suggested 
above. 
 
Figure 3.16. The EPR spectrum of CuSMHD, CuSBHD, Cu(SMML)2 and 
Cu(SM4CB)2 at 1 mM in frozen DMF.  Microwave frequency 9.50 GHz, 
microwave power 0.25 mW, modulation amplitude 0.2 mT, modulation 
frequency 100 kHz, time constant 164 ms, T=50 K. 
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Table 3.11. EPR parameters measured from the spectra of the copper(II) 
complexes.  
Compound g//   g" A//[a]    f[b] $2 
CuSMHD 2.15 2.06 460 (153) 141 0.64 
CuSBHD 2.16 2.06 451 (150) 143 0.64 
Cu(SMML)2 2.15 2.05 438 (146) 147 0.61 
Cu(SMLA)2 2.15 2.06 438 (146) 147 0.62 
Cu(SBML)2 2.15 2.05 438 (146) 147 0.61 
Cu(SBLA)2 2.15 2.05 443 (148) 145 0.61 
Cu(SM4CB)2 2.15 2.05 504 (168) 128 0.67 
Cu(SB4CB)2 2.15 2.05 531 (177) 121 0.70 
Cu(SBCM)2 2.15   2.05 478 (159) 135 0.65 
[a] Unit in MHz, in bracket = A// x 10-4 cm-1 [b] Unit in cm.  
 
The spectra in DMF (see Appendices) for all Cu(II) parent complexes also show the 
presence of an additional minor component. Because of their lability, the bidentate 
Schiff base Cu(II) complexes may exhibit different solution and solid state structures 
(Jansson et al., 2010). In particular, transoid or cisoid ligands conformation (Figure 
3.17) with respect to the central metal-coordinated rings may exist for such 
complexes in an open chained system (Beshir et al., 2008; Blumberg and Peisach, 
2003; Da Silva et al., 1999).  
 
Figure 3.17. Transoid and cisoid ligands conformation. 
 
The aliphatic acid or ester substituted parent compounds Cu(SMML)2, Cu(SBML)2,  
Cu(SMLA)2  and Cu(SBLA)2 demonstrated that the g// region for the minor species 
shifted further to the left of the magnetic field whereas for aromatic Cu(SM4CB)2 
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and Cu(SB4CB)2, the presence of the minor species was further to the right of the 
magnetic field relative to the dominant species. Although there is no evidence to 
make a definitive assignment, single crystals of both Cu(SMML)2 and Cu(SMLA)2 
were determined by X-ray diffraction to adopt cisoid orientation. It can be argued 
that the predominant orientation in the solid may be indicative of an energetically 
preferred state in solution. Thus, the observation may serve as an indirect indication 
that the cisoid orientation is more favourable in aliphatic Cu(II) complexes and can 
be tentatively assigned as the major species. The difference observed in the aromatic 
series Cu(SM4CB)2 and Cu(SB4CB)2 could point toward that both compounds have 
stronger preference for a transoid conformation since the cisoid structure will result 
in more steric hindrance especially with the presence of the aromatic ring. This 
ordering of the structures is also consistent with the interpretation of EPR results 
that the mainly transoid Cu(SM4CB)2 and Cu(SB4CB)2 were more planar as 
compared to the their aliphatic counterparts as indicated by the f values. This 
proposal is also in agreement with the LC-MS results for the Cu(II)-bioconjugate in 
this work that showed two peaks with the same mass.  
 
Other possibilities that can also be taken into account are previous findings that 
reported partially dissociation of CuL2 upon dissolution to afford the corresponding 
1:1 Cu/ligand complexes (Jansson et al., 2010; Diaz et al., 1998; Pogni et al., 2000). 
The observed EPR spectra of the complexes could be a composite of the 1:2 and 1:1 
Cu/ligand complexes. In the case for 1:1 complex, DMF solvent molecules (also O-
donors) are expected to participate in coordination to form CuL(DMF)2 complex. 
Assuming that the minor species is a 1:1 and the dominant species is 1:2, the g// 
region for 1:1 should shift further to the left of the magnetic field (Faller et al., 
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2012). This was observed only for compound Cu(SMML)2, Cu(SBML)2,  
Cu(SMLA)2   and Cu(SBLA)2. In addition, solvent molecules are known to be able to 
alter the geometry of the Cu(II) complexes although their coordination is weak 
(Umamaheswari et al., 2014). Thus, water or an DMF molecule could potentially 
coordinate in the apical position of the Cu(II) complexes giving rise to a penta-
coordinated compound with rhombic symmetry. The spectra of conjugated 
complexes Cu(R1-SB4CB)2 and Cu(R9-SB4CB)2  in aqueous solution revealed the 
minor species observed in pure DMF as the dominant species (Figure 3.18 and 
3.19). However, this analogy is not definitive as the observation could only be the 
result of solvent effect. Other hypotheses could involve the presence of Cu(II)-DMF 
complex although this can in fact be ruled out in this instance since the free Cu2+ 
species in DMF did not match the parent compounds. Figure 3.20 illustrates possible 
representation of the Cu(II) complexes that could exist in solution. 
 
 
 
Figure 3.18. The EPR spectrum of Cu(R1-SB4CB)2 at 1 mM in various 
solvents. #: major species, *: minor species.   
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Figure 3.19. The EPR spectrum of Cu(R9-SB4CB)2 at 1 mM in various 
solvents. #: major species, *: minor species.   
 
Figure 3.20. The different possible species of the Cu(II) complexes that could 
exist in solution. 
 
3.3.3.4 Electrochemistry 
As redox properties have been linked to bioactivity (i.e. SOD and anticancer 
properties) of metal complexes ('ura(ková et al., 1999; Jansson et al., 2010) and in 
order to gain a better understanding of the influence of different functional group 
have on the electronic properties of coordinated metal centers, the electrochemical 
properties of the various Cu(II) complexes were described herein. Figure 3.21 and 
Table 3.12 show the profile of the Cu(II) complexes obtained with SMHD and 
SBHD at a scan rate of 100 mVs"1. Both complexes undergo an electrochemically 
irreversible one-electron reduction at Epc = -0.328 and -0.285 V/(Ag/AgCl and 
standard Fc/Fc+ = 0.56 V), respectively, coupled with an oxidation at Epa= 0.069 and 
0.129 V/(Ag/AgCl). These waves can be assigned to the irreversible 
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oxidation/reduction wave for Cu(II)/Cu(I) (Paterson et al., 2010). The redox 
properties of the ligands were also investigated but they were found to be innocent. 
The irreversible nature of the copper-centered redox waves in the present study 
differed from the analogues CuATSM and CuAATSM (Blower et al., 2003; Cowley 
et al., 2004) previously reported to demonstrate quasi-reversible reduction. The loss 
of reversibility observed in this work is most likely related to the differences in 
geometry rearrangement of Cu(II)/Cu(I) ions in this ligand system that possesses 
two carbons between the two hydrazones functions. The Cu(II)/Cu(I) redox 
potentials of CuSMHD and CuSBHD are also more positive than the previous 
examples. The ease of deformation away from planarity seems to favour reduction. 
The differences in redox potential between CuSMHD and CuSBHD can also be due 
to changes in inductive effects of the substituents. Altering the terminal S-
substitutent (from methyl to benzyl) induces a weak effect on the Cu redox 
potentials which could be rationalized by a stronger electron-donating effect of the 
methyl group (Basha et al., 2012). The oxidation process at higher positive potential 
has previously been assigned to the copper(III/II) redox couple. It is interesting to 
note occurrence of an additional peak, which can be attributed to the reduction of a 
species produced by the second oxidation. However, the nature of this oxidized 
complex has not been determined. 
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Figure 3.21. Cyclic voltammograms of the Cu complexes at 1.7 mM in 
anhydrous deoxygenated DMF containing 0.1 M tetrabutylammonium 
hexafluorophosphate as the supporting electrolyte. Working electrode: glassy 
carbon; counter electrode: Pt wire; reference electrode: Ag/AgCl, scan rate: 
100 mV/s. All sweeps were initiated in the direction of the arrow. 
 
Table 3.12. Electrochemical data for CuSMHD and CuSBHD versus Ag/AgCl. 
 Cu(II)/Cu(I) Cu(III)/Cu(II) 
 Epc/V Epa/V Epc/V Epa/V 
CuSMHD -0.328 0.069 0.195 0.899 
CuSBHD -0.285 0.129 0.357 0.870 
 
All bidentate parent compounds displayed qualitatively similar redox behaviour in 
the series, yet the characteristic one-electron Cu(II)/Cu(I) quasi reversible reduction 
waves were shifted depending on the ligand (Table 3.13). The measured reduction 
potentials clearly correlate with the electron-donating ability of the functional group 
and also the S-substituted dithiocarbazate. Similar to the previous tetradentate series, 
the S-methyl derivatives showed lower Cu(II)/Cu(I)  reduction potential at Epc= -
0.092 to -0.114 V as compared to the S-benzyl derivatives at Epc= -0.021 to -0.079 
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V. Among the functional groups the reduction potential towards the more negative 
can be arranged in the following order Cu(SMML)2 <Cu(SMLA)2 <Cu(SM4CB)2. 
Cyclic voltammograms were also recorded at different scan rates between 0.4 V and 
-0.4 V vs. Ag/AgCl from 0.02 V/s to 0.5V/s for all the compounds which showed 
similar trend. Taking Cu(SMML)2 as an example (Figure 3.22), the peak currents 
were still found to be proportional to scan rates with the peak currents ratio of the 
anodic signal and the cathodic signal (ipa/ipc) remained close to 1 (Table 3.14) 
independent of the sweep rate used indicating the reversibility and stability of the 
electrochemically generated product (Evans et al., 1983). Furthermore, when 
plotting the peak current as a function of the square root of the scan rate for 
reversible electron transfer, a linear correlation was found although not particularly 
perfect suggesting that the redox process is confined to the surface (Figure 3.23). 
However, another indicator of reversible electron transfer called the current 
function, whose values were given by (ip / +1/2) were not entirely constant anymore 
for all scan rates and the most obvious indication that the process was not 
completely reversible was the separation of anodic and cathodic peak potential. 
Inspection of the voltammetric data shows that at increasing scan rates, the reduction 
(Epc) and oxidation (Epa) peaks are shifted to more negative and positive values 
respectively. The separation between them, 2Ep, exceeds the Nernstian requirement 
of 59 mV expected for a reversible one-electron process. For Cu(SMML)2, this 
value increases from 2Ep = 78 mV at 0.05 V/s to 2Ep = 135 mV at 5 V/s indicating a 
kinetic inhibition of the electron transfer process (dos Santos-Claro, 2005). This 
behavior cannot be attributed to some uncompensated solution resistance, as the 
internal standard Fc/Fc+ couple, that shows rapid heterogeneous electron transfer in 
most of the solvents, gave a 2Ep value of 51 mV (measured at v = 0.1 V/s). Thus, 
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any possible uncompensated resistance is sufficiently small so that the resulting 
voltage drops are negligible compared to the 2Ep values attributable to kinetic 
effects (Parajón-Costa et al., 2004). Therefore the reaction of higher scan rates can 
be considered to be quasi-reversible and this quasi-reversibility associated with the 
reduction process probably arises as a consequence of a geometry change towards a 
distorted tetrahedral environment around the Cu(I) species 
. 
Table 3.13. Electrochemical data for the Cu(II) complexes vs Ag/AgCl at 0.1V  
 Cu(II)/Cu(I) Cu(II) 
/Cu(III) 
 Epa[V] Epc[V] 2Ep=Epa-
Epc[mV] 
2E1/2=0.5 
(Epa+Epc) [V] 
ipa/ipc Epa[V] 
Cu(SMML)2  0.002 -0.092  94 -0.045 1.00 1.000 
Cu(SMLA)2 -0.014 -0.095  81 -0.055  0.60 0.998 
Cu(SM4CB)2 -0.011 -0.114 103 -0.063 1.11 1.006 
Cu(SBML)2  0.021 -0.066 87 -0.023 1.01 1.001 
Cu(SBLA)2  0.008 -0.078 86 -0.035 0.84 0.985 
Cu(SB4CB)2  0.015 -0.079 94 -0.032 0.88 1.029 
Cu(SBCM)2  0.077 -0.021 98  0.028 1.19 0.973 
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Figure 3.22. Cyclic voltammograms of the Cu(SMML)2 at 1.7 mM in anhydrous 
deoxygenated DMF containing 0.1 M tetrabutylammonium perchlorate as the 
supporting electrolyte. Working electrode: glassy carbon; counter electrode: Pt 
wire; reference electrode: Ag/AgCl. (a) and (b) Scan rate= 0.1 V/s. (c) Various 
scan rates= 0.02, 0.05, 0.1, 0.2, 0.5 V/s. All sweeps were initiated in the direction 
of the arrow. 
 
 
(a) 
(c) 
(b) 
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Figure 3.23. Plot of the anodic (Ipa) and cathodic (Ipc) current with the square 
root of scan rate for Cu(SMML)2. 
 
Table 3.14. Electrochemical data for the Cu(SMML) vs Ag/AgCl at various 
scan rate (V/s).  
 
 Cu(II)/Cu(I)  
Cu(SMML)2 Epa[V] Epc[V] 2Ep=Epa-
Epc[mV] 
2E1/2=0.5 
(Epa+Epc) [V] 
ia/ic ip / +1/2 
0.02 -0.001 -0.079 78 -0.040 0.97 -68.32 
0.05  0.002 -0.085 87 -0.042 0.96 -65.87 
0.10  0.002 -0.092 94 -0.045 1.00 -67.45 
0.20  0.012 -0.097 109 -0.043 0.95 -63.50 
0.50  0.021 -0.114 135 -0.047 0.95 -60.61 
 
 
3.4 Conclusion 
Two series of metal complexes (either macroacyclic or open chain) with 
dithiocarbazate Schiff base chelating ligands have been successfully synthesized and 
characterized. Although the Schiff bases derived from the keto-ester (methyl 
levulinate), keto-acid (levulinic acid and 4-carboxybenzaldehyde) and natural ketone 
derivative, 3-acetylcoumarin, contained O atoms that could potentially participate in 
coordination, the ligands behaved as bidentate NS ligands coordinating to the central 
metal through the azomethine nitrogen atom and the thiolate sulphur atom in all 
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complexes. Eleven structures of the compounds have been determined by single 
crystal X-ray crystallographic analysis. The 1H, 13C NMR and FTIR spectra of the 
Schiff bases indicated that the ligands retained the thione form in both solid state 
and solution. Only the ligand SBCM existed in both thione and thiolate form in solid 
state. RP-HPLC analysis of the free ligands showed that the aromatic ligands were 
more stable than the aliphatic ligands. Their stability was further improved upon 
complexation. Electronic and EPR spectra showed that most of the paramagnetic 
Cu(II) complexes had distorted square planar geometries with the exception of 
Cu(SB4CB)2, Cu(SM4CB)2 and Cu(SBCM)2 as demonstrated from their empirical 
factor f (= g||/0||). Cu(II) complexes with aliphatic acid and ester bidentate ligands 
(145-147 cm) confirm slightly higher degree of tetrahedral distortion than those with 
tetradentate ligands (141 and 143 cm) in solution. However, Cu(SM4CB)2, 
Cu(SB4CB)2 and Cu(SBCM)2 that possess aromatic acid or coumarin substituents 
(Cu(SM4CB)2 and Cu(SB4CB)2 at ca. 125 cm; Cu(SBCM)2 at f = 135 cm) are in the 
square planar range. The Re(I) and Zn(II) complexes were diamagnetic. There were 
also differences between the macroacyclic and open chain Cu(II) complexes with 
regard to their electrochemistry. The latter series showed Cu(II)/Cu(I) quasi 
reversibility at more positive potential whereas the former series was not reversible 
suggesting that the open chain Cu(II) complexes can accommodate Cu(I) more 
easily as a result of their flexibility. To sum up, this chapter demonstrated that by 
using a convergent synthesis strategy, a library of complexes with tune stabilities, 
geometries and electrochemical properties can be generated. In addition, the 
introduction of carboxylic acid functions opens the possibility to conjugate these 
complexes with vectors. The biological activities of all these compounds were 
evaluated and are discussed in Chapter 5.  
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CHAPTER 4 
FUNCTIONALIZED COMPOUNDS 
 
4.1 Introduction 
4.1.1 Key drawbacks of metallodrugs  
In the past years, much e!ort has been devoted to synthesis and testing of metal 
complexes in search of new metal metallodrugs for biological application. However, 
only a fraction of the thousands of tested metal compounds has entered clinical trials 
or has been approved worldwide with many challenging issues in terms of favorable 
selectivity, solubility, and stability as well as knowledge about their mode of action 
remaining unsolved (Fricker, 2007; Timerbaev et al., 2006).  
 
The poor water solubility of many metal complexes is one of the key drawbacks “in 
the course of their analysis or application” (Miklán et al., 2007, p. 108). Studies in 
aqueous and buffer solutions are of utmost importance for an understanding of the 
mechanism of action of bioactive molecules and the design of stronger chelators 
(Milunovic et al., 2012). Such is the case for thiosemicarbazone derived Schiff base 
metal complexes (Enyedy et al., 2010; Raja et al., 2011).  There is relatively few 
information that is available in the literature for these families of compounds as such 
investigations are often hampered by the low aqueous solubility of the compounds. 
There are also cases in which a high amount of DMSO is used to pre-dissolve the 
metal complexes in order to overcome their poor solubility in aqueous media during 
biological studies. However, the use of DMSO affects the reliability of the results 
obtained. DMSO has been shown to considerably retard the growth of fungi and 
cancerous cells and lead to bacteria and cell death at above certain concentrations 
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(Dolan et al., 2013; Ng et al., 2013). Therefore, compounds that are highly water-
soluble are preferred for biological applications as they enable preclinical 
development of a drug candidate without the use of solubilizers (Bacher et al., 
2013). 
 
Apart from that, cell uptake and metal complex accumulation are also challenges for 
medicinal and bioinorganic chemistry. The efficient and rapid passage of metal 
complexes into cells remains a major hurdle in the design of potential therapeutic 
agents. A significant number of drug candidates and probe molecules fail because of 
insufficient cell uptake, requiring high quantities of drug administration, which often 
leads to undesirable side effects (Rijt et al., 2011) Only molecules in a narrow range 
of molecular weight and polarity are able to directly cross the plasma membrane by 
passive diffusion (Brunner and Barton, 2006). It is therefore critical to optimize the 
properties of their cellular uptake in the effort to develop potent and selective metal 
complexes as chemotherapeutic or diagnostic agents. 
 
The capability to design and synthesize new molecules with tuned functions offers a 
powerful and efficacious way to overcome these shortcomings. Recently, new 
strategies have been developed in an attempt to maximize the impact of drugs on 
cancer cells and minimize the problem of adverse side effects through effective 
delivery of complexes with tumour-targeting properties and biologically-active 
ligands (Hambley, 2007; Storr et al., 2006; Thompson and Orvig, 2006; Thompson 
and Orvig, 2003). The use of multifunctional ligands that adequately bind metal ions 
and also include specific targeting features is an attractive choice which is gaining 
popularity today with applications at the forefront of all areas of medicinal inorganic 
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chemistry research. The field has benefited greatly from advances in targeted ligand 
design, which lead to the development of improved therapeutic agents (Ronconi and 
Sadler, 2007).  
 
4.1.2 Conjugated metal complexes  
By combining ligands or metal complexes with vectors, a large number of new 
bioconjugates with interesting biological properties can be prepared. An excellent 
review by Nils Metzler-Nolte (2010, p. 195) gives an overview of the use of 
peptides “as targeting vectors for the directed delivery of metal-based drugs or 
probes for biomedical investigations”. The numerous peptides that have been 
utilized “include neuropeptides (enkephalin, neuropeptide Y, neurotensin), uptake 
peptides (TAT and poly-Arg) and intracellular localization sequences”. These 
bioconjugates display biomedical applications in radiopharmaceutical, as anticancer 
and antibacterial drugs or targeted CO-releasing molecules as well as in biosensor 
applications. 
 
4.1.2.1 Schiff base conjugate 
As this work involves dithiocarbazate derivatives, the development of Schiff base 
metal complex bioconjugates from the family of nitrogen-sulphur donor ligands will 
be specifically highlighted (Donnelly, 2011; Paterson and Donnelly, 2011). To date, 
the concept of bifunctional ligands has been most successfully applied to 
radioimaging with Cu(II) bis(thiosemicarbazone) (Figure 4.1). Many new 
tetradentate bifunctional bis(thiosemicarbazone) chelators have been designed and 
conjugated to various vectors such as the tumor targeting bombesin derivative 
BBN(7-14)-NH2 that has high affinity for gastrin-releasing peptide (GRP) receptors 
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(Paterson et al., 2010; Hueting et al., 2010), somatostatin derived octreotide that 
detects somatostatin-receptor-positive tumors (Cowley et al., 2007), pyrene 
fluorophore tags for cellular imaging (Lim et al., 2010) and water-soluble glucose 
derivatives (Holland et al., 2007) to name a few. 
 
Figure 4.1. Schematic diagram of a functionalized bis(thiosemicarbazone) 
conjugated to a biologically active molecule (BAM) (Source: Hueting et al., 
2010). 
 
Conjugates of tridentate salicylaldehyde thiosemicarbazone (STSC) and 2-
formylpyridine thiosemicarbazone (FTSC) coupled to a single amino acid of L- or 
D-proline (Pro) with good chelating properties and improved aqueous solubility 
have recently been reported (Milunovic et al., 2012; Bacher et al., 2013). As a result, 
various techniques have been used to conduct detailed studies on the stoichiometry 
and thermodynamic stability of metal ions with the Pro-TSC conjugates in a 
water/DMSO mixture. Most importantly, conjugation resulted in enhancement of 
their antiproliferative activity. While several studies exploring the multifunctional 
ligand-peptide conjugates concept using thiosemicarbazone derivatives have been 
highlighted, there are no reports of its application to dithiocarbazate analogues prior 
to this work. In the following parts, focus will be directed to polyethylene glycol 
(PEG) and cell penetrating peptides (CPPs) which are vectors used for conjugation 
in this work. 
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4.1.2.2 PEGylation 
PEGylation describes the covalent modification of proteins, peptides, antibody 
fragments or non-peptide small drug molecules by attachment to one or more 
polyethylene glycol (PEG) chains. PEG is a non-toxic, non-immunogenic, non-
antigenic polymer that is highly water soluble and has been approved by FDA. 
PEGylation is used as a well-recognized approach for drug delivery (Harris and 
Chess, 2003; Riley and Riggs-Sauthier, 2008; Veronese and Pasut, 2005). The 
introduction of PEG into pharmaceuticals improves their pharmacokinetics with “a 
prolonged residence in body, a decreased degradation by metabolic enzymes and a 
reduction or elimination of protein immunogenicity” (Veronese and Pasut, 2005, p 
1451). There is an emerging interest in the use of metal-PEG complexes in 
biological studies (Stephan et al., 2005; Heldt et al., 2004) including work on the 
modification of cisplatin with PEG (Dhar et al., 2011; Ohya et al., 2001) as well as 
PEGylated iridium cyclometalated complexes that showed improved aqueous 
solubility and cell permeability (Li et al., 2010). 
   
4.1.2.3 Cell penetrating peptide as cell delivery vectors  
Crossing the plasma membrane is a challenge for some molecules with many 
potential drugs not displaying the required balance between lipophilicity and 
positive charge allowing for membrane permeability while supporting aqueous 
solubility. These limitations greatly prevent them from reaching their desired target 
in cellulo and results in the reduction of their therapeutics efficacy (Stewart et al., 
2008). Others like polynucleic acids (PNAs) would not be able to penetrate into cells 
due to the presence of their high negative charge (Walrant et al., 2011). Over the 
past two decades, CPPs, also called “Trojan horse peptides”, have attracted 
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tremendous attention and found numerous applications in biology and medicine 
(Vives, 2005; Fonseca et al., 2009). CPPs are short peptides (5-30 amino acids)  
capable of translocation through the cellular plasma membrane on their own 
or together with cargoes. They often contain basic amino acid side chains 
and are in many cases amphipathic. The first CPPs were derived from 
naturally occurring proteins such as TAT from HIV-TAT and penetratin 
from the Antennapedia homeodomain (Regberg et al., 2012, p. 991). 
  
Subsequently, many new CPPs either protein-derived or synthetic derivatives have 
been produced and optimized as cell delivery agents (Regberg et al., 2012; Dietz and 
Bähr, 2004; Lundberg and Langel, 2003). Their unique ability to cross the plasma 
membrane and internalize in cells make them very powerful tools to revolutionize 
the transportation of a great variety of different substances ranging from small 
therapeutic drugs to large proteins and DNA (Figure 4.2).  
 
Figure 4.2. Applications of cell-penetrating peptides as molecular delivery 
vehicles (Source: Stewart et al., 2008). 
 
The use of CPPs as molecular vehicles also offers a number of benefits over other 
delivery vectors which include lower toxicity and controlled administration. CPPs 
are obviously an excellent vector to transport various materials across the cell 
membrane and will continue to attract much interest for further exploration in the 
synthetic front (Figure 4.3) and prospective applications (Regberg et al., 2012). 
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Figure 4.3. CPP loading and 
targeting strategies. (Source: 
Regberg et al., 2012) 
(A) Covalent conjugation of 
CPP to cargo 
(B) CPP coupled to targeting 
ligand and cargo 
 (C) Activatable CPP, after 
cleavage of the linker the 
peptide dissociates from the 
polyanion and becomes an 
active CPP  
(D) Non-covalent complex of 
CPPs and cargo 
(oligonucleotides or other 
macromolecules) formed by 
electrostatic and hydrophobic 
interactions. 
 
Among the CPPs, arginine-rich derivatives of human immunodeficiency virus- 
trans-activator of transcription (HIV-TAT) are the most studied. The importance of 
guanidinium-side chain of arginine (Arg) has been demonstrated. When the 
positively charged Arg groups were replaced with neutral alanine amino acids, it led 
to drastic reduction of cell uptake. Furthermore, polyarginine are known to penetrate 
cells more successfully than other polycationic peptides of equal length containing 
lysine, ornithine and histidine (Mitchell et al., 2000). High cell uptake for 
polyarginine were observed for chain lengths of 8 to 15 arginine residues with the 
optimum range being 7 to 9 (Wender  et al., 2000) whereas chain lengths longer than 
15 arginine residues were less efficient to cross the cell membrane (Miklán et al., 
2007; Rijt et al., 2011; Brunner and Barton, 2006). Although polyarginine had 
efficiently delivered diverse conjugated proteins and peptides, only limited reports 
are available on its capacity to enhance delivery of metallodrugs. For instance, a 
great increase in nuclear accumulation has been observed by Barton and coworkers 
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(Brunner and Barton, 2006; Puckett and Barton, 2009) for rhodium and ruthenium-
octaarginine conjugates that target DNA mismatches. Dolan et al. (2013) described 
the very water soluble iridium polyarginine conjugate that displayed a doubling of 
increase cytotoxicity with a decrease in IC50 values as compared to the parent 
complex. The conjugate significantly accumulated in the nucleus whereas the parent 
did not. A few prominent papers have established the influence of the peptide chain 
length on bioactivity. For instance, Rijt et al. (2011) showed that the  
there is a correlation between longer arginine chain length and cell uptake, 
nuclear uptake, DNA binding, and cytotoxicity of the osmium conjugates in 
the following order: eight arginine residues >> five arginine residues ! one 
arginine ~ unfunctionalized. 
 
As will be discussed in Chapter 5, antimicrobial evaluation of non-conjugated 
copper(II) complexes exhibit promising biological activities but suffer from low 
water solubility and poor membrane permeability across bacteria. The molecular 
design strategy employed to circumvent these main drawbacks as well as the 
synthetic efforts made to prepare complexes with enhanced bioactivity will be 
presented herein.  
 
4.1.2.4 Design of the metal complex-peptide conjugates  
There are several strategies available to prepare metal complex-peptide conjugates 
(Metzler-Nolte, 2010; Splith et al., 2010; Dirscherl and Koenig, 2008; Heinze et al., 
2008; Kirin et al., 2005; Liolios et al., 2012; Dirscherl et al., 2007) (Scheme 4.1). 
The most common is to couple the metal complex during solid-phase peptide 
synthesis (SPPS) while the peptide is still retained on the resin (Scheme 4.1a). This 
method carries the benefit of advantages from SPPS of convenient, flexible 
incorporation of metal complexes at any position of the amino acid sequence, high 
 yield and high purity of the conjugates providing the compound is stable enough to 
survive all SPPS manipulations. Alternatively, the peptide
first via SPPS followed by in situ sol
4.1b). The other is to attach the metal complexes in solution after the peptide 
synthesis has been completed on the resin, cleaved and purified (Scheme 4.1c). The 
post-labeling second and third options are definit
(option b) or ligands (option c) that are sensitive towards SPPS conditions
two strategies prevent demetallation and decomposition of the metal complexes.
           Scheme 4.1. Strategies to prepare metal comple
To generate the copper complexes in this work, the strategy based on 
with bidentate ligands was employed as shown below (Scheme 4.2). To allow the 
conjugation of the complexes with various vectors (PEG, peptides), 
a reactive function in the ligand structure is required. Among the orthogonal reactive 
functions, carboxylic acid has been chosen since it is an easy
can react with the terminal amine function of the peptides and the PE
Table 4.1 summarized the conjugates that were synthesized and characterized in this 
work.  
-ligand can be synthesized 
ution complexation with metal ions (Scheme 
ely preferable for metal
x conjugated with peptides.
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Scheme 4.2. Synthetic pathway for the synthesis of the functionalized copper 
complexes. 
 
Table 4.1. Selected ligands and their Cu(II) complexes conjugates that were 
synthesized and studied.  
 R1 R2 Compounds 
abbreviation 
Cu(II) complexes 
abbreviation 
Parent 
compound 
-CH2C6H5 -OH SB4CB Cu(SB4CB)2 
 
 
Conjugates 
-CH2 C6H5 -NH-(EtO)2-
CH2CONH2 
PEG-SB4CB Cu(PEG-SB4CB)2 
-CH2 C6H5 -NH-R-CONH2 R1-SB4CB Cu(R1-SB4CB)2 
-CH2 C6H5 -NH-R4-CONH2 R4-SB4CB Cu(R4-SB4CB)2 
-CH2 C6H5 -NH-R9-CONH2 R9-SB4CB Cu(R9-SB4CB)2 
-CH2 C6H5 -NH-RW9-CONH2 RW9-SB4CB Cu(RW9-SB4CB)2 
-CH2 C6H5 -NH-FR-CONH-
Naphth. 
PA%N-SB4CB Cu(PA%N-SB4CB)2 
Parent 
compound 
-CH3 -OH SM4CB Cu(SM4CB)2 
Conjugates -CH3 -NH-R9-CONH2 R9-SM4CB Cu(R9-SM4CB)2 -CH3 -NH-RW9-CONH2 RW9-SM4CB Cu(RW9-SM4CB)2 
Note: R is the one letter nomenclature for arginine and RW9 corresponds to the 
sequence RRWWRRWRR in which W is tryptophan. F is phenylalanine. Naphth. is 
napthylamide.  
 
In this strategy, symmetrical ligands are involved leading to complexes bearing two 
functionalizing groups. Since most of the conjugation work in the literature focuses 
on tetradentate bis(thiosemicarbazones) containing only a single targeting agent (for 
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radiopharmaceutical purposes), having two functional groups may or may not 
produce the desired results. In fact, in some instances, it could be counterproductive 
as this can further compromise the pharmacokinetics. On the other hand, this 
bivalent approach could also impart higher affinity and selectivity. Ma et al. (2011) 
described the preparation of ligands with two carboxylate functional groups that bear 
two tumor-targeting peptides. The presence of dimeric CPPs in ligands (Hoyer et al., 
2012) and Pt complexes (Abramkin et al., 2012) have been reported to dramatically 
improve their capacity to enter various cells increasing their cytotoxicity potential.  
 
A complex having a PEG was first designed to increase the water solubility.  PEG is 
a neutral water solubilizing agent that does not show any antimicrobial activity. 
Therefore it was to be anticipated that this conjugation would highlight only the 
bioactivity of the complex itself, while enhancing its water solubility. In addition, 
PEG functionalized with carboxylic acid and amine is commercially available. To 
eventually modulate the bacteria uptake of the complexes, the ligands were also 
conjugated to a CPP R9. As mentioned before, cell uptake is optimum for peptides 
having from 8 to 15 arginine residues. Since the complexes preparation involved two 
equivalents of ligand in which two peptides were to be introduced leading to a total 
of 18 arginine residues, thus in addition to R9, different peptide chain with lengths 
of one (R1) or four arginines (R4) were introduced to determine their potential 
influence on the antimicrobial activity of the conjugates. In addition to that, some 
CPPs and antimicrobial peptides (AMPs) are known to share several common 
characteristics such as high density in basic residues and an amphipathic secondary 
structure (a hydrophobic side and a cationic side) in membrane environments (Strøm 
et al., 2003). Recent reports have shown that conjugation of metal binding ligands 
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with AMPs significantly enhances the permeability and activity of the compounds 
against bacteria that have developed cross-resistance against conventional antibiotics 
(Chantson et al., 200534 Chantson et al., 200634 Pagès et al., 2013). Since these 
bioactive peptide sequences consist mainly of arginine and tryptophan, it would also 
be desirable to utilize RW9 (a CPP derived from penetratin) as a vector for 
bioconjugation in search of new improved antibacterial agent (Walrant et al., 2011). 
And not least, a peptide known as an inhibitor of bacteria efflux pumps was grafted 
also. The challenge of multi-drug resistance has become a pressing issue in treating 
bacterial infections and one resistance pathway of multi-drug resistant bacteria 
involves the “over-expression of efflux pumps which expel structurally unrelated 
antibiotics thus decreasing their intracellular concentration” (Nikaido and Pagès, 
2012, p. 340; Pagès and Amaral, 2009). Recent attention has been directed to the 
discovery of small molecules that inhibit the efflux pumps of the “resistance-
nodulation-division (RND) family in gram-negative bacteria” (Okandeji et al., 2011, 
p. 7679). These compounds “act by competitively binding the substrate interacting 
sites of RND-family efflux” (Santos et al., 2012, p. 292) and for that reason, the 
efflux pumps inhibitors (EPIs) are often used as adjuvants to restore susceptibility of 
MDR bacterial pathogens to drugs. “The prototypical inhibitor of RND-family 
efflux pumps in gram-negative bacteria is” a C-capped dipeptide, MC-207,110 (Phe-
Arg-%-naphthylamide, PA%N) (Okandeji et al., 2011, p. 7679). In this work, the 
adjuvant PA%N was directly linked to the antibacterial agent, namely the Cu(II) 
complex in order to eventually reveal any synergistic effect. At this moment, there is 
no knowledge of the mechanism of antimicrobial activity of dithiocarbazate derived 
Schiff base compounds and therefore efflux pumps give us a potential starting target. 
It was hoped that during the pursuit of this target, light would be shed on the 
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problem and show the path to improving the activity and pharmacological properties 
of our lead compounds. 
 
 4.2  Methodology 
4.2.1 Materials 
All chemicals and solvents used were similar to those mentioned in Chapter 3 unless 
stated otherwise herein. Peptide synthesis: 4-Methylbenzhydrylamine (MBHA) resin 
(0.54 mmol/g, Iris Biotech GmbH), fluorenlymethyloxycarbonyl(Fmoc)-rink amide 
resin MBHA resin (0.52 mmol/g, Iris Biotech GmbH), tert-butoxycarbonyl (Boc)-L-
Arg (Tos)-OH (Iris Biotech GmbH), Boc-L-Trp (CHO)-OH (Neosystem 
Laboratoire), Fmoc-AEEA-OH (Iris Biotech GmbH), PA%N (Bachem), 
hydroxybenzotriazole, HOBt (Molekula), N,N,N$,N$-Tetramethyl-O-(1H-
benzotriazol-1-yl)uraniumhexafluorophosphate, O-(Benzotriazol-1-yl)-N,N,N$,N$-
tetramethyluronium hexafluorophosphate, HBTU (Novabiochem), 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxid hexa-
fluorophosphate,  HATU (Iris Biotech GmbH), 1-hydroxy-7-azabenzotriazole,  
HOAt (GL BioChem (Shanghai) Ltd/ Applied Biosystems), N,N-
diisopropylethylamine, DIEA (Alfa Aesar), piperidine (Carlo Ebra RS), TFA (Carlo 
Ebra RS), hydrofluoric acid, HF (Merck), triisopropylsilane, TIS (Merck), N-
methyl-2-pyrrolidone, NMP (Merck), acetic acid (AnalaR Normapur,VMR 
chemicals). Buffers: Acetate buffer pH 4 and 6, 0.1 M (Na acetate-Janssen Chimica, 
acetic acid-AnalaR Normapur, VMR chemicals), PBS pH 7.4, 0.01M (Sigma 
Aldrich tablet) and borate buffer ph 9 (Na tetraborate-Acros Organics).   
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4.2.2 Instrumentation 
All instrumentations were similar to those mentioned in Chapter 3 unless stated 
otherwise herein. Peptides and conjugates were characterized by MALDI-TOF-MS 
in the positive ion reflector mode on an ABI Voyager DE-Pro MALDI-TOF mass 
spectrometer (Applied Biosystems) using as matrix a saturated solution of CHCA in 
CH3CN/H2O/TFA (50:50:0.1 v:v:v). LC-MS was carried out using an Applied 
Biosystems QTRAP LC-MS/MS System with a linear gradient elution developed 
from holding time of 5 min at 100% A and then from 0-60% B in 30 min. Eluent A 
was 0.1% formic acid in water, while eluent B was 0.1% formic acid in acetonitrile. 
Experiments were carried out at a flow rate of 10 µL min-1 at room temperature with 
a microLC C18 column1 mm in diameter with UV detector. Peaks were detected at 
220 nm and 280 nm. ITC titrations were performed and analysed using the Nano 
ITC standard volume calorimetry (TA Instruments) apparatus. Aliquots (10 !L) of 
the Cu(II)(OAc)2 solution  were added to the solution of the ligand in 0.1M acetate 
buffer at pH 6. An equilibration time of 300 s was allowed between each addition. 
Measurements were conducted at 25 °C in a 983 µL cell volume with a 250 µL 
syringe with stirring rate 300 RPM. The concentrations of the metal salts and of the 
ligands were adjusted to yield total conversion and a good signal/noise ratio for each 
experiment. All enthalphy of reactions (2H) values were corrected against the heat 
of dilution. ITC results were analyzed using the Nano Analyze software supplied 
(version 2.1.6), utilizing a one binding site model. The crude products (conjugated 
ligands) were analyzed and purified by RP-HPLC using three Waters HPLC systems 
connected to Breeze software:  
System A was similar to Chapter 3. 
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System B consisted of combination of a dual wavelength UV-Vis absorbance 
detector (Waters 2487) and a binary pump (Waters 1525) equipped with and a semi-
preparative cell for purification purposes. Purification of crude products was 
achieved with C8 semi preparative column (250!10mm, 5 µm particles of 300 Å 
pore size). Experiments were carried out at a flow rate of 4 mL min-1 at room 
temperature. Injection volume was 1.5 mL. Sample concentration was 
approximately 10 mg/mL. 
System C consisted of a dual wavelength UV-Vis absorbance detector (Waters 
2487) and a Waters 600 preparative pump.  Purification of crude products was 
achieved with a Waters X-bridge C18 preparative column (19!50mm, 5 µm 
particles of 300 Å pore size). Experiments were carried out at a flow rate of 10 mL 
min-1 at room temperature. Injection volume was 1.5 mL. Sample concentration was 
approximately 10 mg/mL. 
All the peaks were detected at 220 nm and 280 nm. All the HPLC experiments were 
performed using water containing 0.1% of TFA as eluent A and acetonitrile 
containing 0.1% of TFA as eluent B. Several elution gradients were developed for 
the different compounds as detailed in the synthetic section. 
 
4.2.3 Synthesis 
General procedure A  
The PEG derivative was synthesized on solid support by Fmoc strategy using Fmoc 
protected MBHA Rink amide resin (loading 0.52 mmol/g). The resin was swollen in 
DCM one hour prior to use. Fmoc removal was performed by using 20% (v:v) 
piperidine in NMP once for 1 min and then once for 15 min. The resin was washed 
five times with NMP. Then, a solution of Fmoc-AEEA-OH (3 equiv) was 
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preactivated with HBTU/HOBt (3 equiv/3 equiv) and DIEA (6 equiv) in NMP (1 
mL for 0.1 g of resin) and added to the resin in a reaction vessel (polypropylene 
syringe). After completion (monitored by Kaiser test for primary amines, in case of 
positive Kaiser test, the same amino acid was condensed again until a negative test is 
obtained) the Fmoc group of the PEG derivative was removed as previously 
described. A solution of Schiff base (SB4CB) (3 equiv) was preactivated with 
HATU/HOAt (3 equiv/3 equiv) and DIEA (6 equiv) in NMP (1 mL for 0.1 g of 
resin) and added to the resin. The mixture was allowed to react on the automatic 
shaker for 2 hours. Cleavage from the resin was performed by shaking for 3 h with a 
solution of 5 mL of TIS (2.5%), deionised water (2.5%), and TFA (95%). The 
mixture was then filtered and the volume of the solution was reduced by 
evaporation. Cold diethyl ether was then added to precipitate the compound, which 
was then centrifuged for 5 min at 8000 RPM (three times). The compound was 
solubilized in deionised water and lyophilized. The crude product was then purified 
with preparative RP-HPLC.  For N-terminus acetylated PEG, instead of the coupling 
with the ligand, the acetylation was performed with 10% acetic anhydride in DCM 
for 1 hour at room temperature. The compound was cleaved as described but no 
precipitation occurred upon addition of diethyl ether. The crude was purified by 
silica-gel column chromatography. 
  
PEG-SB4CB 
To PEG-NH2 on Fmoc-MBHA Rink amide resin (0.25 g, 0.13 mmol) was added a 
solution of SB4CB (0.129 g, 0.39 mmol, 3 equiv), HATU (0.148 g, 0.39  mmol, 3 
equiv), HOAt (0.053 g, 0.39 mmol, 3 equiv) and DIPEA (0.136 mL, 0.78 mmol, 6 
equiv) in DMF (2.5 mL). The crude peptide material was purified with System C: 
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gradient elution of 5 to 100% of B in A for 10 min. The peak eluted at 7.2 min. The 
fraction was freeze-dried to give PEG-SB4CB as a cream powder. Analytical RP-
HPLC (System A: gradient elution of 5 to 100% of B in A for 30 min): RT = 17.5 
min. HR-MS: m/z = [M+Na]+ Calcd. 497.12877, Found 497.12892. 1H NMR (300 
MHz, CD3OD) ! 8.57 (s, 1H), 8.08 (s, 1H), 7.82 (dd, J = 19.5, 9, 4H), 7.45 – 7.21 
(m, 5H), 4.52 (s, 2H), 3.96 (s, 2H), 3.69 (s, 6H), 3.59 (d, J =6, 2H). 13C NMR (75 
MHz, CD3OD) ! (ppm) 200.29, 175.93, 169.77, 145.41, 138.40, 138.36, 137.28, 
130.54, 129.71, 129.02, 128.71, 128.49, 72.11, 71.38, 71.22, 70.71, 41.05, 39.91. 
 
AcPEG-NH2 (PEGAC) 
PEG-NH2 on Fmoc-MBHA Rink amide resin (0.784 g, 0.42 mmol) was acetylated 
with 10% acetic anhydride in DCM for 1 hour at room temperature.  The crude was 
purified by silica-gel column chromatography eluted with a gradient of MeOH in 
DCM from 4/96 to 10/90 (v:v) MeOH/DCM to yield the expected compound. The 
expected compound fraction was evaporated to give AcPEG-NH2 as a colourless 
oily solid (88 mg, 98%). HR-MS: m/z = [M+Na]+ Calcd. 227.10023, Found 
227.10031. 1H NMR (300 MHz, CD3OD) ) 3.99 (s, 2H), 3.72-3.64 (m, 4H), 3.56 (t, 
J = 6, 2H), 3.40 – 3.34 (m, 2H), 1.95 (s, 3H). 13C NMR (75 MHz, CD3OD) ) 175.95, 
173.71, 72.06, 71.38, 71.22, 70.89, 40.54, 22.65. 
 
General procedure B 
Side-chain protected polyarginine (R1, R4, R9 and RW9) were assembled on 
MBHA resin (loading 0.54 mmol/g) either manually or using the peptide synthesizer 
(Applied Biosystem 433A) with HBTU/HOBt as coupling agents. All amino acids 
were coupled as Boc derivatives. The side chain Arg residue was protected by a 
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tosyl group and the tryptophan side chain was protected by a formyl group. For 
RW9, deformylation was performed with 20% piperidine in NMP for approximately 
2 hours (sequential time length addition 1 min, 3 min, 5 min, 7 min, 15 min, 30 min 
and finally 60 min) prior to Boc removal and coupling to the Schiff base. Boc 
removal was perfomed by using TFA for 1 min (twice) and washed with 10% DIEA 
in DCM. Coupling was the same as for Fmoc synthesis. Cleavage from the resin and 
tosyl protecting group removal was performed using HF in the presence of dimethyl 
sulfide for 2 hours at 0°C. After HF removal, cold diethyl ether was added to 
precipitate the peptide. The precipitate was collected, redissolved using 10% acetic 
acid in water and lyophilized. For N-terminus acetylated peptides, the acetylation 
was performed with 10% acetic anhydride in DCM for 1 hour at room temperature.  
 
R1-SB4CB  
To R1-NH2 on MBHA resin (0.25 g, 0.135 mmol) was added a solution of SB4CB 
(0.135 g, 0.405 mmol, 3 equiv), HATU (0. 154 g, 0.405 mmol, 3 equiv), HOAt 
(0.055 g, 0.405 mmol, 3 equiv) and DIPEA (0.140 mL, 0.810 mmol, 6 equiv) in 
DMF (2.5 mL). The crude peptide material was purified with System C: gradient 
elution of 5 to 100% B in A for 10 min. The peak eluted at 6.06 min. The fraction 
was freeze-dried to give R1-SB4CB as a cream powder. Analytical RP-HPLC 
(System A: gradient elution of 5 to 100% of B in A for 30 min): RT = 16.1 min. LC-
MS: m/z = [M+H]+ Calcd. 486.17, Found 486.10. 1H NMR (300 MHz, CD3OD) ) 
8.10 (s, 1H), 7.86 (dd, J = 27, 9, 4H), 7.44 – 7.22 (m, 5H), 4.61 (dd, J = 9, 3, 1H), 
4.53 (s, 2H), 3.24 (td, J = 7.5, 3, 2H), 2.06 – 1.94 (m, 1H), 1.90 – 1.63 (m, 3H). 13C 
NMR (75 MHz, CD3OD) ! = 200.36, 176.66, 169.66, 158.79, 145.29, 138.74, 
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138.35, 136.70, 130.53, 129.71, 129.26, 128.70, 128.50, 54.55, 42.12, 39.93, 30.44, 
26.65  
 
R4-SB4CB  
To R4-NH2 on MBHA resin (0.25 g, 0.135 mmol) was added a solution of SB4CB 
(0.135 g, 0.405 mmol, 3 equiv), HATU (0. 154 g, 0.405 mmol, 3 equiv), HOAt 
(0.055 g, 0.405 mmol, 3 equiv) and DIPEA (0.140 mL, 0.810 mmol, 6 equiv) in 
DMF (2.5 mL). The crude peptide material was purified with System C: gradient 
elution of 30 to 50% B in A for 10 mins. The peak eluted at 3.34 min. The fraction 
was freeze-dried to give R4-SB4CB as a cream powder. Analytical RP-HPLC 
(System A: gradient elution of 5 to 100% of B in A for 30 min): RT = 14.0 min. 
MALDI-TOF-MS: m/z = [M+H]+ Calcd. 954.48, Found 954.49. 1H NMR (300 
MHz, CD3OD) ) 8.10 (s, 1H), 7.87 (dd, J = 27, 6, 4H), 7.44 – 7.23 (m, 5H), 4.55 – 
4.47 (m, 3H), 4.43 – 4.31 (m, 3H), 3.28 – 3.13 (m, 8H), 2.00 – 1.61 (m, 16H). 
 
R9-SB4CB 
To R9-NH2 on MBHA resin (0.25 g, 0.135 mmol) was added a solution of SB4CB 
(0.135 g, 0.405 mmol, 3 equiv), HATU (0. 154 g, 0.405 mmol, 3 equiv), HOAt 
(0.055 g, 0.405 mmol, 3 equiv) and DIPEA (0.140 mL, 0.810 mmol, 6 equiv) in 
DMF (2.5 mL). The crude peptide material was purified with System C: gradient 
elution of 5 to 100% B in A for 10 min. The peak eluted at 4.86 min. The fraction 
was freeze-dried to give R9-SB4CB as a cream powder. Analytical RP-HPLC 
(System A: gradient elution of 5 to 100% of B in A for 30 min): RT = 13.3 min.  
MALDI-TOF-MS: m/z = [M]+ Calcd. 1733.98, Found 1733.93. 1H NMR (300 MHz, 
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CD3OD) ) 8.11 (s, 1H), 7.89 (dd, J = 39, 9, 4H), 7.44 – 7.23 (m, 5H), 4.53 (s, 2H), 
4.40 – 4.17 (m, 9H), 3.30 – 3.09 (m, 18H), 2.02 – 1.52 (m, 36H). 
 
RW9-SB4CB  
To RW9-NH2 on MBHA resin (0.25 g, 0.135 mmol) was added a solution of 
SB4CB (0.135 g, 0.405 mmol, 3 equiv), HATU (0. 154 g, 0.405 mmol, 3 equiv), 
HOAt (0.055 g, 0.405 mmol, 3 equiv) and DIPEA (0.140 mL, 0.810 mmol, 6 equiv) 
in DMF (2.5 mL). The crude peptide material was purified with System C: gradient 
elution of 5 to 100% B in A for 10 min. The peak eluted at 5.69 min. The fraction 
was freeze-dried to give RW9-SB4CB as a cream powder. Analytical RP-HPLC 
(System A: gradient elution of 5 to 100% of B in A for 30 min): RT = 16.5 min.  
MALDI-TOF-MS: m/z = [M]+ Calcd. 1823.91, Found 1823.27. 1H NMR (300 MHz, 
CD3OD) ) 8.06 (s, 1H), 7.79 (dd, J = 45, 9, 4H), 7.55 (d, J = 6, 1H), 7.46 – 7.22 (m, 
10H), 7.17 – 6.84 (m, 9H), 4.61 (dd, J = 9, 6, 1H), 4.54 (s, 2H), 4.48 (td, J = 4.5, 3, 
2H), 4.33 – 4.21 (m, 3H), 4.14 – 4.00 (m, 3H), 3.35 (s, 5H), 3.27 – 2.95 (m, 15H), 
1.97 – 1.37 (m, 24H). 
 
R9-SM4CB  
To R9-NH2 on MBHA resin (0.25 g, 0.135 mmol) was added a solution of SM4CB 
(0.089 g, 0.405 mmol, 3 equiv), HATU (0. 154 g, 0.405 mmol, 3 equiv), HOAt 
(0.055 g, 0.405 mmol, 3 equiv) and DIPEA (0.140 mL, 0.810 mmol, 6 equiv) in 
DMF (2.5 mL). After cleavage, the crude peptide material was purified with System 
C: gradient elution of 5 to 100% B in A for 10 min. The peak eluted at 4.32 min. 
The fraction was freeze-dried to give R9-SM4CB as a cream powder. Analytical RP-
HPLC (System A: gradient elution of 5 to 100% of B in A for 30 min): RT = 11.8 
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min.  MALDI-TOF-MS: m/z = [M+H]+ Calcd. 1658.95, Found 1658.78. 1H NMR 
(300 MHz, CD3OD) ) 8.11 (s, 1H), 7.91 (dd, J = 39, 9, 4H), 4.42 – 4.20 (m, 9H), 
3.30 – 3.11 (m, 18H), 2.60 (s, 3H), 2.04 – 1.55 (m, 36H). 
 
RW9-SM4CB  
To RW9-NH2 on MBHA resin (0.25 g, 0.135 mmol) was added a solution of 
SM4CB (0.089 g, 0.405 mmol, 3 equiv), HATU (0. 154 g, 0.405 mmol, 3 equiv), 
HOAt (0.055 g, 0.405 mmol, 3 equiv) and DIPEA (0.140 mL, 0.810 mmol, 6 equiv) 
in DMF (2.5 mL). The crude peptide material was purified with System C: gradient 
elution of 20 to 50% B in A for 10 min. The peak eluted at 6.11 min. The fraction 
was freeze-dried to give RW9-SM4CB as a cream powder. Analytical RP-HPLC 
(System A: gradient elution of 5 to 100% of B in A for 30 min): RT = 14.0 min.  
MALDI-TOF-MS: m/z = [M+H]+ Calcd. 1748.89, Found 1748.45. 1H NMR (300 
MHz, CD3OD) ) 8.07 (s, 1H), 7.95 (d, J = 9, 2H), 7.77 (d, J = 6, 2H), 7.55 (d, J = 6, 
1H), 7.46 – 7.28 (m, 5H), 7.19 – 6.84 (m, 9H), 4.57 (dd, J = 15, 9, 1H), 4.49 – 4.36 
(m, 2H), 4.33 – 4.17 (m, 3H), 4.14 – 3.96 (m, 3H), 3.28 – 2.96 (m, 15H), 2.61 (s, 
3H), 1.94 – 1.27 (m, 24H). 
 
AcR1-NH2 (R1AC) 
To R1-NH2 on MBHA resin (0.25 g, 0.135 mmol), the acetylation was performed 
with 10% acetic anhydride in DCM for 1 hour at room temperature. The crude 
peptide material was purified with System C: gradient elution of 0 to 30% B in A for 
10 mins. The peak eluted at 3.26 min. The fraction was freeze-dried to give R4AC 
as a cream powder. Analytical RP-HPLC (System A: gradient elution of 0 to 30% of 
B in A for 30 min): RT = 4.0 min. HR-MS: m/z = [M+H]+ Calcd. 216.14550, 
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Found 216.14556. 1H NMR (300 MHz, CD3OD) ) 4.35 (dd, J = 9, 6, 1H), 3.28 – 
3.17 (m, 2H), 2.01 (s, 3H), 1.96 – 1.83 (m, 1H), 1.75 – 1.59 (m, 3H). 13C NMR (75 
MHz, CD3OD) ) 176.79, 173.61, 54.00, 42.09, 30.38, 26.46, 22.66. 
 
AcR4-NH2 (R4AC)  
To R4-NH2 on MBHA resin (0.25 g, 0.135 mmol), the acetylation was performed 
with 10% acetic anhydride in DCM for 1 hour at room temperature. The crude 
peptide material was purified with System C: gradient elution of 0 to 30% B in A for 
10 min. The peak eluted at 4.36 min. The fraction was freeze-dried to give R4AC as 
a cream powder. Analytical RP-HPLC (System A: gradient elution of 0 to 30% of B 
in A for 30 min): RT = 6.8 min.  MALDI-TOF-MS: [M+K]+ Calcd. 836.02, Found 
722.33; [M+Na]+ Calcd. 820.04, Found 706.37; [M+H]+ Calcd. 684.45, Found 
684.38. 1H NMR (300 MHz, CD3OD) ) 4.38 – 4.24 (m, 4H), 3.21 (t, J = 6.6, 8H), 
2.02 (s, 3H), 1.98 – 1.56 (m, 16H). 
 
AcR9-NH2 (R9AC) 
To R9-NH2 on MBHA resin (0.25 g, 0.135 mmol), the acetylation was performed 
with 10% acetic anhydride in DCM for 1 hour at room temperature. The crude 
peptide material was purified with System B: gradient elution of 0 to 30% B in A for 
30 min. The peak eluted at 9 min. The fraction was freeze-dried to give R9AC as a 
cream powder. Analytical RP-HPLC (System A: gradient elution of 5 to 100% of B 
in A for 30 min): RT = 6.0 min.  MALDI-TOF-MS: [M+K]+ Calcd. 836.02, Found 
1486.90; [M+Na]+ Calcd. 1502.87, Found 1486.90; [M+H]+ Calcd. 1464.95, Found 
1464.93. 1H NMR (300 MHz, CD3OD) ) 4.35 – 4.12 (m, 9H), 3.28 – 3.16 (m, 18H), 
2.04 (s, 3H), 1.96 – 1.63 (m, 36H). 
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AcRW9-NH2 (RW9AC) 
To RW9-NH2 on MBHA resin (0.25 g, 0.135 mmol), the acetylation was performed 
with 10% acetic anhydride in DCM for 1 hour at room temperature. The crude 
peptide material was purified with System B: gradient elution of 5 to 100% B in A 
for 30 mins. The peak eluted at 12 min. The fraction was freeze-dried to give 
RW9AC as a cream powder. Analytical RP-HPLC (System A: gradient elution of 5 
to 100% of B in A for 30 min): RT = 10.6 min. MALDI-TOF-MS: [M+K]+ Calcd. 
836.02, Found 1593.72; [M+Na]+ Calcd. 820.04, Found 1577.75; [M+H]+ Calcd. 
1554.89, Found 1554.78. 1H NMR (300 MHz, CD3OD) ) 7.56 (d, J = 9, 1H), 7.48 – 
7.30 (m, 5H), 7.14 – 6.89 (m, 9H), 4.60 (dd, J = 9, 6, 1H), 4.44 (dd, J = 15, 9, 2H), 
4.34 – 4.21 (m, 2H), 4.15 – 3.98 (m, 4H), 3.36 (d, J = 5.7, 1H), 3.29 – 2.94 (m, 
16H), 2.05 (s, 3H), 1.89 – 1.29 (m, 24H). 
 
Procedure C (Solution synthesis) 
PA"N-SB4CB  
The ligand SB4CB (10 mg, 0.061 mmol, 1 equiv), PA%N.2HCl (23.5 mg, 0.091 
mmol, 1.5 equiv), HATU (17.3 mg, 0.091 mmol, 1.5 equiv) and HOAt (6.2mg, 
0.091 mmol, 1.5 equiv) were placed in a round-bottom flask under argon. Dried 
DMF (1 mL) was added followed by DIEA (0.026 mL, 0.303 mmol, 5 equiv). The 
reaction mixture was stirred overnight at room temperature. Analytical HPLC 
showed conversion of starting material into a less polar product >50%. After 
dilution with water, the crude peptide material was purified with System C: gradient 
elution of 5 to 100% B in A for 10 min. The peak eluted at 8.57 min. The fraction 
was freeze-dried to give PA%N-SB4CB as a yellowish solid. Analytical HPLC: RT = 
21.5 min. MALDI-TOF-MS: m/z = [M+H]+ Calcd. 759.29, Found 759.24. 1H NMR 
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(300 MHz, CD3OD) ) 8.19 (d, J = 3, 1H), 8.06 (s, 1H), 7.86 – 7.73 (m, 7H), 7.58 – 
7.05 (m, 14H), 4.83 (dd, J = 9, 6, 1H), 4.58 (dd, J = 15, 6, 1H), 4.53 (s, 2H), 3.29 – 
3.07 (m, 4H), 2.04 – 1.61 (m, 4H). 
 
Preparation of copper (II) complexes, CuL2 
To the bioconjugate L (mmol, 2 equiv) in methanol was added a solution of 
Cu(OAc)2·H2O (mmol, 1 equiv), the solution mixture was stirred overnight and then 
evaporated to dryness to give brown oily solid.   
 
4.3 Results and discussion 
4.3.1 Synthesis  
The synthesis of the bidentate dithiocarbazate Schiff base ligand bioconjugates with 
PEG and peptides are reported here for the first time as well as the synthesis of their 
Cu(II) complexes. The preparation of eight new ligand-vector conjugates and their 
Cu complexes containing Schiff base ligands derived from the condensation of 
SMDTC/SBDTC with 4-carboxybenzaldehyde and various vectors comprising 
CPPs, PEG and EPI are detailed in this work. In addition, five acetylated vectors 
were also prepared for meaningful comparison during the antimicrobial evaluation. 
The compounds were synthesized using either solid phase peptide synthesis 
techniques or solution phase coupling conditions. The presence of metal ion and/or 
Schiff base in the system can interfere with standard conjugation synthetic 
procedures. Therefore, the procedure needs to be optimized accordingly for each 
compound to prevent hydrolysis, decomposition and demetallation.  
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In the case of Schiff base ligand-PEG conjugate, the conjugation was performed via 
Fmoc strategy using a rink amide resin (Scheme 4.3). The synthesis for PEG 
conjugates was relatively straightforward. The PEG amino acid was coupled using 
standard HBTUand HOBt coupling reagents in basic conditions. After Fmoc 
deprotection, the coupling of the Schiff base was performed using HATU and 
HOAt. Cleavage from the resin of the ligand-PEG conjugate was achieved in the 
cocktail mixture of 95% TFA, 2.5% TIS and 2.5% water. Only one major peak 
assignable to the product was observed in the crude chromatogram (Figure 4.4). The 
ligand was purified by reverse-phased HPLC and the complex was formed in 
MeOH. The acetylated PEG carboxamide was synthesized similarly to be used as a 
control compound for the biological tests. 
 
 
Scheme 4.3. Synthesis of the PEGylated copper complex by Fmoc strategy. (a) 
20% piperidine in NMP, 1 ! 5 min, 1 ! 30 min. (b) HBTU, HOBt, DIEA, Fmoc-
AEEA-OH, anhydrous DMF, 30 min-1 hr. (c) HATU, HOAt, DIEA, Schiff base 
ligand, anhydrous DMF, 2 hr (d) 95% TFA, 2.5% TIS and 2.5% H2O, 3 hr (e) 
Cu(OAc)2 in MeOH, r.t. overnight. 
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(a) 
          
(b)
 
Figure 4.4. Chromatograms of PEG-SB4CB synthesized via Fmoc strategy. (a) 
Crude (b) Purified. Detection at ! = 220 nm (top) and 280 nm (bottom). The 
peak at 17.5 min corresponds to the expected product. 
 
 
While the Fmoc strategy was relatively straightforward for PEG conjugates, the 
synthesis was problematic for polyarginine conjugates. Problems arose because the 
CPPs themselves were difficult to assemble using Fmoc strategy which required 
multiple repeat couplings and long reaction times. Although the synthesis was 
monitored by the Kaiser test which indicated that the coupling and deprotection at 
each step was successful, the final result after cleavage of the conjugates from the 
resin was not satisfactorily with the presence of a mixture of polyarginine (R9, R8, 
R7) or Fmoc-protected polyarginine in the chromatograms of crude products. In 
addition to that, the HPLC profile was not always reproducible and at times, 
hydrolysis of the Schiff base hydrazone moiety was observed with the hydrolyzed 
byproduct peak being almost equal to the peak of the desired product. As a result, 
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preparation of the polyarginine peptides was then performed using Boc-strategy on 
MBHA resin to obtain C-carboxamide peptides. The CPPs couplings were 
performed using tosyl and formyl as side-chain protecting groups for arginine and 
tryptophan respectively and HBTU/HOBt as coupling reagents (Scheme 4.4). The 
Boc groups were removed using pure TFA for 1 min the first time and repeat for 5 
mins. The ligands were introduced at the N-terminal amino group of the protected 
resin bound polyarginine with HATU/HOAt as coupling agents for efficient 
coupling without the need for repeat coupling. The compounds were removed from 
the resin simultaneously with the cleavage of the tosyl side-chain protecting groups 
in HF in the presence of anisole and dimethysulfide (Me2S) as radical scavengers. 
However, in some cases the presence of anisole led to an unexpected byproduct, 
which has a very similar retention time to that of the expected compound, 
consequently, only Me2S was employed (Figure 4.5). If the conjugates were found to 
contain formyl-protected tryptophan, the formyl deprotection was subsequently 
carried out with 20% piperidine in NMP prior to coupling with Schiff base ligands. 
Otherwise, when deformylation was carried out after the coupling of the Schiff base, 
total hydrolysis of the Schiff base moiety resulted. The product was purified by RP-
HPLC and compounds were obtained as yellow powders readily soluble in either 
water or organic solvents such as DMSO, DMF and methanol. N-acetylated versions 
were synthesized for all conjugated peptides by following the same procedures. The 
final acetylation was performed using acetic anhydride in DCM 10/90 v:v. 
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Scheme 4.4. Synthesis of ligand-peptide conjugates by Boc-strategy. (a) HBTU, 
HOBt, DIEA and Boc-Arg(Tos)-OH in NMP for 30 min. (b) Neat TFA, 2 ! 1 
min then 20% DIEA in DCM. (c) HATU, HOAt, DIEA and Schiff base ligands 
in anhydrous DMF for 2 hr. (d) HF and Me2S for 2 hr at 0°C. (e) Cu(OAc)2 in 
MeOH, r.t. overnight.  
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(a) 
(b) 
(c) 
(d) 
Figure 4.5. RP-HPLC 
chromatograms 
obtained on a C8 
column. Samples were 
eluted  using a 
gradient of acetonitrile 
from 5 to 95% in 
water over 30 min 
with 1mL min-1  flow 
rate at room 
temperature (both 
solvents contain 0.1% 
TFA). Detection: ! = 
220 nm (top) and 280 
nm (bottom) 
 
(a) HPLC profile of 
the crude R9-SM4CB 
conjugate from Boc-
strategy with the 
addition of anisole 
during HF-cleavage. 
The peak at ~6 min is 
the hydrolyzed 
compound, the peak at 
11.8 min is the desired 
product while the 
peak at ~14.5 min is 
the byproduct caused 
by anisole. 
 
(b) RP-HPLC profile 
of the crude R9-
SM4CB conjugate 
from Boc-strategy 
without the addition of 
anisole during HF-
cleavage. The 
byproduct observed in 
(a) caused by anisole 
was no longer visible. 
 
(c) RP-HPLC elution 
profile of the crude 
R9-SM4CB conjugate 
from Fmoc-strategy. 
The profile was less 
well resolved as 
compared to Boc-
strategy and not 
always reproducible.  
 
(d) RP-HPLC elution 
profile of the purified 
R9-SM4CB. 
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It should also be noted that among the early attempts to functionalize the parent 
compounds, aliphatic side chain ligands from levulinic acid were utilized. However, 
the standard SPPS were unsuccessful as they resulted in total hydrolysis of the 
Schiff base moiety. Although alternative approaches were adopted to synthesize the 
conjugate in solution via ring-opening of succinic anhydride and formation of acyl 
chloride, the ligands were found to be unstable under these reaction conditions. This 
showed that aliphatic side chain ligands are not suitable for use in bioconjugation. 
The rigid carboxylate benzyl ring in 4-carboxylbenzaldehyde derivatives (SM4CB 
and SB4CB) provided suitable stability and functionality for coupling by SPPS. The 
ability to survive the synthesis and purification conditions is important and the stable 
4-carboxybenzaldehyde derived Schiff base ligands were deemed most suitable for 
bioconjugation in this work.  
 
The conjugation of SB4CB with the efflux pump inhibitor PA%N was effected 
through solution synthesis (Scheme 4.5). 
 
Scheme 4.5. Solution synthesis of PA"N-SB4CB (a) HATU, HOAt, DIEA and 
Schiff base ligand mixture in anhydrous DMF overnight at r.t. (b) in MeOH 
overnight.!
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The carboxyl group of SB4CB was coupled to the free N-terminal amino group of 
phenylalanine with the coupling agents HATU/HOAt in anhydrous DMF. The 
reaction progress was monitored by RP-HPLC. Although an excess of PA%N was 
used, the reaction did not proceed to completion even after 24 hours with the peaks 
corresponding to the starting materials still visible in the chromatograms (Figure 
4.6). The product PA%N-SB4CB along with the unreacted starting material were 
separated using preparative HPLC.  
(a) 
  
(b) 
 
Figure 4.6. Chromatograms of PA"N-SB4CB synthesized in solution. (a) Crude 
(b) Purified. The peak at 21.5 min corresponds to the expected product. 
 
 
The purity of each ligand and aceylated peptide was confirmed by the presence of a 
single peak in the reverse-phased HPLC chromatogram. The purity for all the 
compounds was ensured to be >95%. The copper complexes were finally obtained 
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by mixing a 0.5 equivalent of Cu(OAc)2 to the ligand in MeOH. All ligand 
conjugates and their respective complexes were comprehensively characterized 
spectroscopically. 
 
4.3.2 Characterization of ligands conjugates 
4.3.2.1 NMR 
All ligands were analyzed by NMR spectroscopy in order to confirm the integrity of 
the Schiff base hydrazone moiety. For illustration, the example of R1-SB4CB will 
be discussed here while the rest of the spectra are available in the Appendices. 1H 
and 13C spectra of R1-SB4CB in CD3OD are shown in Figure 4.7. The presence of 
the Schiff base is immediately apparent from the NMR spectra of the bioconjugates. 
R1-SB4CB possesses peaks that corresponds to the SB4CB moiety: characteristic 
resonance signals at ) 8.10 ppm and 7.90-7.80 ppm attributed to -CH=N and the 
aromatic ring of 4-carboxybenzaldehyde moiety, the 5 aromatic protons of SBDTC 
in the region of 7.43-7.23 ppm and the presence of a singlet of the S-CH2 protons 
observed at 4.53 ppm. These chemicals shifts of SB4CB moiety are consistent in 
almost all the NMR spectra of the bioconjugates with exception of RW9-SB4CB 
and PA%N- SB4CB in which the SB4CB aromatic region multiplets overlapped with 
the peptides tryptophan, phenylalanine and napthylamide protons. For SM4CB 
derived conjugates, the aromatic ring in the region of 7.43-7.23 ppm and S-CH2 
protons at 4.53 ppm were absent while the distinctive methyl signal for SMDTC was 
clearly visible at 2.61 ppm. Signals arising from the protons of arginine were 
observed at ca. 4.85-4.59 ppm, 3.26-3.21 ppm and 2.06-1.62 ppm corresponding to 
&-CH, )-CH2 and %, --CH2 respectively. The &-CH2 peaks shifted highfield with 
increasing number of arginine with the signals observed at ca. 4.40-4.17 ppm for 
128 
 
R9-SB4CB. In RW9 derivatives, the tryptophan %-CH2 signal partially overlapping 
with the arginine )-CH2 protons as well as the CD3OD solvent peak while the &-CH 
of tryptophan can be easily located between ca. 4.60-4.45 ppm. Such overlappings 
were also observed for PA%N-SB4CB in which the protons of &-CH and %-CH2 each 
overlapped with the CD3OD solvent peaks at 4.78 ppm and 3.31 ppm. For PEG-
SB4CB, the 10 protons of PEG can be found in the region ca. 4.00-3.50 ppm. In 
principle, dithiocarbazate derivatives can exhibit thione-thiol tautomerism due to the 
presence of thioamide function –NH-C(S)SR. In the 13C NMR spectra of R1-
SB4CB, the presence of -NH-C(=S)S at ) 200.36 ppm indicates that the Schiff bases 
predominate as the thione form in solution (if thiol form is present, a signal at ca. 
158 ppm will be observed) (How, 2008). This signal was shifted downfield due to 
the deshielding effect of the neighbouring amine nitrogen and electronegative 
sulphur. The CH=N signal of the Schiff base occurred at 145.29 ppm indicative of 
the hydrazone bond which was formed when 4-carboxybenzaldehyde reacted with 
the SBDTC. The -S-CH2 peak occurred relatively upfield at 39.93 ppm. The 
aromatic carbons were observed around 138-128 ppm as expected for carbons in 
aromatic rings. In addition, the spectrum also showed the expected signals with 
carbon atoms of arginine giving four signals at ) 26.65, 30.44, 42.12 and 54.55 ppm 
while the two amide and one amine carbon atoms gave signals at ) 176.66, 169.66 
and 158.79 ppm. Overall, the NMR spectra of all the bioconjugates were comparable 
and in agreement with the expected structure, which confirm their formation. 
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Figure 4.7. 1H and 13C spectra of the Schiff base-conjugate (R1-SB4CB). 
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4.3.2.2 MALDI-TOF-MS/ESI-MS 
In addition to NMR, the ligand-conjugates were also analyzed with mass 
spectrometry either MALDI-TOF-MS or ESI-MS for molecules of molecular weight 
less than 500. The mass spectral data of the compounds are shown in the 
Appendices. As an example, the mass spectrum of one of the ligand-conjugates, R9-
SB4CB, is shown in Figure 4.8. The MALDI mass spectra of the new ligand 
conjugates mainly gave peaks that correspond to their protonated form. The MALDI 
mass spectra of all ligands also showed the fragment corresponding to the 
hydrolyzed Schiff base moiety (cleavage of C=N bond). Since the MALDI analysis 
involves laser irradiation and the use of an acidic matrix, it was anticipated that this 
observed hydrolysis could occur during the mass experiment. In some cases, this 
peak was the main peak with a larger relative abundance than that of the targeted 
ligand-conjugate itself. 
 
   
Figure 4.8. MALDI spectra of R9-SB4CB. The hydrolyzed fragment (cleavage 
of C=N bond) is noticeable during MALDI characterization. 
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4.3.3 Characterization of metal-complexes conjugates  
The targeted Cu(II) complexes of the above described bidentate Schiff base ligands 
involve two identical ligands and a copper(II) ion. Consequently, all the 
bioconjugate complexes were prepared in situ by mixing methanolic solutions of the 
ligands and Cu(II)(OAc)2 in a 2:1 ratio. The hydrophilic polyarginine may contain 
many bound water molecules and trifluoroacetate counterions. Therefore, it is 
difficult to ascertain the actual peptide concentration based on the weight of the 
lyophilized conjugate. The concentration was thus determined with reference to the 
extinction coefficient of the Schiff base chromophore that absorbs at 340 nm. Upon 
complexation, the colour of the reaction mixture changes to brown, which serves 
evidence for complexation in the duration when left to stir overnight. As both the 
ligands and metal complexes showed the same retention time in RP-HPLC, the 
reaction could not be monitored or purified using HPLC. The expected 
complexation was monitored by UV-Vis spectroscopy and the identification of the 
complexes was further confirmed by EPR, LC-MS and ITC as discussed below. 
 
4.3.3.1 UV-Vis  
UV-Vis titrations were performed to ascertain the formation of the expected ML2 
complex. The titration was carried out in MeOH, which mirrored the actual synthetic 
procedure and also in acetate buffer pH 6 for aqueous solution studies. Upon 
addition of Cu(OAc)2, the changes in UV-Vis spectra are noticeable with a broad 
absorption band arising from the formed complex which range from 300-400 nm 
with "max ~325!nm (log !! " 3.96) while the intensity of the band corresponding to 
ligands at "max ~340 nm (log !! "!4.64) decreases. For all the ligands, the titration, 
performed at a concentration in the range of 10-5 M, proceeds with a sharp end-point 
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at 0.5 equivalent with clear isosbestic points indicative of a single complexation 
event. This low-energy region of the UV-Vis spectrum is the same for the 
conjugated ligands and the parent compounds, which strongly suggests an identical 
Cu coordination into the Schiff base ruling out possible coordination to peptide 
chains of the bioconjugate. The 1:2 stoichiometry of the complex was verified by the 
plot of absorbance (abs.) against equivalent of Cu. Examples of UV-Vis titration 
curves obtained are shown in Figure 4.9. 
(a) 
 
(b)  
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(c) 
 
Figure 4.9. UV-Vis titration of various ligands (concentration set at ca.  2.5 x 10-
5 M) with Cu(OAc)2.H2O (concentration set at ca. 5 x 10-4 M)  at 25°C. a) 
Titration of R1-SB4CB in methanol and its corresponding titration curve 
monitored at 340 nm. b) Titration of SM4CB in acetate buffer pH 6 and its 
corresponding titration curve monitored at 340 nm for comparison with 
conjugated compounds. c) Titration of R9-SM4CB in acetate buffer pH 6 and 
its corresponding titration curve monitored at 340 nm. 
 
 
Understanding the behavior of these compounds in aqueous and buffer systems 
under physiological conditions (pH range 6.0-7.4) is important for the study of 
biological activity. Many Schiff bases derived from S-substituted dithiocarbazate 
prepared to date and their metal complexes suffer from poor aqueous solubility that 
hinders investigation of their properties. The tremendous increase in solubility of 
their bioconjugate derivatives allows for some investigations to be carried out as 
well as their complexation in aqueous solution. The complexation of Cu(II) was 
confirmed to be pH dependent.  After screening a range of aqueous buffer solutions, 
acetate buffer (pH 6) was utilized as it does not interfere with the UV absorption and 
the complexation proceeded well. Attempts were unsuccessful with water (no 
complexation) and buffers such as HEPES (no complexation), TRIS (no 
complexation), MOPS (changes in the UV-Vis signature too small for analysis), 
PBS (precipitation of the ligands) and borate buffer (reduction of the Cu(II) ion / 
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formation of hydroxide at high pH). When the reaction solutions were monitored by 
UV-Vis, the distinct "max shift and end-point at 0.5 equivalents were observed at pH 
6 (0.1 M acetate buffer) and pH 7.4 (0.01M PBS) but were not observed at pH 4 (0.1 
M acetate buffer) and 9 (0.1 M borate buffer) (Figure 4.10). As mentioned earlier, 
Schiff bases derived from DTC readily undergo thiol-thione tautomerism at 
equilibrium mixture in solution (Ali et al., 2003). In the presence of metal ions, the 
equilibrium state is more favourable towards the thiol form that spontaneously 
deprotonate to give a thiolate anion for metal coordination (Hossain et al., 1996; 
Tarafder et al., 2002a). At low pH, the deprotonation required for coordination is 
presumably suppressed. Furthermore, the thione sulphur has strong electron 
withdrawing effect that causes the amide proton to be slightly acidic which is 
stabilized in strong acidic condition. No complexation at high pH could be due to 
hydrolysis of Schiff bases, reduction of the Cu(II) ion or formation of hydroxide that 
resulted in precipitation. 
(a) 
 
Figure 4.10. UV-Vis spectra obtained by addition of Cu(OAc)2.H2O at 25°C to a 
solution of R9-SB4CB (ca. 2.5 x 10-5 M) at a) pH 4 (0.1 M acetate buffer), b) pH 
7.4 (0.01 M PBS buffer) and at c) pH 9 (0.1 M borate buffer).  
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(b) 
 
(c) 
 
 
Figure 4.10 (continued). UV-Vis spectra obtained by addition of Cu(OAc)2.H2O 
at 25°C to a solution of R9-SB4CB (ca. 2.5 x 10-5 M) at a) pH 4 (0.1 M acetate 
buffer), b) pH 7.4 (0.01 M PBS buffer) and at c) pH 9 (0.1 M borate buffer).  
 
4.3.3.2 LC-MS 
The identities of all metal complexes were verified by LC-MS experiments 
involving an electron spray ionisation. Table 4.2 summarizes the data for all Cu(II) 
dithiocarbazate Schiff base ligand-conjugates in solution in MeOH. Both copper 
complexes Cu(R1-SB4CB)2 and Cu(PEG-SB4CB)2 gave the expected signals in the 
electrospray mass spectra (positive ion detection mode) which correspond to the 
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protonated cations with the expected isotope pattern. The identities of Cu(PAßN-
SB4CB)2 and Cu(R4-SB4CB)2 were confirmed by their respective double charged 
(2+) ions.. As shown in Figure 4.11, the chromatogram of R1-SB4CB showed two 
well-separated peaks with identical MS spectra and the same behavior was observed 
for its metal complex Cu(R1-SB4CB)2. This may highlight the presence of 
diastereoisomers (E/Z hydrazone bound or cisoid/transoid complexes). The same 
was observed for Cu(R4-SB4CB)2 and Cu(PEG-SB4CB)2 but for Cu(PA%NSB)2 the 
second peak was not very obvious. It is also interesting to note that the isotopic 
pattern of Cu(R1-SB4CB)2 and Cu(PEG-SB4CB)2 seems to be the result of an 
overlapping of two isotopic patterns. The copper (II) complexes also showed several 
similar fragment ions of [CuL]+ and the ligand [L+H]+ most likely due to 
decomposition in the gas phase. The hydrolyzed ligand signal appeared when 
MALDI was used however was not apparent in the ES-MS spectra due to the fact 
that electron-spray ionization is generally considered a “softer” technique. 
 
Table 4.2. LC-ES-MS data for all Cu(II) dithiocarbazate Schiff base ligand-
conjugates and R1-SB4CB for comparison. 
 
Compound Rt 
[min] 
Exact Masscalcd 
[MH+] 
Exact Massexpt 
 
Cu(R1-SB4CB)2 15.1 & 17.6 1032.27 [M+H]+ = 1031.9 & 1030.1 
R1-SB4CB 15.3 & 17.5 486.18 [M+H]+ = 486.1 
Cu(PEG-SB4CB)2 15.2 & 16.1 1010.21 [M+H]+ = 1010.6 & 1011.5 
Cu(PA%NSB)2 15.2 1578.50 [M+2H]2+ = 789.1 
Cu(R4-SB4CB)2 14.0 & 17.3 1968.87 [M+2H]2+ = 986.1 and 986.1 
Cu(R9-SB4CB)2 Results pending 
Cu(R9-SM4CB)2 Results pending 
Cu(RW9-SB4CB)2 Results pending 
Cu(RW9-SM4CB)2 Results pending 
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Figure 4.11. LC chromatogram of Cu(R1-SB4CB)2 (top) and R1-SB4CB 
(bottom) showing the two isomeric peaks with similar molecular mass. A linear 
gradient elution developed from holding time of 5 min at 100% (0.1% formic 
acid in water ) and then from 0-60% (0.1% formic acid in acetonitrile) in 30 
min. Experiments were carried out at a flow rate of 10 µL min-1 at room 
temperature with peaks detection at 220 nm and 280 nm. 
 
4.3.3.3  ITC 
Isothermal Titration Calorimetry (ITC), commonly used in the characterization of 
interactions between biomolecules, provides a complete thermodynamic 
characterization of an interaction (Grossoehme et al., 2010; Cisnetti et al., 2012; 
Ostermeier et al., 2010). In this work, ITC experiments were undertaken to 
determine the thermodynamic parameters for the interaction of selected peptide 
conjugate ligands with Cu(II) ions during complexation in aqueous solution. The 
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metal ion was titrated into the ligand and all experiments were run in duplicate or 
triplicate and corrected for buffer interactions. ITC directly measures the heat 
released after each injection of copper. The curves obtained were fitted using the 
integrated software, which calculates the enthalpy of the reactions (5H), the 
stoichiometry (n) and the association constant (Kass). For the compounds in this 
work, the reactions were endothermic with 5H values ranging from 12.2 to 159.8 kJ 
mol-1 (Table 4.3). For all combinations tested, the association constant (log Kass) was 
of the order ca. 6, in the same range as the parent compound, and the stoichiometry 
close to the theoretical value of 0.5. These data strongly support the formation of the 
expected ML2 complexes in agreement with the UV-Vis titrations: Cu2+ + 2(L) . 
[CuL2]2+. Also, the conjugation doesn’t seem to affect the complex formation to a 
large extent. An example of the ITC experiment for Cu(R9-SB4CB)2, the most 
stable complex, is shown below (Figure 4.12). 
 
Table 4.3. Thermodynamic parameters of conjugated ligand complexation with 
copper determined by ITC at 25 °C.  
 log(Kass) 5H (kJ mol-1) n 
5S 
(J mol-1K-1) 
Cu(R1-SB4CB)2 6.00 74.4 0.42 364.5 
Cu(R9-SM4CB)2 6.56 12.2 0.53 166.4 
Cu(R9-SB4CB)2 5.94 24.9 0.49 196.5 
Cu(RW9-SB4CB)2 6.72 60.8 0.55 332.4 
Cu(RW9-SM4CB)2 6.75 36.1 0.43 249.0 
Cu(SB4CB)2 [a] 5.30 264.6 0.43 984.2 
[a] Parent compounds are given for the purpose of comparison. 
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Figure 4.12. ITC titration of Cu(R9-SB4CB)2, Cu(OAc)2 (concentration at ca. 5 
x 10-5 M) was added every 300 s to the ligand R9-SB4CB solution 
(concentration at ca. 1 x 10-5 M) in 0.1M acetate buffer at pH 6.. The top curve 
represents the corrected heat flow with time. The bottom curve represents the 
heat of reaction (measured by peak integration) as a function of Cu/ligand 
ratio. The solid line is the best theoretical fit to the experimental data. The 
three first points were removed for the fitting. 
 
Note: ITC experiments had been carried out for R4, PABNSB, PEG-SB4CB and 
SM4CB but to no avail. R4 suffered from peptide aggregation while PABNSB, 
PEG-SB4CB and SM4CB were not sufficiently water soluble for meaningful 
investigations. 
 
4.3.3.4 EPR 
Metal binding to the Schiff base ligand-vector conjugates were investigated using 
EPR spectroscopy for this paramagnetic d9 Cu(II) system (Table 4.4). The EPR 
spectra of frozen solutions of the parent compounds Cu(SB4CB)2 and Cu(R9-
SB4CB)2 in DMF (1 mM) show a well-resolved axial Cu(II) signal with significant 
separation of g" and g! (Figure 4.13). Both spectra, with g!"> g" are typical of axially 
symmetric mononuclear d9 CuII complexes in a ground state doublet with the 
unpaired electron residing in a dx2- y2 orbital. The g and A parameters, and especially 
g! and A!, indicate that the metal coordination environment involves two nitrogen 
atoms in a square-planar geometry for all complexes. The EPR spectra of the 
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bioconjugated complexes are expected to be very similar to those of their parent 
compounds, as observed here. The close similarity of the spectra is a strong 
indication that the Cu(II) ion is indeed coordinated to the ligand moiety of SB4CB 
or SM4CB in the bioconjugated system rather than unspecifically bound to the 
peptide sequence. Furthermore, the similarity of the EPR parameters of the 
complexes indicate that conjugation of the C-functionalized Schiff base ligands with 
polyarginine and other vectors such as PEG and PA%N has very little effect on its 
Cu(II) chelating behaviour. Due to the importance of water as a medium in 
biological investigation, the EPR spectrum of Cu(R9-SB4CB)2 was also recorded in 
acetate buffer at pH 6 (Figure 4.14). Although the compound showed larger 
distortion from planarity with the increase of f value as compared to the spectra 
measured in DMF, the f value is still within the square planar range. In addition, the 
spectrum was different from that of aquated Cu(II) ions in aqueous solution 
indicating that the ligands remained coordinated  to Cu(II) ions in that environment. 
 
Figure 4.13. The EPR spectra of both parent and conjugated compounds (1 
mM) in frozen DMF were indicative of the same species being formed with 
approximate calculated g? and g! values of ~2.05 and ~2.15, respectively. 
Microwave frequency 9.50 GHz, microwave power 0.25 mW, modulation 
amplitude 0.2 mT, modulation frequency 100 kHz, time constant 164 ms, T = 50 
K. 
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Figure 4.14: EPR spectra of 1mM Cu(R9-SB4CB)2 and Cu(OAc)2 in frozen 
acetate buffer  pH 6 (0.1 M) are different from one another. Microwave 
frequency 9.50 GHz, microwave power 0.2 mW, modulation amplitude 0.2 mT, 
modulation frequency 100 kHz, time constant 164 ms, T = 50 K. 
 
 
Table 4.4. EPR parameters measured from the spectra of the copper( II) 
complexes. 
Compound g// g? A//[a]  f[b] $2 
Cu(R1-SB4CB)2 2.16 2.06 523 (174) 124 0.71 
Cu(PEG-SB4CB)2 2.15 2.06 541 (180) 119 0.71 
Cu(PA%NSB)2 2.16 2.06 515 (172) 126 0.70 
Cu(R4-SB4CB)2 2.16 2.06 509 (170) 127 0.69 
Cu(R9-SB4CB)2 2.16 2.06 513 (171) 126 0.70 
Cu(R9-SM4CB)2 2.16 2.06 524 (175) 123 0.71 
Cu(RW9-SB4CB)2 2.16 2.06 514 (171) 126 0.70 
Cu(RW9-SM4CB)2 2.16 2.06 519 (173) 125 0.70 
Cu(SB4CB)2[c] 2.15 2.05  531 (177) 121 0.70 
Cu(SM4CB)2[c] 2.15 2.05  504 (168) 128 0.67 
Cu(R9-SB4CB)2-pH 6 2.13 2.05 463 (154) 138 0.61 
[a] Unit in MHz, in bracket = A// x 10-4 cm-1 [b] Unit in cm. [c] Parent compounds 
for comparison purpose. 
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4.3.3.5 Electrochemistry  
The electrochemistry properties of Cu(R1-SB4CB)2, Cu(PEG-SB4CB)2 and 
Cu(PA%N-SB4CB)2 were also tested in DMF (Table 4.5) . The voltametric waves 
were not reversible unlike those of the parent compounds (Figure 4.15). This 
observation may be due to slow electron transfer or the bulkiness/hindered structure 
of the functionalized compounds.  
 
 
Figure 4.15. Cyclic voltammograms of Cu(R1-SB4CB)2 and Cu(SB4CB)2, 1.7 
mM in anhydrous deoxygenated DMF with 0.1 M tetrabutylammonium 
perchlorate as the supporting electrolyte. Working electrode: glassy carbon; 
counter electrode: Pt wire; reference electrode: Ag/AgCl, scan rate: 100 mV/s. 
All sweeps were initiated in the direction of the arrow. 
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Table 4.5. Electrochemical data vs Ag/AgCl. 
 
4.4 Conclusion 
This work shows the successful synthesis of copper complexes with bidentate 
dithiocarbazate Schiff base-conjugates which further demonstrates the ligands 
versatility for bioconjugation via SPPS for the first time. A series of ligand-
bioconjugates were readily synthesized by either SPPS or solution phase synthesis. 
The synthetic pathways investigated are robust and can be applied to other 
bioconjugating groups. The conjugated ligands were characterized with HPLC, 
NMR and MS. Cu(II) ion complexation was achieved in situ and studied by a 
combination of LC-MS, UV-Vis, EPR, ITC and CV. The results indicate specific 
structural features of the metal bioconjugate complexes prepared in situ that exactly 
match those of the parent metal complexes. The formation of the desired complexes 
has been proven unambiguously and these complexes show dissociation constants in 
the low micromolar range. The effect of the vector conjugate is evident in the 
increase of the water solubility of the ligands and their metal complexes thus 
allowing investigation in aqueous solution to be carried out. The successful 
conjugation and facile complexation with copper suggest that the Schiff bases 
SB4CB and SM4CB may be suitable for further optimization with other targeting 
 Cu(II)/Cu(I) Cu(II)/ 
Cu(III) 
 Epa[V] Epc[V] 2Ep=Epa-
Epc[mV] 
2E1/2=0.5 
(Epa+Epc) [V] 
ipa/ipc Epa[V] 
Cu(SB4CB)2 0.015 -0.079 94 -0.032 0.88 1.029 
Cu(R1-
SB4CB)2 
0.200 -0.083 - - - 1.103 
Cu(PEG-
SB4CB)2 
0.171 -0.098 - - - 1.103 
Cu(PA%N-
SB4CB)2 
0.193 -0.082 - - - 1.090 
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groups. Such optimization is anticipated to result in enhanced biological properties 
as well as offering the possibility of being utilized for radioimaging. In addition, 
only two different substituents on the S-dithiocarbazate moiety (a methyl and a 
benzyl) were investigated in this work but many others can be introduced in the 
same way, which would potentially give access to a larger library of complexes. All 
the compounds presented here were further evaluated for their potential 
antimicrobial activity which will be discussed in the next chapter. 
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CHAPTER 5 
BIOLOGICAL ACTIVITIES 
 
5.1 Introduction 
5.1.1 Mechanism of action of antimicrobial agents and multi-drug resistance  
Bacteria could be broadly classified into Gram-positive and Gram-negative groups 
based on the outcome of Gram staining. The major difference between both groups 
is the structural organization outside the plasma membrane as shown in Figure 5.1 
(Lolis and Bucala, 2003).  According to Salton and Kim (1996), “most Gram-
positive bacteria have a thick (20 to 80 nm) and continuous cell wall which is 
composed largely of peptidoglycan”. The peptidoglycan is linked covalently to 
“other cell wall polymers such as the teichoic acids, polysaccharides, and 
peptidoglycolipids”.  On the contrary, Gram-negative bacteria have a thin (5 nm to 
10 nm) peptidoglycan layer and another outer membrane structure outside the layer. 
In addition, lipoprotein molecules can be found in between the membrane structure 
and peptidoglycan layer while the lipopolysaccharides (LPS) are on the exterior 
surface of the outer membrane structure. 
 
During an infection, “bacterial cells grow and divide, replicating repeatedly to reach 
large numbers”. In order to do so, bacteria “must synthesize or take up many types 
of biomolecules” causing cell deaths and disruption of cell function of the host 
organisms (Neu and Gootz, 1996). Bacteria could also promote infection and disease 
by producing toxins that can exert their effects directly on a target cell or by 
disabling the immune system (Deisingh and Thompson, 2002). 
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Figure 5.1. Structural features of the cell wall that distinguishes the Gram-
positive from the Gram-negative bacteria (Source: Lolis and Bucala, 2003) 
 
Antibacterial agents act against bacteria by interfering with vital processes for 
growth and division (Figure 5.2) that are specific to bacteria. They can be separated 
into groups depending on their target as listed by Neu and Gootz (1996) and 
O'Connell et al. (2013): 
(1) Cell walls.  
These peptidoglycan cell walls in bacteria and their synthetic pathways are 
an interesting target for specific treatment. For instance, penicillins and 
cephalosporins (ß-lactam antibiotics) inhibit peptidoglycan polymerization 
while vancomycin (a glycopeptide) not only inhibits this polymerization but 
also prevents the polymer cross-linking. 
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(2) Cytoplasmic membranes.  
Polymyxin binds to the bacterial LPS and then disrupts the plasma 
membrane causing leakage.  
(3) Bacterial nucleic acid synthesis.  
Quinolones prevent DNA replication by binding to topoisomerase!IV or 
DNA gyrase. Nitroimidazoles such as metronidazole is reduced by an 
electron transport protein in anaerobic bacteria. The reduced drug damage 
DNA. Rifampin blocks mRNA synthesis by binding to DNA directed RNA 
polymerase 
(4) Protein synthesis or ribosome function.  
Aminoglycosides and tetracycline interfere with ribosome function by 
binding to the 30S ribosomal subunit and thus preventing translation 
initiation and tRNA binding. Another class of protein synthesis inhibitors 
includes chloramphenicol, erythromycin and clindamycin that disrupt 
translocation and peptidyl transferase activity by binding to the 50S 
ribosomal subunit. 
(5) Metabolic pathway or folate synthesis.  
Both sulfonamides and trimethoprim interfere with folate metabolism in the 
bacterial cell by competitively blocking the biosynthesis of tetrahydrofolate 
needed for DNA replication.  
Antibacterial agents that kill bacteria as demonstrated by antibiotics that inhibit cell-
wall construction are categorized as bactericidal while agents that only prevent or 
slow down the growth of the bacteria as exemplified by tetracyclines which stop 
protein synthesis are termed as bacteriostatic (O'Connell et al., 2013).  In addition, 
“antimicrobial agents such as penicillin are active against only a narrow spectrum of 
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bacteria whereas others such as ampicillin inhibit a broad range of Gram-negative 
and Gram-positive bacteria” (Coates et al., 2002, p. 898). The combination of 
several antimicrobial agents has been known to display higher activity in 
comparison to using the individual component alone. For instance, sulfamethoxazole 
and trimethoprim (also known as co-trimoxazole) are synergistic in inhibiting folic 
acid metabolism by acting at different sites (Masters et al., 2003). Sulfamethoxazole 
and trimethoprim have specific affinity for pteridine synthetase and dihydrofolate 
reductase, respectively. Nonetheless, the combinations of antimicrobial agents 
should be practiced with caution to ensure that the result is not detrimental in which 
one agent reduces the efficacy of the other. 
 
Figure 5.2. Mechanism of antimicrobial agents. (Source: Neu and Gootz ,1996) 
 
 
Over the years, evolution of bacteria has resulted in varied mechanisms to protect 
themselves from the toxicity of antibacterials which lead to the challenge of multi-
drug resistance (MDR) (Walsh, 2000; Taubes, 2008; Boucher et al., 2009; Stratton, 
2003; Cloete, 2003). This has become a severe issue in treating bacterial infections 
as the worldwide dissemination of resistant bacteria has dramatically compromised 
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the efficiency of the antibiotic families and consequently increases the frequency of 
therapeutic failure (Pagès and Amaral, 2009). Tenover (2006, p. S3) has also stated 
that: 
Bacteria may be intrinsically resistant to 61 class of antimicrobial agents, or 
may acquire resistance by de novo mutation or via the acquisition of 
resistance genes from other organisms. Acquired resistance genes may 
enable a bacterium to produce enzymes that destroy the antibacterial drug, to 
express efflux systems that prevent the drug from reaching its intracellular 
target, to modify the drug’s target site, or to produce an alternative metabolic 
pathway that bypasses the action of the drug. 
 
Therefore, continuous effort to discover new antibacterials with novel mechanism of 
action and to further understand the resistance mechanisms is required in order to 
fight the issue of MDR. Two classes of antimicrobial agents, the antimicrobial 
peptides and the efflux pump inhibitors are the focus of the following discussion. 
 
5.1.2 Antimicrobials peptides  
Since the synthetic work detailed herein involves CPPs that are known to share 
similar features with antimicrobial peptides (AMPs), it is worthwhile to highlight 
this class of compounds to aid interpretation and discussion of the results. The 
investigation of AMPs as antibacterial agents is currently of great interest as such 
compounds may offer several advantages over traditional antibacterial agents. The 
advantages highlighted by O'Connell et al. (2013, p. 10720) include AMPs reduced 
tendency to create resistance and their appealing “immunomodulatory, anti-
inflammatory and anti-endotoxin activities”. These peptides also share the same 
fundamental structural features: they are relatively small in size ranging from 12 to 
50 amino acid residues, they contain a net excess of positively charged residues and 
around 50% of hydrophobic residues resulting in amphipathic structure which is a 
crucial prerequisite to interact with the bacteria membrane (Strøm et al., 2003; 
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O'Connell et al., 2013). The phospholipid membrane of bacterial cells is the main 
target for AMPs. As shown in Figure 5.3 (Zasloff, 2002), bacterial membranes differ 
from the membranes of plants and mammalians in which the outer leaflet of the 
bilayer that is exposed to the extracellular environment is composed mainly of 
negatively charged lipids in bacteria whereas the leaflet in multicellular animal is 
made of neutral lipids. Many hypotheses have therefore been presented for the 
mechanism of action of AMPs (Brogden, 2005; Hancock and Lehrer, 1998) 
including 
fatal depolarization of the normally energized bacterial membrane, the 
creation of physical holes that cause cellular contents to leak out, the 
activation of deadly processes such as induction of hydrolases that degrade 
the cell wall, the scrambling of the usual distribution of lipids between the 
leaflets of the bilayer, resulting in disturbance of membrane functions, and 
the damaging of critical intracellular targets after internalization of the 
peptide (Zasloff, 2002, p. 390).  
 
 
 
Figure 5.3. The membrane target of antimicrobial peptides of multicellular 
organisms and the basis of specificity (Source: Zasloff, 2002) 
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5.1.3 Efflux pumps and inhibitors  
As previously mentioned in Chapter 4 (p.107), one primary resistance pathway of 
multi-drug resistant bacteria involves the over-expression of efflux pumps. The 
pumps have different affinity towards the diverse antibacterial drugs but most of the 
drugs are recognized by either one or more than one efflux pumps. From the 
illustration of Piddock (2006) in Figure 5.4a, 
there are five main families of efflux pumps in bacteria: the ATP binding 
cassette (ABC) family, the major facilitator superfamily (MFS), multi-drug 
and toxic compound extrusion (MATE) family, the resistance nodulation 
division (RND) family, and the small multi-drug resistance (SMR) family. 
While members of the ABC, MFS, MATE and SMR families of efflux 
pumps are commonly observed in Gram-positive bacteria, efflux pumps in 
the RND, MFS and ABC families are often found in Gram-negative bacteria 
(Okandeji et al. 2011, p. 7679).  
 
There is certainly a good deal of attention to combat efflux pumps due to their 
crucial role in many MRD phenotypes of pathogenic bacteria. According to 
Okandeji et al. (2011), two strategies can be applied: either circumventing their 
activity by preparing “derivatives of antibacterial drugs that are poor substrates of 
efflux pumps” or directly inhibit the efflux pumps through identification of an 
original anti resistance weapon called the efflux pump inhibitors (EPIs). EPIs cannot 
be considered as antibiotics but as adjuvants that will help other antibiotics to be 
efficient. A number of chemicals, such as phenylalanine arginine-%-napthylamide 
(PA%N), 1-(1-naphthylmethyl)-piperizine, quinoline derivatives as well as natural 
products like  alkaloid reserpine have been found to inhibit bacterial efflux pumps 
(Kuete et al., 2011; Stavri et al., 2007). The use of these EPIs facilitates significant 
reduction of resistance to antibiotics in which the isolates were previously resistant 
(Kuete et al., 2011). In the search of new and potent antimicrobial agents in this 
study, the role of efflux pump had been investigated using pump-deleted strains and 
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PA%N-conjugates. The efflux pumps AcrAB and TolC of RND-family were chosen 
for investigation because they are often linked with the resistance of Gram-negative 
bacteria that are problematic to treat until now (Pagès and Amaral, 2009; Nikaido 
and Pagès, 2012; Vecchione et al., 2009; Okandeji et al., 2011; Piddock, 2006; 
Kuete et al., 2011; Stavri et al., 2007).   
 
 
Figure 5.4. (a) Diagrammatic comparison of the five families of efflux pumps 
(Source: Piddock, 2006) (b) Targeting the efflux pump. Illustrations of various 
targets in the efflux pump complex of RND family (Source: Pagès and Amaral, 
2009)  
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5.1.4 Contribution of metal complexes to the improvement of antimicrobial 
agents 
The rich coordination geometry of metals offers an exciting platform for the 
discovery of new and potent metallodrugs with novel mechanisms of action (Sadler: 
N. J. Farrer and P. J. Sadler, 2011). These attributes may allow antibacterial metal 
complexes to be less likely to induce resistance in bacteria or at least to delay 
development of resistance. The geometrical arrangement of ligands in metal 
complexes, which vary according to the number and types of ligands bound to the 
metal centre, and to the coordination preference of the metal, affect their bioactivity 
(Ng et al., 2013). In the past few decades, we have witnessed the development and 
evolution of potential antibacterial agents derived from metal-based compounds 
although the mechanisms of their action are still not well understood. Patra et al. 
(2012b) reviewed work that explored organometallic derivatization of existing drugs 
as an attractive approach to overcome the resistance issue. For instance, organo 
ruthenium derivatives of quinolones (topoisomerase II enzyme inhibitor which 
unwinds DNA and interferes with DNA replication) showed good activity and were 
proven to have direct interaction with double-stranded DNA (Turel et al., 2010, 
Chen et al., 2004). It is interesting to note that organometallic derivatives of 
platensimycin (bacterial fatty acid biosynthesis inhibitor) appeared to completely 
change the mechanism of action. The compound no longer inhibited FabF enzyme 
but exhibited multi-causal death effect (Patra et al., 2009; Patra et al., 2012a). The 
review also discussed metal-specific mode of action of potential metallodrugs 
derived from arsenic, silver and gold ions. In some cases, it has been shown that the 
activity of a metal-derivatized drug could be the sum of the activity of the original 
drug and the inherent toxicity of the metal ion (Patra et al., 2012b). In reviews by 
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Beraldo and Gambinob (2004), and Pelosi (2010) the significant bioactivities of 
Schiff base ligands derived from semicarbazones and thiosemicarbazones and their 
metal complexes were demonstrated.  Enhancement of activity upon complexation 
was shown to be related to changes in either lipophilicity or redox effects with 
possible mechanisms of action involving production of free radicals, metal complex 
DNA interaction or inhibition of metalloenzymes. In very recent years, modification 
of metallocenes with peptides has been shown to not only enhance activity but also 
to alter the specificity of the compounds towards either Gram-positive or Gram-
negative bacteria. (Metzler-Nolte, 2010; Chantson et al., 2005; Chantson et al., 
2006). This strategy was also utilized by Jean-Marie Pages, Isabelle Artaud and 
coworkers (Pagès et al., 2013) in preparing a multicomponent metal chelating group-
short antimicrobial peptide-fluorescent tag conjugate. The compound proved to be 
active against multi-drug resistant clinical isolates while the imaging investigation 
allowed determination of the localization and accumulation of the active compound 
inside bacteria (Pagès et al., 2013). Previously, the team had developed highly 
efficient inhibitors of bacterial metalloenzymes involved in the N-formyl-
methionine excision pathway of nascent polypeptides (Petit et al., 2009; Huguet et 
al., 2012; Mamelli et al., 2009). They adopted the strategy of delivering the drug 
inhibitor via a metal-chaperone (Alimi et al., 2012). Metallodrugs consist of two 
parts: the drug, usually a hydroxamic acid, and an ancillary ligand as shown in 
Figure 5.5 below. The mechanism of action involves dissociation of the 
metallodrugs inside the bacteria promoting the delivery of the drug to its target 
(Artaud et al., 2014).  
155 
 
 
Figure 5.5. Example of a metallodrug that consists of hydroxamic acid and an 
ancillary ligand (Alimi et al., 2012). 
 
All the examples above clearly demonstrate that there is a need to expand 
investigations in the field of metals in medicine and they attest to the significant role 
of metals in combating multi-drug resistance in bacteria to address the toxic effects 
of antimicrobial agents. Strategies used to search for effective drugs for a given 
target are of two types. The first involves a detailed knowledge of the target that 
allows the tailoring of suitable inhibitors whereas the second, a screening procedure, 
is applied when a compound is expected to show bioactivity but the target(s) against 
which it is effective is not known (Ferrari et al., 2002a). In this work, latter 
procedure was adopted. While much developmental effort has focused on the 
anticancer activity of dithiocarbazate Schiff bases and their metal complexes, study 
of the antimicrobial activity of these types of compounds has not been thoroughly 
explored. Therefore, a number of Cu(II) analogs were synthesized without specific 
molecular targets in view. The compounds were screened against a range of 
microbes with the intention of subsequently trying to correlate the biological 
activities with both solid and solution structures and their physico-chemical 
properties in order to orient further synthetic efforts towards obtaining the optimum 
geometry around the Cu ion essential to promote higher bioactivities and ultimately 
to reveal their mode of action. 
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5.2 Methodology  
5.2.1 Antimicrobial testing (MIC determination) 
5.2.1.1 Bacterial strains, culture media and chemicals 
The bacteria chosen for this study are listed in the Table 5.1 below. The 
microorganisms studied included reference (from the American Type Culture 
Collection) and clinical (Laboratory collection) strains of gram negative bacteria  E. 
coli, E. aerogenes, A. baumannii, K. pneumoniae, P. aeruginosa and Salmonella 
enterica (S. enterica) serotype Typhimurium as well as gram positive S. aureus. 
EA289 is an E. aerogenes KANS (sensitive to kanamycin, MDR isolate that exhibits 
active efflux of norfloxacin and efflux pump overproduction), EA298 constructed 
from EA289 is deleted of TolC (Pradel and Pagès, 2002). AG100 is an E. coli Wild 
Type (WT) and AG100A is its KANR (resistant to kanamycin) derivative, deleted of 
AcrAB and hypersensitive to chloramphenicol, tetracycline, ampicillin and nalidixic 
acid (Viveiros et al., 2005). Strains were grown at 37°C on Mueller-Hinton medium 
24 h prior to any assay. Mueller-Hinton broth (MHB) was used for the susceptibility 
test. Chemicals polymyxin!B nonapeptide (PMBN) were obtained from Sigma-
Aldrich and the culture medium was purchased from Becton Dickinson. 
157 
 
Table 5.1. Bacteria strains. 
KANR, resistance to kanamycin 
 
5.2.1.2 Determination of bacterial susceptibility 
The respective minimum inhibition concentration (MIC) of the sample against 
targeted bacteria were determined using the broth dilution method previously 
described (Mallea et al., 1998). Susceptibilities were determined in 96-wells 
microplates with an inoculum of 2!105 cfu in 200 µL of MHB containing two-fold 
serial dilutions of samples. MICs were determined in the presence of 5 % or 0.5% of 
DMSO. In the first case, a 20! concentration range of each compound was prepared 
in DMSO 100%. In the second case, a 200! concentration range of each compound 
was prepared in DMSO 100% and then diluted with H2O to obtain a 20! 
concentration range in DMSO 10%. Then 10 µl of these ranges were added to 190 
µl of inoculum. The MICs of samples were determined after 18 h incubation at 
37°C, following addition (50 !l) of 0.2 mg/mL iodonitrotetrazolium (INT) and 
incubation at 37°C for 30 minutes. MIC is defined as the lowest sample 
Bacteria 
strains Features References 
Escherichia coli 
AG100 Wild-type E. coli K-12 (Viveiros et al., 2005) 
AG100A AG100 %acrAB::KANR (Viveiros et al., 2005) 
Enterobacter aerogenes 
EA289 KAN sensitive derivative of EA27 (Pradel and Pagès, 2002)  
EA298 EA 289 tolC::KANR (Pradel and Pagès, 2002) 
Acinetobacter baumannii 
ATCC19606 Reference strain - 
Klebsiella pneumoniae 
ATCC12296 Reference strain - 
Pseudemonas aeruginosa 
PA 01 Reference strain - 
Salmonella enterica serotype Typhimurium 
SL696 Wild-type, metA22, trpB2, strAi20 (Plesiat and Nikaido, 1992) 
Staphylococcus aureus 
SA1199 Wild-type clinical, methicilin-
susceptible 
(Kaatz et al., 1987) 
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concentration that prevented the color change of the medium and exhibited complete 
inhibition of microbial growth. The range of samples concentration used for MIC 
determination is universally accepted to be in doubling dilution steps up and down 
from 1 mg/L as required (Andrews, 2001). Therefore, the sample dilution range was 
from 0-128 µM. Samples were tested alone or in the presence of PMBN at 51.2 
mg/L final concentration (1/5 of its direct MIC). All assays were performed in 
duplicate or triplicate. Ciprofloxafin was used as standard antibiobic reference. 
 
5.2.2  In vitro cytotoxicity testing  
The cell lines used for testing, MCF-7 (human breast cancer cells possessing nuclear 
esstrogen receptor) and MDA-MB-231 (human breast cancer cells without nuclear 
estrogen receptor) were obtained from the National Cancer Institute, U.S.A. Both 
cell lines were cultured in RPMI-1640 / DMEM (High glucose) (Sigma) medium 
supplemented with 10% fetal calf serum. The cells were plated into 96-well plate at 
cell density 6000 cells/well and incubated for 24 hours. After 24 hours, the media 
(5% serum) were discarded and cells rinsed with PBS solution. 200 µL of a series of 
concentrations (50.0, 25.0, 10.0, 5.0, 1.0 and 0.5 µM) for each sample prepared was 
added to each well. The 96-well plate was incubated for another 72 hr, after which 
the well plate was removed from incubator. Cytotoxicity was determined using the 
microtitration of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay (Sigma, USA) as reported by Mosmann (1983). 20 µL of MTT 
solution (5 mg/mL) was added to each well. The plate was wrapped with aluminium 
foil and incubated for 4 hours. After 4 hours, 200 µL of sample containing MTT 
solution was discarded from the well. 200 µL of DMSO was added to each well to 
dissolve the formazan crystals formed. The effect of the compound on cell line 
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viability was measured on an automated spectrophotometric plate reader (model 
MRX II microplate Elisa reader) at a test wavelength of 570 nm. Cytotoxicity was 
expressed as IC50, i.e. the concentration that reduced the absorbance of treated cells 
by 50% with reference to the control (untreated cells). The IC50 values were 
determined from the plotted absorbance data for the dose-response curves. Controls 
that contained only cells were included for each sample. Tamoxifen was used as the 
cytotoxic standard.  
 
5.3 Results and discussion 
The free Schiff bases and their Cu(II) complexes as well as their bioconjugates 
described in the previous chapters were tested in collaboration with Dr. Laure 
Maigre and Professor Jean-Marie Pagès of Facultés de Médecine (UMR-MD1), 
Université de la Méditerranée, Marseille, France for the compounds ability to inhibit 
the growth of nine strains of both gram-negative and gram-positive bacteria. The 
effects of membrane permeabilizing agent (PMBN) and efflux pumps were 
investigated in an attempt to link the activity of these compounds with the bacteria 
penetration and the detoxification mechanisms of bacteria. Such investigations 
constitute the pioneering effort with these dithiocarbazate derivatives. 
 
5.3.1 Antimicrobial evaluation 
5.3.1.1 Macroacyclic Cu(II) system with tetradentate NNSS ligands 
The initial synthesis and MIC evaluation involved tetradentate bis(dithiocarbazate) 
ligands and their respective Cu(II) complexes as shown in Table 5.2. As noted in 
previous chapters, a major drawback of these dithiocarbazate-Schiff bases is their 
poor solubility in aqueous solution. To ensure complete dissolution of the tested 
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compounds, up to 5% (v:v) of DMSO was used. Indeed, it is not ideal since DMSO 
could be toxic to bacteria at such a high concentration and/or could modify the 
membrane permeability (Yu and Quinn, 1994), thus affecting the apparent MIC 
values.  
 
DMSO effect 
It has been shown that solutions from 1% to 10% DMSO considerably affect the 
growth of fungi and cancerous cells, and with a 15% solution, growth of certain 
bacteria is effectively eliminated (Notman et al., 2006; Yu and Quinn, 1998; Ng et 
al., 2013). This is also the case for bacteria strains A. Baumannii and P. Aeroginosa 
at 5% of DMSO thus preventing the determination of the MIC under this condition. 
DMSO has also been reported to enhance permeability of the lipid membrane and 
also to cause the cell membrane to become less rigid facilitating membrane diffusion 
of exogenous species (Randhawa, 2006; Ghajar and Harmon, 1968; Anselet al., 
1969; Dolan et al., 2013). As shown below (Figure 5.6), in comparison to 5% 
DMSO, 0.5% DMSO would not significantly affect the growth of the bacteria as 
compared to 5% DMSO. Therefore, it is important to keep in mind that DMSO is 
not necessarily innocent.  
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(a) 
 
    
(b) 
 
Figure 5.6. Influence of DMSO on the growth of bacteria strains over time. (a) 
AG100 and (b) EA289 
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      Table 5.2. Antimicrobial activity of the tetradentate series. 
 
 
  
 Minimum inhibitory concentration (MIC)  (µM) 
Compound Gram- Gram+ 
 E. coli E. aerogenes A. baumannii K. pneumoniae 
P. 
aeruginosa S. enterica S. aureus 
 AG100WT 
AG100A 
acrAB- 
EA289 
 acrAB+ 
EA298 
 tolC- 
ATCC 
19606 
ATCC  
11296 PA01 SL696 SA1199 
% DMSO 0.5 5 0.5 5 0.5 5 0.5 5 0.5 0.5 5 0.5 0.5 5 0.5 5 
SMHD >128 >128 >128 >128 >128 128-64 >128-128 >128 64 128 64 128-64 >128 >128 32 64-32 
+PMBN 32 32 16 16 >128-128 64 128 32 16 64 32-16 16-8 64 32 32-16 64-32 
CuSMHD >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 
+PMBN >128 >128 >128 1-2 >128 >128 >128-128 0.5-1 >128 >128 >128 >128 >128 >128 >128 >128 
SBHD >128 128 >128 128 >128 128-64 >128-128 64 >128 >128 128 >128 >128 >128 >128 64-32 
+PMBN >128 64 128-32 32-16 >128-128 64 
>128-
64 16-4 128-64 128-64 32-16 64-32 >128 64 16 128 
CuSBHD >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 
+PMBN >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 
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Colour code: MIC values or average MIC values 6 64 µM = red, "10 µM = green, in between 64 µM and 10 µM = colourless.  MIC values 
higher than 64 µM indicate inactivity.  
SBPY >64 >64 >64 >64 >64 >64 >64 >64 >128 >128 >128 >128 >128 >128 128 128-64 
+PMBN 64 64 32 16 >64 64 32 4 >128-128 >128 64 >128-128 64 64-32 128-64 128 
Cu(Ac)2 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 
+PMBN >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 >128 
Ciprofloxacin 0.03 0.06 0.008 0.015 64 64 32 32 2 0.25 - 0.5-0.25 0.03 - 1 - 
+PMBN 0.015 0.03 0.008 0.008 64 128 32 16 2 0.125 - - 0.03 - 1-0.5 - 
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Differences could be observed among the MIC values obtained with different 
concentrations of DMSO (0.5% or 5%) for certain molecules, particularly for 
CuSMHD against the mutated strains E. coli acrAB- and E. aerogenes TolC-. For 
this molecule, the MICs obtained with concentrations of DMSO, 2.5%, 1.5% and 
1% were all > 128 µM while with 5% DMSO, the MIC value was in the range 1-2 
and 0.5-1 µM, respectively. Because of the effect of DMSO on bacterial growth, it 
was not possible to confirm that the value truly reflects specific antimicrobial 
activity of the compound itself but it more likely corresponds to a synergetic effect 
of DMSO and the compound. The MIC values at 0.5% DMSO are more significant 
and will be discussed. However, in 0.5% DMSO, partial precipitation of the 
compounds could not be excluded which would lead to the determination of 
overestimated MIC values i.e. underestimation of the biological effect at the 
apparent concentration. 
 
Influence of membrane permeabilizing agent on bioactivity 
Since it has been reported that the low permeability of the outer membrane (Stratton, 
2003; Cloete, 2003; Tenover, 2006; Strøm et al., 2003; Zasloff, 2002; Pagès  and 
Amaral, 2009; Nikaido and Pagès, 2012) is a prime factor limiting intracellular 
activity of potential antimicrobial compounds, it is expected that the presence of a 
membrane permeabilizing agent would act synergistically with the compounds under 
study to promote their antimicrobial efficiency by facilitating increased uptake of the 
compounds. Among the permeabilizing agents, Polymyxin B nonapeptide (PMBN) 
has been used. PMBN is a cationic cyclic peptide derived from the antibacterial 
peptide polymyxin B (PMB). PMBN is an extremely poor antimicrobial agent but it 
is still capable of binding to lipid A of Gram-negative bacteria lipopolysaccharide 
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(LPS) like its parent compound, rendering the bacteria susceptible to various 
hydrophobic antibiotics. This capacity of PMBN to bind to bacteria with relatively 
high affinity and to permeabilize their outer membrane is often referred to as 
“sensitizing activity” and points to a novel therapeutic direction (Tsubery et al., 
2000 and Tsubery et al., 2001). The compounds were therefore tested in the 
presence and absence of sub-inhibitory concentrations of PMBN (used at 1/5 its 
direct MIC value). Without PMBN all compounds were inactive against the strains 
tested (MIC > 64 µM) except for the ligands SMHD and SBHD against S. aureus. 
However, a significant increase of up to 3-fold improvement of MIC values on both 
Gram-negative and Gram-positive bacteria was observed for the organic compounds 
SMHD, SBHD and SBDP in presence of PMBN. These results strongly suggest that 
the compounds, although toxic, do not penetrate the bacteria membrane efficiently. 
This lack of penetration hinders their intrinsic toxicity and leads to an apparent high 
MIC.  
 
Efflux of the compounds 
The role of efflux pumps was investigated using pump-deleted strains of Gram-
negative E. coli and E. aerogenes. SMHD also seems more active (16 µM) towards 
the isogenic derived strain, in which the efflux pump AcrAB genes are deleted as 
compared to wild-type E. coli (64 µM). No significant activity was observed for 
SMHD in the absence likewise in presence of efflux pump for E. aerogenes. SBPY 
show differences in the MDR clinical isolate EA289 overexpressing the AcrAB 
efflux pump and on its efflux negative TolC- derivative EA298 with improvement in 
MIC from >64 µM to 32 µM. These results confirmed that SBPY is recognized by 
the efflux pumps and expelled from the bacteria thus limiting their bioactivity. 
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Effect of the dithiocarbazate substituent  
Nevertheless, the ligand SMHD showed a broad range of moderate activity in the 
presence of PMBN with the most promising MIC values at or around 16 µM against 
E.Coli acrAB-, A. Baumannii, P. aeroginosa and S. aureus thus making it a potential 
candidate for improvement. It is known that the biological activity of dithiocarbazate 
compounds can be greatly modified in the presence of different substituents. For 
instance, inhibition of E. coli and S. aureus by the Schiff base prepared from 2-
benzoylpyridine with SMDTC is highly effective whereas that of the SBDTC 
compound shows no activity (Hossain et al., 1996).  
 
Differences in activity against gram-positive and gram-negative bacteria  
Apart from that, both SMHD and SBHD were moderately active against gram 
positive S. aureus. Typically, antibacterial molecules are more active toward Gram-
positive than Gram-negative bacteria (Lessa et al., 2012; Bolla et al., 2011), as the 
additional outer membrane of the latter organisms impairs or slow down the drug 
uptake, which could be the case here. 
 
Effect of complexation 
Contrary to what has been usually reported in the literature that metal complexation 
enhances the bioactivity of ligands (Nandi et al., 1984; Joseph et al., 2012), in this 
case, the formation of the copper complexes induces a loss of antibacterial potency 
of the compounds. Similar losses in activity were previously reported with Pd(II) 
and Pt(II) complexes with acetone Schiff bases (Ali et al., 2002). The observation 
for this tetradentate series of compounds can be explained by the lower solubility of 
the metal complexes or by the lower stability of the hydrazone moiety in the case of 
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the free ligands. As mentioned before (Chapter 3, p. 51), depending on the pH, the 
ligands can be hydrolyzed in aqueous solution leading to several reactive products 
that can be toxic towards bacteria. At this stage it is not possible to deduce a clear 
structure-activity relationship from the limited number of compounds tested. 
Nonetheless, the Cu series complexed with tetradentate ligands was found to show a 
wide range of activity from non-active to active. 
 
5.3.1.2 Open chain Cu(II) system with bidentate NS ligands with acid or ester 
functionality 
Efforts have been devoted to significantly improve the aqueous solubility of the 
above-mentioned compounds and to address the lack uptake of compounds due to 
low permeability of the outer membrane as well as the efficiency of efflux pumps. 
The synthesis was extended to another series based on Cu(II) complexes of bidentate 
ligands which are more soluble. 
 
Influence of membrane permeabilizing agent on bioactivity 
The bidentate ligands involved aliphatic ester, aliphatic acid or aromatic acid 
functionalities and were derived from both SMDTC and SBDTC. They were 
initially screened against a panel of four strains of bacteria with and without the 
presence of PMBN and the more promising compounds were further tested, in total 
nine strains of bacteria. These bidentate compounds were much more water soluble 
than their tetradentate counterparts and MIC studies could be performed with only 
0.5% of DMSO. It has been previously shown that this amount does not inhibit the 
growth of bacteria. The general observations of the results summarized in Table 5.3 
indicated that the bidentate series was more active than the tetradentate series in 
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0.5% DMSO. Upon introduction of PMBN, the impressive improvement in 
biological activity showed that these compounds also did not cross the cell 
membrane of Gram-negative bacteria efficiently. In the following discussion only 
results obtained in presence of PMBN will be discussed. 
 
Table 5.3. Antimicrobial activity of non-conjugated bidentate series. 
 
 
 
 
Minimum Inhibitory concentration (MIC) (µM) 
 
E. coli E. aerogenes 
Compound AG100 WT 
AG100A 
AcrAB- 
EA289 
AcrAB+ 
EA298 
TolC- 
SMML >128 >128 >128 >128 
+ PMBN 1/5 64 32 >128 128 - 64 
Cu(SMML)2 >128 128 >128 >128 
+ PMBN 1/5 64 16 >128-128 64 - 16 
SMLA >128 >128 >128 >128 
+ PMBN 1/5 64 32 >128 128 - 64 
Cu(SMLA)2 >64 >64 >64 >64 
+ PMBN 1/5 64 32 >64 32 
SBML >128 128 >128 >128- 128 
+ PMBN 1/5 16 16 >128-128 64 - 16 
Cu(SBML)2 >128 32-16 >128 >128 
+ PMBN 1/5 16 4 >128 4 
SBLA >128 128 >128 128 
+ PMBN 1/5 32 8 128 64 - 16 
Cu(SBLA)2 >128 >128 >128 >128 
+ PMBN 1/5 32-16 8-4 >128 8 
SBEL >128 >128 >128 >128 
+ PMBN 1/5 32 16 >128-128 128 - 16 
SM4CB >64 >64 >64 >64 
+ PMBN 1/5 >64 >64 - 32 >64 >64 
Cu(SM4CB)2 >64 >64 >64 >64 
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+ PMBN 1/5 64 32 >64 64 
SB4CB >64 >64 - 64 >64 >64 
+ PMBN 1/5 32 16 >64 16 
Cu(SB4CB)2 >64 >64 >64 >64 
+ PMBN 1/5 8 8 >64 8 - 4 
Colour code: MIC values or average MIC values 6 64 µM = red, "10 µM = 
green, in between 64 µM and 10 µM = colourless.  MIC values higher than 64 
µM indicate inactivity.  
 
Efflux of the compounds 
The influence of the efflux pump was verified by the improvement in MIC values 
against strains of E. coli and E. aerogenes lacking the selected efflux pump. Most 
compounds showed at least 2-fold increase in antimicrobial activity towards E. coli 
AcrAB- and E. aerogene TolC-. In contrast, only SBML, Cu(SB4CB)2 and SM4CB 
showed no difference in activity against pump-deleted strains with the first two 
compounds having similar MIC values against E. coli strains and the latter against E. 
aerogenes strains indicating that the compounds were not driven out by the pump. 
Therefore, the reduction in antimicrobial activity of most compounds tested, like 
many of the current antibiotics, can be also primarily attributed to the presence of 
efflux pumps 
 
Planarity of the ligands 
Another factor that could affect the bioactivity of the Schiff bases is their planarity. 
Investigations by Olczak et al. (2007) has suggested that planarity of the pyridin-2-yl 
or pyrazin-2-ylformamide thiosemicarbazone fragment could be a prerequisite for 
tuberculostatic activity.  The antimicrobial activity of the ligands SMML, SBML, 
SBEL and SBLA in which their crystal structures have been solved, can be arranged 
as SMML< SBEL< SBML< SBLA against all the 4 strains tested.  The more active 
SBLA also appeared to be most planar when considering the inclination angles 
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between (i) the allylic (=C(CH3)CH2CH2) and the terminal carbocyclic acid/ester (-
COOR) planes (ii)  the dithiocarbazate and the allylic planes, but appears to acquire 
greater perpendicularity of the benzyl ring towards the dithiocarbazate plane.  
 
Stability of the ligand 
The results demonstrated that the free ligand SB4CB with the aromatic acid 
substituent exhibited the lowest MIC values indicating a higher potency among the 
compounds in this series. This efficacy might be due to the presence of the aromatic 
ring that increases the stability of the compounds. It has been noted in the Chapter 3 
(p. 52) that the aliphatic Schiff bases (SMML, SMLA, SBML, SBLA and SBEL) 
were hydrolyzed when chromatographed by RP-HPLC with solvent system 
containing 0.1% TFA. On the other hand, the aromatic Schiff bases (SM4CB and 
SB4CB) were found to be stable when monitored by HPLC and UV-Vis 
spectroscopy under similar conditions. No hydrolysis was observed even after 24 
hours (18 hours is the duration required for MIC assay).  
 
Effect of complexation 
Many of the well known antibiotics like tetracyclines, quinolones and bleomycin are 
chelating agents and their actions are improved by the presence of metal ions, in 
particular copper ion (Ming, 2003; Efthimiadou et al., 2008). Thus, the synthesis and 
study of metal complexes with drugs used in clinical practice as well as promising 
ligands which may exhibit synergistic activity has attracted much attention as an 
approach to new drug development (Turel et al., 2010). Upon complexation with 
copper, most of the non-conjugated bidentate series compounds tested in this work 
showed equal or lower MIC values. The free copper (II) acetate was also screened 
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against all strains and was found inactive (MIC >128 !M). The lack of growth 
inhibition activity for copper (II) acetate confirmed that the observed growth 
inhibition within experimental threshold was not due to the intrinsic biological 
activity of copper (II) free metal (Ng et al., 2013). To compare the complexation 
effect independently from the efficiency of the ligands, the ratio of MIC of the free 
ligand to that of the Cu(II) complex (which had been multiplied by 2 due to the 
coordination of two ligands in a complex) was calculated for the series of molecules 
and for each strain. A ratio above one is taken to mean that the enhanced biological 
activity is the result of a synergistic effect afforded by the complexation (the activity 
is due not only to the ligand itself) whereas a ratio less than one implies that the 
complexation is deleterious. As shown in Figure 5.7, the beneficial effect of the 
complexation for the ligands highly depends on the bacteria strain.  
 
Figure 5.7. Effect of complexation on the non-conjugated bidentate series of 
molecules against the different strains of E. coli (AG100 T and AG100A acrAB-
)   and E. aerogenes (EA289 acrAB- and EA298 tolC-). The ratio MIC (free 
ligand) / MIC(complexed ligand) has been calculated with the MIC (in presence 
of PMBN) reported  according to the stoichiometry of the complex.  
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The complexation did not play a crucial role on the three first tested strains E. coli 
WT, E. coli acrAB- and E. aerogenes acrAB+ since majority of the MIC ratio values 
were 1. Only Cu(SB4CB)2, Cu(SBML)2 and Cu(SMLA)2 showed positive 
complexation effect towards E. coli WT, E. coli AcrAB- and E. aerogenes AcrAB+, 
respectively. Interestingly, the complexation improved the activity for most of 
compounds with the exception of Cu(SM4CB)2 against the efflux pump TolC 
deleted E. aerogenes strain whereas such an effect is not observed on the strain 
possessing the TolC pump. This also demonstrated that complexation effectively 
decreases the efflux of the active molecules in the TolC pump deleted strain. The 
observed efficiency of the metal complexes could be linked to the significant 
changes in the physico-chemical properties of the compounds upon chelation. For 
instance, the molecular weight is doubled, the spatial geometry varied and new 
redox properties appear since the compounds now involved a metal. Besides that, 
the polarity of the metal complex is reduced to a greater extent in comparison to its 
free ion because of the overlap of the ligand orbital and partial sharing of the 
positive charge of the metal ion with the donor groups. Furthermore, it increases the 
delocalization of ,-electrons over the whole chelate ring and enhances the 
lipophilicity of complexes in aqueous solutions, which may modify the interactions 
with cellular membranes (Raman, et al., 2003; Tiwari et al., 2012; Lobana et al., 
2009). The changes in the metal complexes may also be compatibility with the 
hydrophobic pocket in the target site of the bacteria which further strengthen the 
binding of the complexes to the microbe contributing to their enhanced activity 
(Ming, 2003; Efthimiadou et al., 2008).   
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Effect of the dithiocarbazate substituent 
There is also a general trend that the S-benzyl derived ligands and their metal 
complexes showed better activity than the S-methyl derivatives in this series. There 
have been mixed past reports on the bioactivity between SBDTC derivatives as 
compared to the SMDTC (Hossain, et al., 1996; Pavan et al., 2010). The stronger 
activity of S-benzyl derivatives could possibly be attributed to a higher cellular 
uptake due to an increased lipophilicity. In order to further access the structure-
activity relationship, the biological activities of the compounds were correlated with 
the electrochemical properties as well as their structures in both solid state (SCXRD) 
and solution (EPR). 
 
Redox potential of metal complexes 
The redox potentials for the two series were recorded by cyclic voltammetry in 
anhydrous DMF. The obvious differences between the two series were that Cu(II) 
complexes of the bidentate series revealed a quasi-reversible reduction wave for 
Cu(II)/Cu(I) couples with Epc ranging from -0.066 V to -0.114 V/(Ag/AgCl with  
Fc/Fc+ = 0.563  V) (Chapter 3, page 88-94). On the other hand, both CuSMHD and 
CuSBHD in the tetradentate ligands series underwent an electrochemically 
irreversible one-electron reduction at Epc = -0.328 and -0.285 V which were more 
negative than their bidentate counterparts. The more positive redox potential could 
be an explanation for the greater activity of the bidentate series. A higher redox 
potential means that Cu(II) reduction is easier, and consequently a higher content of 
Cu(I) could be continuously generated due to the reversibilty. Cu(I) is prone to 
participate in Fenton-type reactions that produce reactive oxygen species (ROS), 
which can damage biomolecules within cells (Jansson et al., 2010). Radical 
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generation has also been proposed as a mechanism of cytotoxicity of Cu(II) and 
Fe(III) thiosemicarbazone (Jansson et al., 2010). This certainly suggests that the role 
of the reduction of the Cu(II) complexes in the antimicrobial action of the 
compounds cannot be excluded. In both series, the redox potentials were higher in 
the case of the benzyl-substituted compound than in the case of the methyl, which 
could be explained by a weaker electron-donating effect of the benzyl group. Again, 
the complexes having the higher redox potential were found to be more active. This 
supports the suggestion that the easier reduction to Cu(I) may be responsible for the 
increased activity. 
 
Geometry of metal complexes 
As previously mentioned in Chapter 3 (page 25, 88), there are correlation among 
redox potential, geometry and biological activity. Because of the difference in 
geometric preferences for Cu(II) (Jahn-Teller distortion favors square planar 
geometry) and Cu(I) (as a d10 ion, there is no electronic preference for a particular 
geometry) (Rorabacher, 2004), it would be anticipated that compounds with more 
positive Cu(II)/Cu(I) reduction potential (which goes with Cu(I) being more stable) 
are the least planar. The enhanced flexibility of the bidentate series as compared to 
the tetradentate series may facilitate increased square planar distortion leading to 
incorporation of Cu(I) ion that prefer non-square planar geometries. The information 
with regard to the deviation from planarity in the solid state can be accessed from 
the crystal structures. The crystal structures were obtained for Cu(SMML)2, 
Cu(SMLA)2, CuSMHD and CuSBHD. The bond angles about the central copper 
metal were consistent with a distorted square planar geometry with the sum of the 
angles around Cu exceeds 360°. The bidentate series, Cu(SMML)2 and Cu(SMLA)2 
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(374.33° and 380.12°, respectively) displayed a more significant distortion than 
CuSMHD and CuSBHD (367.65° and 360.9° respectively). The angles between two 
N-Cu-S planes confirmed the deviation from planarity of the complexes in the order 
Cu(SMLA)2 > Cu(SMML)2 > CuSMHD > CuSBHD. The bidentate series with more 
positive Cu(II)/Cu(I) redox potentials also demonstrated higher antimicrobial 
activity than their more planar tetradentate counterparts although the difference in 
bioactivity between the compounds in the same series was less pronounced. The 
EPR spectra recorded in DMF for both series indicated distorted square planar 
geometry for most Cu(II) complexes. Referring to the empirical factor f (= g||/0||) 
(Joseph et al., 2012; Krishna et al., 2008) of the compounds shown in Chapter 3 (p. 
83), Cu(II) complexes with aliphatic acid and ester bidentate ligands (145-147 cm) 
confirm slightly higher degree of tetrahedral distortion than those with tetradentate 
ligands (141 and 143 cm) in solution. However, there are exceptions with 
Cu(SM4CB)2 and Cu(SB4CB)2 formed by the more active aromatic acid bidentate 
ligands. Both complexes revealed lower f values (128 and 121 cm, respectively) 
which are in the square planar range. 
  
At this stage, the growth inhibitory mechanism of action and molecular target for the 
compounds carried out in this work is unclear. Nonetheless, others mechanisms of 
action are possible. For example, square planar Cu(II) complexes have often been 
associated with their ability to interact with DNA, the central target for most 
therapeutic agents (Manikandamathavan, et al., 2013). One of the proposed 
mechanism for these complexes involved the reduction of the DNA-intercalated 
Cu(II) complexes by glutathione or ascorbate, and followed by reoxidation of Cu(I) 
with dioxygen or in the presence of hydrogen peroxide. This leads to the generation 
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of active radicals which cause oxidative stress with irreversible damage to DNA 
resulting in induction of apoptosis (Gilbert et al., 1999; da Silveira et al, 2008; 
Borrás et al., 2007). Different binding interactions that affect metabolic pathways or 
even equally critical cellular processes have also been observed for Cu(II) 
thiosemicarbazone analogues. Their anti-tumour activity has been attributed to either 
inhibition of the enzyme ribonucleotide reductase, topoisomerase IIa or more 
recently a multi-drug resistance protein (MDR1) (Bisceglie, et al., 2012; Ferrari, et 
al., 2004; Finch, et al., 2000; Kovala-Demertzi et al., 1999). Although these 
proposed mechanisms are ambiguous, results point towards structure and redox 
potential dependent antimicrobial efficacy of the dithiocarbazate compounds.  
 
5.3.1.3 Functionalized compounds 
Having identified the most promising ligand (SB4CB) and Cu(II) complex, 
Cu(SB4CB)2, the ligand was further functionalized with various vectors and the 
MIC values are shown in Table 5.4.  
Table 5.4. Antimicrobial activity of bioconjugate series. 
 
    
Minimum Inhibitory concentration (MIC) 
(µM) 
E. coli E. coli 
Compound 
AG100 
WT 
AG100A 
acrAB- 
EA289 
acrAB+ 
EA298 
tolC- 
PEGAC >128 >128 >128 >128 
+ PMBN 1/5 >128 >128 >128 >128 
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PEG-SB4CB >128 64 >128 >128 
+PMBN 1/5 16 8 >128 16 
Cu(PEG-SB4CB)2  >128 >128 >128 >128 
+ PMBN 1/5 16 4 >128 8-4 
PA%N-SB4CB  >128 >128 >128 >128 
+ PMBN 1/5 >128 >128 >128 >128 
Cu(PA%N-SB4CB)2  >128 >128 >128 >128 
+ PMBN 1/5 >128 >128 >128 >128 
R1AC >128 >128 >128 >128 
+ PMBN 1/5 >128 >128 >128 >128 
R1-SB4CB  >128 32 >128-128 128-64 
+PMBN 1/5 16 8 128 16 
Cu(R1-SB4CB)2  >128 64 >128 128-64 
+ PMBN 1/5 16-8 4 >128 8-4 
R4AC >128 >128 >128 >128 
+ PMBN 1/5 >128 >128 >128 >128 
R4-SB4CB  32 16-8 64 16 
+PMBN 1/5 16 4 64 8-4 
Cu(R4-SB4CB)2 16-8 8-4 >64-32 8 
+ PMBN 1/5 8 2 >64-64 4-2 
R9-Ac 8 8 8 8 
+ PMBN 1/5 4 4 8 8 
R9-SB4CB  8 8 8 4 
+PMBN 1/5 4 4 4 4 
Cu(R9-SB4CB)2  4 4 4 4 
+ PMBN 1/5 2 2 4 2 
RW9-Ac 2 2 8 - 4 2 
+ PMBN 1/5 2 2 4 2 
RW9-SB4CB 16 - 4 16 16 - 8 8 
+ PMBN 1/5 8 8 8 8 
Cu(RW9-SB4CB)2 8 - 4 8 - 4 16 - 8 8 - 4 
+ PMBN 1/5 8 4 8 8 
Colour code: MIC values or average MIC values 6 64 µM = red, "10 µM = 
green, in between 64 µM and 10 µM = colourless.  MIC values higher than 64 
µM indicate inactivity.  
 
Influence of membrane permeabilizing agent on bioactivity 
The antimicrobial activity and water solubility of this series were observed to be 
improved with conjugation in comparison to the parent compounds with the 
exception of PA%N conjugates. The PEG and R1 conjugates demonstrated 
significant improved activity only upon introduction of PMBN. This indicates that 
the addition of a neutral PEG and a positive charge from R1 were not sufficient for 
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uptake across the cell membrane of the bacteria. In contrast, it is positive to 
highlight that R4, R9 and RW9 conjugates were already active without the presence 
of PMBN. The increase in the cationic nature of the polyarginine derivatives allows 
better interaction and subsequently permeability across the negatively charged 
bacteria membrane as anticipated. Therefore, the MIC values obtained for these 
compounds either showed no difference or improved only 2-fold with the presence 
of PMBN. The slightly better activity in some cases of the polyarginine derivatives 
with PMBN point out that conjugation has yet to bring about optimum uptakes and 
the improved MIC values may be a result of synergistic effect between PMBN and 
conjugated ligands. Nonetheless, polyarginine conjugates appeared to be most 
efficient in crossing the cell membrane compared to the unconjugated compounds 
and other vectors.  
 
Efflux of the compounds 
The PEG, R1 and R4 conjugates also showed at least 2-fold increase in MIC values 
against pump deleted strains E. coli AcrAB- and E. aerogene TolC-. However, for 
R9 and RW9 derivatives, the MIC values remained the same with or without the 
presence of efflux pump. This is another encouraging observation that conjugation 
to CPP R9 and RW9 is beneficial as they are not affected by the efflux pumps. The 
PA%N conjugate was inactive against all strains tested. This conjugate was initially 
designed to assess the effect of efflux pump as well as to reveal any synergistic 
effect of the conjugate with possible new mechanism of action. However, the lack of 
activity reported with regards to this conjugate certainly demised the potential for 
positive synergistic effect.  
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Influence of arginine chain lengths on bioactivity 
In addition to the noticeable trend with PMBN and efflux pumps, there is also 
correlation of higher bacterial growth inhibition potency with arginine chain lengths. 
The improvement of the MIC values averaged against all four strains upon 
conjugation of SB4CB to polyarginine is in the following order: R9-SB4CB > RW9-
SB4CB> R4-SB4CB > R1-SB4CB > SB4CB. In order to identify the contribution of 
each moiety in the conjugates, acetylated free peptides and PEG were tested as well. 
The acetylated vectors PEGAC, R1AC and R4AC were totally inactive with MIC 
>128 µM. The improved activity observed for the conjugates of these three vectors 
could have benefited from the better water solubility, permeability and cell uptakes 
of the conjugates. In contrast, RW9AC proved to be highly active against all the 
strains while R9AC also showed activity against them. As previously mentioned 
(Chapter 5, p. 149), CPPs and antimicrobial peptides are known to show similar 
characteristics, in particular amphiphilicity, which is a crucial factor determining the 
antibacterial activity of peptides. This seems to be the case for the CPP RW9. 
Noting the antimicrobial activity of the acetylated R9AC and RW9AC, these two 
vectors could have contributed their activity to the improved MIC values as 
demonstrated by the conjugates.   
 
Effect of complexation 
According to the Figure 5.8, most of the bioconjugated Cu(II) complexes showed 
equal or lower MIC values compared to the ligands indicating that complexation 
with Cu(II) did not contribute significantly to the observed activity of the ligands. 
The conjugates also showed resemblance to the parent compound in which 
complexation improved the efficiency against E. aerogenes TolC- strain as 
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demonstrated by the compounds Cu(PEG-SB4CB)2 and Cu(R1-SB4CB)2. On the 
other hand, both compounds showed deleterious ligands effect against E. coli WT.  
 
 
 
Figure 5.8. Effect of complexation on the conjugated bidentate series of 
molecules against the different strains of E. coli (AG100 T and AG100A acrAB-
)   and E. aerogenes (EA289 acrAB- and EA298 tolC-) 
 
Final antimicrobial evaluation against 9 strains of bacteria  
Despite the MIC ratio values, R9 and RW9 conjugates proved to be most potent 
derivatives that could escape from the efflux pump and penetrate cell membrane 
with good aqueous solubility. It therefore worthwhile to further explore their 
antimicrobial activity by extending the MIC determination to another five strains of 
bacteria for the conjugates, the acetylated vectors as well as the parent compounds 
for comparison (Table 5.5). The parent compounds SB4CB and Cu(SB4CB)2 were 
most active against gram positive bacteria S. aureus even without the presence of 
PMBN and both compounds also showed a wide spectrum of activity against the 
other gram negative strains in the presence of PMBN.  
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  Minimum inhibitory concentration (MIC)  (µM) 
Compound Gram- Gram+ 
 E. coli E. aerogenes A. baumannii 
K. 
pneumoniae 
P. 
aeruginosa S. enterica S. aureus 
 AG100WT 
AG100A 
acrAB- 
EA289 
acrAB+ 
EA298 
tolC- 
ATCC 
19606 
ATCC 
11296 PA01 SL696 SA1199 
SB4CB >64 >64 - 64 >64 >64 128 >128 >128 >128 16 
+ PMBN 1/5 32 16 >64 16 32 32 32 32 8 
Cu(SB4CB)2 >64 >64 >64 >64 >128 >128 >128 >128 8 - 4 
+ PMBN 1/5 8 8 >64 8 - 4 32 >128 64 64 8 
SM4CB >64 >64 >64 >64 >128 >128 >128 >128 64 - 32 
+ PMBN 1/5 >64 >64 - 32 >64 >64 64 128 32 >128 64 
Cu(SM4CB)2 >64 >64 >64 >64 >128 >128 >128 >128 16 
+ PMBN 1/5 64 32 >64 64 >128 >128 128 >128 32 
R9-Ac 8 8 8 8 >128 16 >128 64 - 16 >128 
+ PMBN 1/5 4 4 8 8 >128 16 >128 8 - 4 64 - 32 
R9-SB4CB 8 8 8 4 32 32 128 - 64 16 4 
+ PMBN 1/5 4 4 4 4 32 16 128 8 4 
Cu(R9-SB4CB)2 4 4 4 4 64 32 32 8 2 
+ PMBN 1/5 2 2 4 2 64 16 32 4 1 
R9-SM4CB 8 8 16 - 8 16 - 8 64 32 - 16 128 16 8 
+ PMBN 1/5 4 4 8 8 32 16 - 8 >128 4 2 
Cu(R9-SM4CB)2 8 - 4 4 8 4 64 16 64 8 8 - 4 
+ PMBN 1/5 4 2 4 4 64 8 128 4 - 2 1 - 0.5 
Table 5.5. Final antimicrobial evaluation against 9 strains of bacteria  
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Colour code: MIC values or average MIC values 6 64 µM = red, "10 µM = green, in between 64 µM and 10 µM = colourless.  MIC values 
higher than 64 µM indicate inactivity.  
RW9-Ac 2 2 8 - 4 2 64 - 32 16 - 8 64 - 32 4 - 2 4 
+ PMBN 1/5 2 2 4 2 128 - 64 8 4 - 2 1 2 
RW9-SB4CB 16 - 4 16 16 - 8 8 32 32 16 8 4 
+ PMBN 1/5 8 8 8 8 32 >16 8 4 2 
Cu(RW9-
SB4CB)2 8 - 4 8 - 4 16 - 8 8 - 4 64 - 32 32 16 8 4 - 2 
+ PMBN 1/5 8 4 8 8 32 >16 8 4 1 
RW9-SM4CB 8 - 2 8 - 4 8 - 4 4 8 16 - 8 16 4 - 2 2 - 1 
+ PMBN 1/5 8 4 8 8 16 16 16 - 8 2 - 1 1 
Cu(RW9-
SM4CB)2 2 8 - 4 8 4 16 - 8 16 - 8 16 2 - 1 1 
+ PMBN 1/5 4 2 4 4 16 16 8 1 1 - 0.5 
Ciprofloxacine 0.03 0.008 64 32 2 0.25 0.5- 0.25 0.03 1 
+ PMBN 1/5 0.015 0.008 64  32 2 0.125  -  0.03 1 - 0.5 
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It is likely that the complexes were more active against the Gram-positive bacteria 
due to the ease of penetration through the cell wall as compared to the Gram-
negative bacteria. It should be noted that SM4CB, the less active S-methyl analogue 
of SB4CB ligand was also functionalized with R9 and RW9 in order to better 
understand the conjugation effect. This led to further positive results including the 
synthesis of a new compound, R9-SM4CB that was active against most of the 
bacteria. It is particularly interesting to note the construct of active R9-SM4CB 
against S. aureus with MIC values of 8 µM (without the presence of PMBN) from 
R9AC (MIC >128 µM) and SM4CB (MIC= 64 µM), both of which were inactive 
under identical conditions. Comparing the efficacy of the compounds against the 
different strains of bacteria, the MIC values of the ligands conjugates were 
considerably better as compared to the parent compounds. Upon conjugation, the 
functionalized compounds exhibited improved antimicrobial activity with MIC 
values in the micromolar concentration range, as low as 1-0.5 µM.  However, in 
comparison with the R9 and RW9 acetylated free peptides, the improvement in MIC 
values of the conjugates were less striking although there were some exceptions that 
will be discussed herein. RW9AC proved to be active against E. coli, E. aerogenes, 
K. pneumoniae, S. enterica and S. aureus but less active against A. baumannii and P. 
aeruginosa. While R9AC also showed activity against some of the bacteria strains, it 
was completely inactive against A. baumannii, P. aeruginosa and S. aureus. 
Conjugation to R9 did not essentially change the antibacterial activity of R9 against 
gram-negative bacteria E. coli, E. aerogenes ArcAB+, K. pneumoniae, P. 
aeruginosa and S. enterica. The no improvement observation could mean that the 
activity is only due to the peptide and not to the parent compound. The RW9 
conjugates showed either similar or increased MIC values as compared to acetylated 
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RW9 when evaluated against E. coli, E. aerogenes, K. pneumoniae and S. enterica. 
The conjugation of Schiff base with RW9 apparently compromises the antimicrobial 
activity of RW9 although the compounds were still active with respect to the 
bacteria mentioned previously. Notwithstanding this, R9 conjugates displayed 2 to 
4- fold of enhancement in activity against A. baumannii from inactive R9AC 
(MIC>128 µM) to moderately active (MIC 32 and 64 µM for R9-SB4CB and R9-
SM4CBCB, respectively). Likewise, RW9-SM4CB (MIC 8 µM) also showed 
improvement from RW9AC with the same strain. The highlight of the MIC results 
was definitely the high activity against the Gram-positive S. aureus in which R9-
SB4CB, R9-SM4CB and RW9-SM4CB all showed better MIC values than their 
parent ligands as well as their respective acetylated free peptides. In addition, the 
MIC values of the conjugates were even more effective than ciprofloxacine against 
the E. aerogenes strains and also showed comparable MIC values with the standard 
drug towards S. aureus.  
 
Since the parents compounds already showed activity without the introduction of 
PMBN against S. aureus and also PMNB does not significantly improve the MIC 
values of R9 and RW9 conjugates, the complexation effect will be discussed using 
MIC values ratio with and without PMBN as shown in Figure 5.9 and 5.10. Among 
the conjugates, only Cu(R9-SM4CB)2, Cu(RW9-SB4CB)2 and Cu(RW9-SM4CB)2 
showed positive synergistic complexation effect against P. aeruginosa, E. coli 
AcrAB- and E. coli WT  respectively, without the presence of PMBN. In the 
presence of PMBN, the efficacy of complexation effect towards S. aureus was 
evident from the MIC ratio values of 2 and 1.33 for Cu(R9-SB4CB)2 and Cu(R9-
SM4CB)2, respectively.  It was also apparent that complexation exacerbates the 
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ligand effect of RW9 derivatives with the most ratios less than 1 as observed in both 
graphs. However, the complexation effect was more favourable towards R9 
derivatives as shown by Cu(R9-SB4CB)2 with ratio of 2 against  P. aeruginosa and 
S. aureus and Cu(R9-SM4CB)2 with  ratio of 1.33 against S. aureus in the presence 
of PMBN.  
 
 
Figure 5.9. Effect of complexation on Cu(SB4CB)2, Cu(SM4CB)2 Cu(R9-
SB4CB)2, Cu(RW9-SB4CB)2, Cu(R9-SM4CB)2, Cu(RW9-SM4CB)2 against the 
different strains without the presence of PMBN. 
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Figure 5.10. Effect of complexation on Cu(SB4CB)2, Cu(SM4CB)2 Cu(R9-
SB4CB)2, Cu(RW9-SB4CB)2, Cu(R9-SM4CB)2, Cu(RW9-SM4CB)2 against the 
different strains in the presence of PMBN. 
 
The EPR spectra for all of the Cu(II) bioconjugates were recorded and the redox 
potentials for Cu(R1-SB4CB)2, Cu(PEG-SB4CB)2 and Cu(PA%NSB)2 were also 
evaluated (Chapter 4, p. 142). A general observation demonstrated that the EPR 
properties of the bioconjugates were similar to their parent compounds adopting a 
square planar geometry in solution. From the electrochemistry investigation, the 
Cu(II) bioconjugates showed a non-reversible negative shift of the redox couple 
Cu(II)/Cu(I) potential in the range -0.083 to -0.098 V as compared to Cu(SB4CB)2 at 
-0.072 V. The loss of reversibility observed herein does not compromise the 
bioactivity of the compounds Cu(R1-SB4CB)2 and Cu(PEG-SB4CB)2, instead the 
bioconjugates derivatives showed enhanced antimicrobial efficacy. This could 
suggest a difference type of mechanism for the bioconjugates.  
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5.3.2 Cytotoxicity 
In view of the well known cytotoxic activity of sulfur–nitrogen Schiff base chelating 
agents and their metal complexes and also to judge their utility for further 
development as anticancer agents, selected compounds were tested for their 
cytotoxicity against two breast cancer cell lines MDA-MB-231 (human breast 
carcinoma cells not expressing nuclear estrogen receptors, ER-) and MCF-7 (human 
breast carcinoma cells expressing nuclear estrogen receptors, ER+). Measurement of 
the cytotoxicity was carried out using MTT assay (Mosmann, 1983) based on the 
metabolic reduction of tetrazolium salt to form water insoluble formazan crystals 
with tamoxifen as standard. DMSO was used as negative control in the assay and the 
final content of DMSO for each compound tested was 0.5% or less. The 
concentration required to reduce growth of cancer cells by 50% (IC50) are shown in 
Table 5.6 for both tetradentate series and bidentate NS series derived from 3-
acetylcoumarin.  
Table 5.6. Cytotoxic assay results.  
 IC50 (!M) 
 MCF7 MDA-MB231 
Tetradentate series 
SMHD 138.90  9.61 
SBHD 9.69 1.05 
CuSMHD 2.60 2.34 
CuSBHD 1.49 0.71 
Bidentate series 
SBCM inactive inactive 
Re2(SBCM)2 19.41 8.61 
Zn(SBCM)2 inactive inactive 
Cu(SBCM)2 5.97 8.31 
Tamoxifen  11.20 13.40 
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For the tetradentate series, it interesting to note that the structure-activity 
relationship observed in the antibacterial tests differed from their cytotoxicity. Both 
ligands displayed at least 9-fold better toxicity towards the MDA-MB231 cell line 
that does not express estrogen nuclear receptors, indicating that ligand toxicity is not 
only mediated by these receptors. The more lipophilic SBHD exhibits a stronger 
toxicity in comparison to SMHD (Pavan et al., 2010). Complexation of Schiff base 
ligands with metal ions has been found to produce synergistic effects on the 
antiproliferative activities of the parent ligands since the complexes showed a 
marked cytotoxicity with IC50 values < 5.0 µM towards both cell lines. Again the 
bioactivity of the complexes does not involve estrogen receptors because they are 
more active on MDA-MB231 cells. On both cell lines, the benzyl substituted 
complex CuSBHD showed slightly better IC50 values. The stronger activity of 
CuSBHD could possibly be attributed to a higher cellular uptake due to an increased 
lipophilicity. Likewise, the 3-acetylcoumarin derived bidentate series also 
highlighted that complexation played a significant role in improving the bioactivity 
of the compound. The ligand SBCM was found to be inactive towards both MCF-7 
and MDA-MB231 cell lines. However, complexation of the Schiff base ligand with 
Cu(II) and Re(I) with the exception of Zn(II) showed marked cytotoxicity with IC50 
values < 10 !M. Re2(SBCM)2 displayed better selectivity towards MDA-MB231 
whereas Cu(SBCM)2 was more potent against MCF7. All the Cu(II) complexes were 
most potent in both series and have lower IC50 values in comparison to standard 
tamoxifen making them potential anticancer agents for consideration. The difference 
in selectivity observed between the Cu(II) complexes of bidentate (MCF7) and 
tetradentate (MDA-MB231) series may result from their differences in ligand 
substituents, physico-chemical and redox potential.  The bioactive Re2(SBCM)2 with 
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the presence of tricarbonyl core may also offer novel exploratory derivatives for 
future investigations in the treatment of cancer as novel pharmaceutical as well as 
potential probe for sub-cell imaging. While the mechanism of action against breast 
cancer cell lines for dithiocarbazate compounds has yet to be definitively determined 
but an in vitro study by Cheah (2007) and Awidat (2005) on some dithiocarbazato 
compounds suggested that they induce apotopsis by DNA fragmentation and 
suppression of the expression of certain oncogenes. Previously mentioned 
mechanisms in the antimicrobial section i.e. inhibition of the enzyme ribonucleotide 
reductase, topoisomerase IIa or multi-drug resistance protein as well as production 
of ROS have also been linked to their anti-cancer activity. 
 
5.4 Conclusion 
It was demonstrated that the bidentate Schiff base (SB4CB) and its Cu(II) complex 
Cu(SB4CB)2 with aromatic acid functionality possess the most remarkable 
antibacterial effect against a wide spectrum of bacteria. The pioneering conjugation 
strategy investigated in this work demonstrated the utility of the combination of 
functionalized dithiocarbazate derivatives with vectors (CPPs) to generate 
bioconjugates with enhanced antimicrobial activity, membrane permeability and 
water solubility. The results highlighted various trends and factors that govern 
antimicrobial activities of the tested compounds. It was clearly evident that 
antimicrobial activities of the compounds are strongly dependent on their 
substitutents. Introduction of the carboxylic acid moiety and SBDTC increases the 
antimicrobial activity within the bidentate series. The complexation with copper has 
a synergetic effect on the antimicrobial activity of these compounds. The increased 
activity of the complexes could be associated with their increased lipophilicity, 
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better fitness and size of the molecules towards binding sites as well as various 
geometrical arrangements including square planar and distorted forms inducing a 
tuning in redox potential. The observed cyclic voltammetric behaviour of bidentate 
copper(II) complexes showed a Cu(II)/Cu(I) redox quasi-reversibility and a positive 
shift as compared to the tetradentate series which may also contribute to their 
toxicity. In addition, the biological activity depends on factors such as the bacteria 
strain and the vectors used for bioconjugation. A deep understanding of the structure 
and activity of metal complexes against microorganisms is invaluable toward future 
development of antibiotic agents.  The antimicrobial activity of the compounds can 
be summarized as follows:  
 
Tetradentate series (S-benzyl derivatives<S-methyl derivatives, Cu (II) 
complexes<Ligands) <Bidentate series (Aliphatic<Aromatic, S-methyl 
derivatives<S-benzyl derivatives, Ligands<Cu (II) complexes) <Peptide conjugate 
series (PA%N<PEG<R1<R4<RW9/R9)< their Cu (II) complexes (MIC * 1-0.5 µ M) 
 
All the selected Cu(II) complexes assayed against breast cancer cells lines (MCF-7 
and MDA-MB-231) exhibited good cytotoxicity with lower IC50 values (0.71-8.31 
µM)  in comparison to their respective ligands and standard drug tamoxifen. This 
highlights the relevance of metal complexation strategy to stabilize the ligands and 
improve their bioactivity.  
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CHAPTER 6 
CONCLUSION AND RECOMMENDATIONS 
 
In conclusion, a total of 43 compounds were synthesized and characterized in this 
work. These compounds comprised of 10 Schiff base ligands derived from either 
SMDTC or SBDTC, 8 ligand-peptides/PEG conjugates, 5 acetylated peptides/PEG 
and 19 metal complexes. Single crystal structures were solved for 11 compounds. 
Only SMHD and SBHD were NNSS tetradentate ligands while the others behaved 
as bidentate NS ligands coordinating to the central metal through the azomethine 
nitrogen atom and the thiolate sulphur atom in their respective complexes. The 
antimicrobial activity of the compounds showed improvement going from 
macroacyclic tetradentate series to open chain bidentate series and finally the 
bioconjugates series. This work also allows new insight into the relationship 
between the structural/electrochemical properties and biological activity of the 
compounds. The bidentate series demonstrated higher antimicrobial activity than 
their more planar tetradentate counterparts as in the solid state, the crystal structures 
of Cu(SMML)2 and Cu(SMLA)2  from the bidentate series displayed a more 
significant distortion from square planar than CuSMHD and CuSBHD of the 
macroacyclic tetradentate series. EPR data also support the slightly greater distortion 
of the bidentate series in comparison to the tetradentate series in solution with the 
exception of Cu(SB4CB)2 and Cu(SM4CB)2 that fall in the square planar range. 
Both series also differed in their electrochemical properties in which bidentate series 
showed Cu(II)/Cu(I) quasi reversibility at more positive potential whereas 
tetradentate series was not reversible. The Cu(II) R9 derivatives of SB4CB and 
SM4CB possess the most remarkable antibacterial effect against a wide spectrum of 
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bacteria. In addition, these R9-conjugates managed to address drawbacks that are 
often associated with most metal complexes involving the issues of poor water 
solubility and lack of uptake of the compounds due to low permeability of the outer 
membrane as well as the efficiency of bacteria efflux pump. The successful 
conjugation and facile complexation with copper for Schiff bases SB4CB and 
SM4CB offer exciting potential for them to be further optimized with different 
vectors in the future. The selected Cu(II) compound assayed against breast cancer 
cells also exhibited good cytotoxicity. The fact that the Cu (II) complexes are more 
efficient than the ligands is appealing. Taking into account, the serious side effects 
and upcoming resistance of clinical reference drugs, these new compounds are 
useful lead candidates for the development of novel therapeutic agents to treat 
bacterial infections and cancer.  
 
Hitherto, the mechanism of action of the compounds has yet to be verified. 
Therefore, efforts to determine the concentration and location of the compounds 
inside cells will be the next crucial step for intracellular understanding. This is 
important in order to increases the compounds chances of succeeding in in vivo 
assay, clinical trials and ultimately to be used as therapeutic drugs.  Attaching the 
lead compound to a probe or fluorescence moiety would allow cell imaging 
experiments to be carried out. Parallel studies involving the recognition of 
biomolecules as specific targets such DNA binding and cleavage, protein or enzyme 
inhibitors as well as depolarization 3,3$-Dipropylthiadicarbocyanine iodide 
(DiSC3(5)) or ortho-nitrophenyl-%-D-galactopyranoside (OPNG) membrane 
permeabilization assay (for bacteria) are also essential in order shed light on the 
mode of action of these compounds under biological conditions. It is also expected 
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that the application of computational analysis like docking will facilitate a deeper 
understanding of the molecular interaction. In addition, Density Functional Theory 
(DFT) and Quantitative Structure-Activity Relationship (QSAR) studies will enable 
elucidation of key structural and chemical parameters required to develop potent 
compounds. The data compilation will be beneficial in the long run as the 
information may allow utilization of virtual high throughput screening (HTS) 
approach to prescreen lead dithiocarbazate compounds in silico for diseases prior to 
synthesis or bioactivity assay validation. This approach would be an excellent 
strategy in both time- and cost-effective manner as compared to the carpet bombing 
strategy.  
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APPENDICES 
Molecular structures of all compounds synthesized and characterized in this work. 
(a) Macroacyclic Cu(II) system with  tetradentate NNSS ligands. 
 
(b) Open chain Cu(II) system with bidentate NS ligands with acid or ester 
functionality. 
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(c) Open chain metal system with bidentate NS ligands with natural ketone 
moiety. 
 
(d) Acetylated vectors. 
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(e) Functionalized compounds. 
 
  
226 
 
 
  
227 
 
A. NMR spectra 
 
Figure A1.  1H NMR spectrum of SBHD 
 
 
 
Figure A2.  13C NMR spectrum of SBHD 
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Figure A3.  1H NMR spectrum of SMHD 
 
 
 
Figure A4.  13C NMR spectrum of SMHD 
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Figure A5.  1H NMR spectrum of SBPY 
 
 
Figure A6.  13C NMR spectrum of SBPY 
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Figure A7.  1H NMR spectrum of SMLA 
 
 
 
Figure A8.  13C NMR spectrum of SMLA 
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Figure A9.  1H NMR spectrum of SBML 
 
 
 
Figure A10.  13C NMR spectrum of SBML 
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Figure A11.  1H NMR spectrum of SBLA 
 
 
 
Figure A12.  13C NMR spectrum of SBLA 
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Figure A13.  1H NMR spectrum of SBEL 
 
 
 
Figure A14.  13C NMR spectrum of SBEL 
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Figure A15.  1H NMR spectrum of SM4CB 
 
 
 
Figure A16.  13C NMR spectrum of SM4CB 
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Figure A17.  1H NMR spectrum of SBCM 
 
 
Figure A18.  1H NMR spectrum of Zn(SBCM)2 
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Figure A19. 1H NMR spectrum of Re2(SBCM)2 
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Figure A20.  1H NMR spectrum of PEG-SB4CB 
 
 
 
Figure A21.  13C NMR spectrum of PEG-SB4CB 
 
238 
 
 
Figure A22.  1H NMR spectrum of PEGAC 
 
 
 
Figure A23.  13C NMR spectrum of PEGAC 
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Figure A24.  1H NMR spectrum of R1AC 
 
 
 
Figure A25.  13C NMR spectrum of R1AC 
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Figure A26.  1H NMR spectrum of R4-SB4CB 
 
 
 
Figure A27.  1H NMR spectrum of R4-AC 
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Figure A28.  1H NMR spectrum of R9-SB4CB 
 
 
 
Figure A29.  1H NMR spectrum of R9-SM4CB 
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Figure A30.  1H NMR spectrum of R9AC 
 
 
 
Figure A31.  1H NMR spectrum of RW9-SB4CB 
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Figure A32.  1H NMR spectrum of RW9-SM4CB 
 
 
 
 Figure A33.  1H NMR spectrum of RW9AC 
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Figure A34.  1H NMR spectrum of PA"N-SB4CB 
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B. Mass Spectra 
 
Figure B1.  ESI-MS spectrum of CuSBHD 
 
 
 
Figure B2.  ESI-MS spectrum of CuSMHD 
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Figure B3.  ESI-MS spectrum of SBPY 
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Error = 0.8 ppm 
Figure B4.  HR-MS spectrum of SMML 
 
 
 
Error = 0.5 ppm 
Figure B5.  HR-MS spectrum of SMLA 
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Error = 0.4 ppm 
Figure B6.  HR-MS spectrum of SM4CB 
 
 
 
Error = 0.5 ppm 
Figure B7.  HR-MS spectrum of SBML 
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Error = 0.5 ppm 
Figure B8.  HR-MS spectrum of SBEL 
 
 
 
 
Error = 0.5 ppm 
Figure B9.  HR-MS spectrum of SBLA 
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Error = 0.2 ppm 
Figure B10.  HR-MS spectrum of SB4CB 
 
 
 
 
Figure B11.  ESI-MS spectrum of Cu(SMML)2 
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Figure B12.  ESI-MS spectrum of Cu(SMLA)2 
 
 
Figure B13.  ESI-MS spectrum of Cu(SM4CB)2 
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Figure B14.  ESI-MS spectrum of Cu(SBML)2 
 
 
 Figure B15.  ESI-MS spectrum of Cu(SBLA)2 
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Figure B16.  ESI-MS spectrum of Cu(SB4CB)2 
 
 
 
 
Error = 1.0 ppm 
Figure B17.  HR-MS spectrum of SBCM 
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Figure B18.  ESI-MS spectrum of Cu(SBCM)2 
 
 
 
 
 
Figure B19.  ESI-MS spectrum of Zn(SBCM)2 
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Figure B20.  ESI-MS spectrum of Re2(SBCM)2 
 
 
 
Error = 0.3 ppm 
Figure B21.  HR-MS spectrum of PEG-SB4CB 
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Error = 0.4 ppm 
Figure B22.  HR-MS spectrum of PEGAC 
 
 
Error = 0.3 ppm 
Figure B23.  HR-MS spectrum of R1AC 
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Figure B24.  MALDI-TOF-MS full spectrum of R4-SB4CB 
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Figure B25.  MALDI-TOF-MS enlarged spectrum of R4-SB4CB 
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Figure B26.  MALDI-TOF-MS full spectrum of PA"N-SB4CB 
260 
 
 
 
Figure B27.  MALDI-TOF-MS enlarged spectrum of PA"N-SB4CB 
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Figure B28.  MALDI-TOF-MS full spectrum of R9-SB4CB 
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Figure B29.  MALDI-TOF-MS enlarged spectrum of R9-SB4CB 
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Figure B30.  MALDI-TOF-MS full spectrum of RW9-SB4CB 
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Figure B31.  MALDI-TOF-MS enlarged spectrum of RW9-SB4CB 
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Figure B32.  MALDI-TOF-MS full spectrum of R9-SM4CB 
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Figure B33.  MALDI-TOF-MS enlarged spectrum of R9-SM4CB 
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Figure B34.  MALDI-TOF-MS full spectrum of RW9-SM4CB 
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Figure B35.  MALDI-TOF-MS enlarged spectrum of RW9-SM4CB 
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Figure B36.  MALDI-TOF-MS full spectrum of R4AC 
270 
 
 
Figure B37.  MALDI-TOF-MS enlarged spectrum of R4AC 
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Figure B38.  MALDI-TOF-MS full spectrum of R9AC 
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Figure B39.  MALDI-TOF-MS enlarged spectrum of R9AC 
273 
 
 
Figure B40.  MALDI-TOF-MS full spectrum of RW9AC 
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Figure B41.  MALDI-TOF-MS enlarged spectrum of RW9AC 
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Figure B42.  LC-MS (EMS) spectrum of R1-SB4CB at 17.6 min 
 
 
 
 
Figure B43.  LC-MS (EPI) spectrum of R1-SB4CB at 17.6 min 
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Figure B44.  LC-MS (EMS) spectrum of R1-SB4CB at 15.3 min 
 
 
Figure B45.  LC-MS (EPI) spectrum of R1-SB4CB at 15.3 min 
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Figure B46.  TIC (EMS) chromatogram of R1-SB4CB 
 
 
Figure B47.  TIC (EPI) chromatogram of R1-SB4CB 
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Figure B48.  ESI-MS spectrum of Cu(R1-SB4CB)2 
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Figure B49.  LC-MS [EMS and ER (inset)] spectra of Cu(R1-SB4CB)2 at 17.6 
min 
 
 
Figure B50.  LC-MS (EPI) spectrum of Cu(R1-SB4CB)2 at 17.6 min 
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Figure B51.  LC-MS [EMS and ER (inset)] spectra of Cu(R1-SB4CB)2 at 15.3 
min 
 
 
Figure B52.  LC-MS (EPI) spectrum of Cu(R1-SB4CB)2 at 15.3 min 
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Figure B53.  TIC (EMS) chromatogram of Cu(R1-SB4CB)2 
 
 
Figure B54.  TIC (EPI) chromatogram of Cu(R1-SB4CB)2 
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Figure B55.  ESI-MS spectrum of Cu(PEG-SB4CB)2 
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Figure B56.  LC-MS [EMS and ER (inset)] spectra of Cu(PEG-SB4CB)2 at 16.1 
min 
 
Figure B57.  LC-MS (EPI) spectrum of Cu(PEG-SB4CB)2 at 16.1 min 
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Figure B58.  LC-MS [EMS and ER (inset)] spectra of Cu(PEG-SB4CB)2 at 15.2 
min 
 
 
Figure B59.  LC-MS (EPI) spectrum of Cu(PEG-SB4CB)2 at 15.2 min 
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Figure B60.  TIC chromatogram of Cu(PEG-SB4CB)2 
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Figure B61.  ESI-MS spectrum of Cu(PA"N-SB4CB)2 
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Figure B62.  TIC (EMS) chromatogram of Cu(PA"N-SB4CB)2 
 
Figure B63.  TIC (EPI) chromatogram of Cu(PA"N-SB4CB)2 
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Figure B64.  LC-MS [EMS and ER (inset)] spectra of Cu(PA"N-SB4CB)2 
 
 
Figure B65.  LC-MS (EPI) spectrum of Cu(PA"N-SB4CB)2 
 
 
 
289 
 
 
 
Figure B66.  LC-MS [EMS and ER (inset)] spectra of Cu(R4-SB4CB)2 at 14.0 
min 
 
 
Figure B67.  LC-MS (EPI) spectrum of Cu(R4-SB4CB)2 at 14.0 min 
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Figure B68.  LC-MS [EMS and ER (inset)] spectra of Cu(R4-SB4CB)2 at 17.3 
min 
 
 
Figure B69.  LC-MS (EPI) spectrum of Cu(R4-SB4CB)2 at 17.3 min 
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Figure B70.  TIC (EMS) chromatogram of Cu(R4-SB4CB)2 
 
 
Figure B71.  TIC (EPI) chromatogram of Cu(R4-SB4CB)2 
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C. UV-Vis spectra 
 
 
Figure C1.  UV-Vis spectrum of SMLA at 25 !M  
 
 
 
Figure C2.  UV-Vis spectrum of Cu(SMLA)2 at 25 !M and 1 mM 
 
 
 
Figure C3.  UV-Vis spectrum of SBML at 25 !M  
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Figure C4.  UV-Vis spectrum of Cu(SBML)2 at 25 !M and 1 mM 
 
 
 
Figure C5.  UV-Vis spectrum of SBLA at 25 !M  
 
 
 
Figure C6.  UV-Vis spectrum of Cu(SBLA)2 at 25 !M and 1 mM 
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Figure C7.  UV-Vis spectrum of SBEL at 25 !M  
 
 
 
Figure C8.  UV-Vis spectrum of SM4CB at 25 !M  
 
 
 
Figure C9.  UV-Vis spectrum of Cu(SM4CB)2 at 25 !M  
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Figure C10.  UV-Vis spectrum of SB4CB at 25 !M  
 
 
 
Figure C11.  UV-Vis spectrum of Cu(SB4CB)2 at 25 !M  
 
 
 
 
Figure C12.   UV-Vis titration of Cu-R4SB4CB  
296 
 
 
Figure C13.  Plot of absorbance against equivalent of Cu for UV-Vis titration of 
Cu-R4SB4CB 
 
 
Figure C14.  UV-Vis titration of Cu-PABNSB4CB 
 
 
 
Figure C15.  Plot of absorbance against equivalent of Cu for UV-Vis titration of 
Cu-PABNSB4CB 
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Figure C16.  UV-Vis titration of Cu-PEGSB4CB  
 
 
 
Figure C17.  Plot of absorbance against equivalent of Cu for UV-Vis titration of 
Cu-PEGSB4CB  
 
 
Figure C18.  UV-Vis titration of Cu-RW9SM4CB   
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Figure C19.  Plot of absorbance against equivalent of Cu for UV-Vis titration of 
Cu-RW9SM4CB  
 
 
Figure C20.  UV-Vis titration of Cu- RW9SB4CB  
 
 
Figure C21.  Plot of absorbance against equivalent of Cu for UV-Vis titration of 
Cu-RW9SB4CB  
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Figure C22.  UV-Vis titration of Cu-R9SB4CB  
 
 
Figure C23.  Plot of absorbance against equivalent of Cu for UV-Vis titration of 
Cu-R9SB4CB  
 
 
Figure C24.  UV-vis spectra of SBCM, Cu(SBCM)2, Zn(SBCM)2 and 
Re2(SBCM)2  recorded at 25 !M in DMSO using a cell length of 1 cm. The 
insert shows the d-d band of the complex Cu(SBCM)2 at concentration of 1 
mM. 
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D. FT-IR spectra 
 
Figure D1.  FT-IR spectrum of SMHD 
 
 
Figure D2.  FT-IR spectrum of CuSMHD 
 
 
Figure D3.  FT-IR spectrum of SBPY 
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Figure D4.  FT-IR spectrum of SMLA 
 
 
Figure D5.  FT-IR spectrum of Cu(SMLA)2 
 
Figure D6.  FT-IR spectrum of SBML 
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Figure D7.  FT-IR spectrum of Cu(SBML)2 
 
 
Figure D8.  FT-IR spectrum of SBLA 
. 
 
Figure D9.  FT-IR spectrum of Cu(SBLA)2 
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Figure D10.   FT-IR spectrum of SBEL 
 
 
Figure D11.   FT-IR spectrum of SM4CB 
 
 
Figure D12.   FT-IR spectrum of Cu(SMH4CB)2 
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Figure D13.   FT-IR spectrum of SB4CB 
 
 
Figure D14.   FT-IR spectrum of CuS(SB4CB)2 
 
 
 
Figure D15.   FT-IR spectrum of Re2(SBCM)2 and SBCM 
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Figure D16.   FT-IR spectrum of Cu(SBCM)2 
 
 
Figure D17.   FT-IR spectrum of Zn(SBCM)2 
 
 
 
 
 
 
 
 
 
 
 E. Crystal structures parameters 
 
Table E1: Crystallographic data and structure refinement details for compounds SBPY, SMHD, CuSMHD and CuSBHD.
 
Compounds SBPY 
CCDC 930513 
Formula C14 H16 N2 S2 
Mr 276.41 
Crystal size, mm3 0.21 x 0.20 x 0.04 
Crystal system monoclinic 
Space group P 21/c 
a, Å 9.2991(4) 
b, Å 15.9635(8) 
c, Å 9.4848(5) 
&, ° 90 
%, ° 96.1550(10) 
-, ° 90 
Cell volume, Å3 1399.87(12) 
Z  4 
T, K 100 
F000 584 
µ, mm–1 0.364 
" range, ° 2.51 – 32.16 
Reflection collected 22 601 
Reflections unique 4 867 
Rint 0.0431 
GOF 1.175 
Refl. obs. (I>2#(I)) 4 092 
Parameters 165 
SMHD CuSMHD CuSBHD 
   
C10H18N4S C10H16CuN4S4 C22H24CuN4S4 
322.54 384.07 536.27 
0.24 ! 0.06 ! 0.03 0.4!0.12!0.18 0.28 ! 0.22 ! 0.11 
triclinic  monoclinic monoclinic 
P   C2/c P21/c 
5.1646 (5) 24.6441 (8) 10.79369 (13) 
 7.2792 (8) 7.9100 (2) 18.8337 (2) 
10.7840 (12) 16.8972 (6) 11.84121 (15) 
100.65 (1) 90 90 
90.751 (9) 111.167(4) 103.4104(13) 
107.305 (10) 90 90 
379.39 (8) 3071.62 (19) 2341.51 (5) 
1 8 4 
150  150 150 
170 1576 1108 
5.662 1.956 1.308 
4.18-71.56 2.55-28.96 2.22-28.98 
4869 19393 59768 
1455 3704 5779 
0.042 0.029 0.033 
1.0039 0.9869 0.9773 
1209 3483 5129 
82 172 280 
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R, wR (all data) 0.0733,0.1273 0.0552, 0.1208 0.0217, 0.0498 0.0338,0.0736 
Final R, wR  (I>2#(I)) 0.0603,0.1217    0.0457, 0.1126  0.0198, 0.0488   0.0287, 0.0698 
Largest diff. peak and 
hole (e-.Å-3) 
-0.344; 0.536 -0.35; 0.52 -0.34; 0.36 -0.56; 0.72 
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Table E2: Crystallographic data and structure refinement details for 
compounds for compounds SMML, SBML and SBEL. 
 
  
Compound SMML SBML SBEL 
CCDC CCDC 999789 CCDC 999788 CCDC 999786 
Empirical Formula C8 H14 N2 O2 S2 C14 H18 N2 O2 S2 C15 H20 N2 O2 S2 
Mr 234.33 310.42 324.45 
Crystal size, mm3 0.31 x 0.30 x 0.28 
0.33 x 0.31 x 
0.19 
0.31 x 0.29 x 
0.22 
Crystal system monoclinic monoclinic monoclinic 
Space group P 21/c P 21/n P 21/n 
a, Å 8.1149(2) 12.7266(4) 12.7529(5) 
b, Å 13.0536(3) 7.2329(2) 7.4369(3) 
c, Å 11.0433(3) 16.7849(5) 17.3690(7) 
&, ° 90 90 90 
%, ° 105.4960(10) 97.5740(10) 97.5530(10) 
-, ° 90 90 90 
Cell volume, Å3 1127.28(5) 1531.57(8) 1633.02(11) 
Z ; Z’ 4 ; 1 4 ; 1 4 ; 1 
T, K 100(1) 100(1) 100(1) 
F000 496 656 688 
µ, mm–1 0.450 0.350 0.331 
" range, ° 2.47 – 36.41 1.89 – 33.74 1.87 – 36.30 
Reflection collected 36 241 16 603 21 234 
Reflections unique 5 508 4 539 6 657 
Rint 0.0213 0.0429 0.0315 
GOF 1.090 1.041 1.046 
Refl. obs. (I>2#(I)) 5 091 4 102 5 868 
Parameters 130 183 192 
wR2 (all data) 0.0811 0.0978 0.0905 
R value (I>2#(I)) 0.0674 0.0352 0.0319 
Largest diff. peak and 
hole (e-.Å-3) -0.386 ; 0.423 -0.406 ; 0.632 -0.380 ; 0.473 
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Table E3: Crystallographic data and structure refinement details for 
compounds for compounds SBLA, Cu( SMML)2 and Cu(SMLA)2. 
 
 
 
 
 
 
Compound SBLA Cu(SMML)2 Cu(SMLA)2 
CCDC CCDC 999787 CCDC 999785  CCDC 999784 
Empirical Formula C13 H16 N2 O2 S2 C16 H26 Cu N4 O4 S4 
C15 H26 Cu N4 O5 
S4 
Mr 296.40 530.19 534.18 
Crystal size, mm3 0.13 x 0.10 x 0.02 0.16 x 0.11 x0.07 0.18 x 0.14 x0.08 
Crystal system triclinic monoclinic monoclinic 
Space group P -1 C 2/c P 21/n 
a, Å 6.708(3) 12.9400(3) 11.8086(6) 
b, Å 10.448(4) 12.4444(3) 9.1068(5) 
c, Å 11.565(5) 13.8556(3) 21.0888(11) 
&, ° 76.170(9) 90 90 
%, ° 87.778(9) 91.4150(10) 97.626(2 
-, ° 71.867(10) 90 90 
Cell volume, Å3 747.4(5) 2230.49(9) 2247.8(2) 
Z ; Z’ 2 ; 1 4 ; $ 4 ; 1 
T, K 100(1) 100(1) 100(1) 
F000 312 1100 1108 
µ, mm–1 0.355 1.384 1.377 
" range, ° 1.81 – 30.05 2.27 – 36.33 1.88 – 30.63 
Reflection collected 9 990 41 767 52 414 
Reflections unique 3 748 5 390 6 889 
Rint 0.0224 0.0401 0.0301 
GOF 1.013 1.028 1.154 
Refl. obs. (I>2#(I)) 2 250 4 325 6 006 
Parameters 174 135 270 
wR2 (all data) 0.1732 0.0711 0.0855 
R value (I>2#(I)) 0.0617 0.0283 0.0342 
Largest diff. peak and 
hole (e-.Å-3) -0.642 ; 0.441 -0.380 ; 0.616 -0.428 ; 0.584 
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Table E4: Crystallographic data and structure refinement details for 
compounds for compounds Re2( SBCM)2. 
 
 
Compound Re2(SBCM)2 
CCDC 1001600 
Empirical Formula C44 H30 N4 O10 Re2 S4 
Mr 1275.36 
Crystal size, mm3 0.19 x 0.14 x 0.03 
Crystal system monoclinic 
Space group P 21/c 
a, Å 14.7072(4) 
b, Å 12.6588(3 
c, Å 12.1386(3) 
&, ° 90 
%, ° 99.3740(10) 
-, ° 90 
Cell volume, Å3 2229.73(10) 
Z ; Z’ 2 ; 1/2 
T, K 100(1) 
F000 1232 
µ, mm–1 5.674 
" range, ° 2.13 – 30.65 
Reflection collected 54 115 
Reflections unique 6 872 
Rint 0.0446 
GOF 1.028 
Refl. obs. (I>2#(I)) 5 059 
Parameters 290 
wR2 (all data) 0.0519 
R value (I>2#(I)) 0.0225 
Largest diff. peak and hole 
(e-.Å-3) -0.901 ; 1.625 
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F. RP-HPLC chromatograms  
 
 
Figure F1.  RP-HPLC chromatogram of SMHD  
 
 
 
Figure F2.  RP-HPLC chromatogram of CuSMHD  
 
 
 
Figure F3.  RP-HPLC chromatogram of SBPY  
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Figure F4.  RP-HPLC chromatogram of SMDTC  
 
 
 
Figure F5.  RP-HPLC chromatogram of SBDTC  
 
 
 
Figure F6.  RP-HPLC chromatogram of SMLA 
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Figure F7.  RP-HPLC chromatogram of Cu(SMLA)2 
 
 
 
Figure F8.  RP-HPLC chromatogram of SBML 
 
 
 
Figure F9.  RP-HPLC chromatogram of Cu(SBML)2 
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Figure F10.  RP-HPLC chromatogram of SBLA 
 
 
 
Figure F11.  RP-HPLC chromatogram of Cu(SBLA)2 
 
 
 
Figure F12.  RP-HPLC chromatogram of SBEL 
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Figure F13.  RP-HPLC chromatogram of CuSM4CB 
 
 
 
Figure F14.  RP-HPLC chromatogram of SB4CB 
 
 
 
Figure F15.  RP-HPLC chromatogram of CuSB4CB 
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Figure F16.  RP-HPLC chromatogram of SBCM 
 
 
 Figure F17.  RP-HPLC chromatogram of Zn(SBCM)2 
 
 
 
Figure F18.  RP-HPLC chromatogram of Re2(SBCM)2 
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Figure F19.  RP-HPLC chromatogram of Cu(SBCM)2 
 
 
 
Figure F20.  RP-HPLC chromatogram of R1-SB4CB (crude)  
 
 
 
Figure F21.  RP-HPLC chromatogram of R1-SB4CB (purified)  
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Figure F22.   RP-HPLC chromatogram of R4-SB4CB (crude)  
 
 
 
Figure F23.  RP-HPLC chromatogram of R4-SB4CB (purified)  
 
 
 
Figure F24.   RP-HPLC chromatogram of R9-SB4CB (crude)  
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Figure F25.  RP-HPLC chromatogram of R9-SB4CB (purified)  
 
 
 
Figure F26.  RP-HPLC chromatogram of RW9-SB4CB (crude) 
  
 
 
Figure F27.   RP-HPLC chromatogram of RW9-SB4CB (purified)  
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Figure F28.   RP-HPLC chromatogram of RW9-SM4CB (crude)  
 
 
 
Figure F29.   RP-HPLC chromatogram of RW9-SM4CB (purified) 
 
 
 
Figure F30.   RP-HPLC chromatogram of R1-Ac (crude)  
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Figure F31.   RP-HPLC chromatogram of R1-Ac (purified)  
 
 
 
Figure F32.   RP-HPLC chromatogram of R4-Ac (crude)  
 
 
 
Figure F33.   RP-HPLC chromatogram of R4-Ac (purified)  
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Figure F34.   RP-HPLC chromatogram of R9-Ac (crude)  
 
 
 
Figure F35.   RP-HPLC chromatogram of R9-Ac (purified)  
 
 
 
Figure F36.   RP-HPLC chromatogram of RW9-Ac (crude)  
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Figure F37.   RP-HPLC chromatogram of RW9-Ac (purified)  
 
 
Figure F38. RP-HPLC chromatogram obtained from the SPPS Fmoc synthesis 
of the aliphatic ligand, SMLA-R9 conjugate. None of the major peaks 
correspond to the desired product as observed by MALDI-TOF-MS. The 
coupling and deprotection were difficult and the Schiff base was hydrolysed 
resulting in the product R9-ketone (m/z: 1521, RT = 6.5 min) and R9-Fmoc (m/z: 
1645, RT = 10.5 min).  
 
 
 
 
 
 
 
 
 
 
 
 
 
324 
 
 
 
 
G. CV 
 
Figure G1.  Cyclic voltammograms of ferrocene  
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Figure G2.   Cyclic voltammograms of the Cu(SMLA)2 
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Figure G3.   Cyclic voltammograms of the Cu(SM4CB)2 
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Figure G4.   Cyclic voltammograms of the Cu(SBML)2 
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Figure G5.   Cyclic voltammograms of the Cu(SBLA)2 
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Figure G6.   Cyclic voltammograms of the Cu(SB4CB)2 
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Figure G7.   Cyclic voltammograms of the Cu(SBCM)2 
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Figure G8.  Plot of the anodic (Ipa) and cathodic (Ipc) current with the square 
root of scan rate for Cu(SBCM)2 and (above) cyclic voltammograms of 
Cu(SBCM)2 at 0.1 V/s in the range of -1.5 V to 1.5 V. 
 
Table G1.  Electrochemical data for the Cu(SBCM)2  vs Ag/AgCl at various 
scan rate (V/s).  
 Cu(II)/Cu(I)  
Cu(SMML)2 Epa[V] Epc[V] 2Ep=Epa-
Epc[mV] 
2E1/2=0.5 
(Epa+Epc) [V] 
ia/ic ipc / +1/2 
0.02 0.082 -0.015 97 0.034 0.91 -43.6 
0.05 0.079 -0.019 98 0.060 0.87 -43.9 
0.10 0.089 -0.027 116 0.031 0.78 -46.5 
0.20 0.089 -0.033 122 0.056 0.83 -40.2 
0.50 0.102 -0.049 151 0.053 0.78 -36.6 
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H. ITC 
 
Figure H1.  ITC titration of Cu(R1-SB4CB)2 
 
 
 
  
Figure H2.   ITC titration of Cu(RW9-SB4CB)2 
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 Figure H3.  ITC titration of Cu(R9-SM4CB)2 
 
 
 
  
Figure H4.  ITC titration of Cu(RW9-SM4CB)2 
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Figure H5.  ITC titration of Cu(SB4CB)2 
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I. EPR  
 
Figure I1.   The EPR spectrum of Cu(SMLA)2  at 1 mM   
 
 
 
Figure I2.   The EPR spectrum of Cu(SBML)2  at 1 mM   
 
 
   
Figure I3.  The EPR spectrum of Cu(SBLA)2  at 1 mM   
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Figure I4.  The EPR spectrum of Cu(SB4CB)2  at 1 mM   
 
 
 
Figure I5.  The EPR spectrum of Cu(R9-SM4CB)2  at 1 mM   
 
 
 
Figure I6.  The EPR spectrum of Cu(R1-SB4CB)2  at 1 mM   
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Figure I7.  The EPR spectrum of Cu(PEG-SB4CB)2  at 1 mM   
   
 
   
Figure I8.  The EPR spectrum of Cu(PA"N-SB4CB)2  at 1 mM   
 
 
 
Figure I9.  The EPR spectrum of Cu(R4-SB4CB)2  at 1 mM   
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Figure I10.  The EPR spectrum of Cu(R9-SM4CB)2  at 1 mM   
 
 
 
Figure I11.  The EPR spectrum of Cu(RW9-SB4CB)2  at 1 mM   
  
 
      
Figure I12.  The EPR spectrum of Cu(RW9-SM4CB)2  at 1 mM   
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Figure I13.  The EPR spectrum of Cu(SBCM)2  at 1 mM   
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J. Elemental analysis 
Table J1.   CHNS data  
 
 CuSMHD       Cu(SB4CB)2 
      
Cu(SM4CB)2      Cu(SMML)2 
      
Cu(SMLA)2      CuSBHD 
    
Cu(SBLA)2      Cu(SBML)2 
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Cu(SBCM)2 
    
 
SBHD 
 
SMHD 
 
 
Re2(SBCM)2 (mass = 2.183 mg) and Zn(SBCM)2  (mass = 1.997 mg) 
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